{"meta":{"query_hash":"fdc8860e50c3","filters":{"venue":"Investigational New Drugs"},"cohort_total":191,"direct_labels_cover":1,"predictions_cover":191,"exported":191,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fdc8860e50c3","api":"https://metacan.xera.ac/api/v1/cohort?venue=Investigational+New+Drugs"},"results":[{"id":"W137248159","doi":"10.1023/a:1026211620793","title":"A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; McGill University; Baker Hughes (Canada); Ottawa Regional Cancer Foundation; Hôpital Notre-Dame","funders":"McGill University","keywords":"Oligodendroglioma; Topotecan; Medicine; Oncology; Cancer research; Internal medicine; Chemotherapy; Glioma; Astrocytoma","score_opus":0.016566857196750384,"score_gpt":0.2629395205782845,"score_spread":0.24637266338153413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W137248159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927448,0.0025246493,0.00043884566,0.00044260573,0.00018254528,0.0011235916,0.001005166,0.00007027191,0.00146755],"genre_scores_gemma":[0.9905614,0.0027795779,0.0009535501,0.0006147148,0.00019134929,0.001225143,0.002267547,0.000040548086,0.0013661919],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992841,0.00029267912,0.00002886051,0.00012347914,0.000058679187,0.00021216908],"domain_scores_gemma":[0.99904054,0.00018866254,0.00009543006,0.00007381666,0.00006140726,0.0005401168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015069548,0.0020818887,0.0038948967,0.00079148024,0.00067768205,0.0014665967,0.0012928181,0.001507371,0.0025042158],"category_scores_gemma":[0.0011501065,0.0007979327,0.0020855009,0.00090966205,0.0013469844,0.0012933915,0.00041855883,0.0039059753,0.0007950227],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82194185,0.047226418,0.011977238,0.00077115523,0.002966639,0.00078321586,0.00035706602,0.0030210651,0.030949717,0.0003947768,0.0037786264,0.07583223],"study_design_scores_gemma":[0.6197398,0.35916972,0.012935045,0.000024712954,0.0012639463,0.0005250128,0.00012183495,0.001140433,0.0026170888,0.00021199005,0.0022013185,0.000049184382],"about_ca_topic_score_codex":0.0046053627,"about_ca_topic_score_gemma":0.008698279,"teacher_disagreement_score":0.0046053627,"about_ca_system_score_codex":0.001775122,"about_ca_system_score_gemma":0.0028139572,"threshold_uncertainty_score":0.012879431},"labels":[],"label_agreement":null},{"id":"W1419213143","doi":"10.1007/s10637-015-0275-x","title":"Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Cancer research; Clonogenic assay; Chloroquine; Cell growth; Cell cycle; Medicine; U87; Biology; Cell culture; Pathology; Glioma; Cancer; Internal medicine","score_opus":0.028273027919605703,"score_gpt":0.26436842016810513,"score_spread":0.23609539224849943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1419213143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855906,0.009301543,0.0011628193,0.00034617315,0.00004541572,0.00003575234,0.0002335498,0.00012779885,0.0031563248],"genre_scores_gemma":[0.996099,0.0023094905,0.00048845494,0.000045242792,0.000022192842,0.000010311953,0.00011581801,0.000007670299,0.0009016897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995935,0.000010110841,0.000002512962,0.0000040370783,0.000007482098,0.000016541337],"domain_scores_gemma":[0.99992526,0.000021040858,0.000018646413,0.0000056517347,0.000010821747,0.00001863404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000690256,0.00021986195,0.0002000436,0.00018470158,0.00010514434,0.00013486616,0.00015007562,0.00012022197,0.0009787122],"category_scores_gemma":[0.00011804059,0.0000708455,0.00014998177,0.00008529036,0.00020889484,0.00009809725,0.00009909091,0.00032637294,0.00013208303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001801693,0.00011807326,0.0009650226,0.00018972345,0.000018614322,0.0001267193,0.00003466131,0.00016780586,0.98140436,0.00020378751,0.00037544259,0.014594055],"study_design_scores_gemma":[0.00037414895,0.003554098,0.014850795,0.000020076382,0.000053696454,0.000604962,0.00006160651,0.00066003593,0.9728442,0.0001006654,0.0068658018,0.000009962282],"about_ca_topic_score_codex":0.0018282676,"about_ca_topic_score_gemma":0.0033854255,"teacher_disagreement_score":0.0018282676,"about_ca_system_score_codex":0.00016650475,"about_ca_system_score_gemma":0.00033700967,"threshold_uncertainty_score":0.0036352277},"labels":[],"label_agreement":null},{"id":"W1539780911","doi":"10.1007/s10637-006-9022-7","title":"A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials","funders":"","keywords":"Medicine; Adverse effect; Rash; Internal medicine; Multiple myeloma; Nausea; Vomiting; Clinical endpoint; Anemia; Gastroenterology; Phases of clinical research; Diarrhea; Pharmacokinetics; Pharmacology; Clinical trial; Oncology","score_opus":0.01286201718875107,"score_gpt":0.26738986107407725,"score_spread":0.2545278438853262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539780911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884289,0.003885464,0.00053122285,0.0008243825,0.00024208988,0.0019780453,0.0014207084,0.00012815933,0.0025608845],"genre_scores_gemma":[0.9851769,0.0029903022,0.0016745863,0.0012761548,0.00024943985,0.0010778761,0.0038407114,0.000030868207,0.0036831116],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996619,0.00014079512,0.000015022529,0.000051484287,0.00003737334,0.00009339597],"domain_scores_gemma":[0.99950194,0.000075771255,0.00005542307,0.000031934967,0.000029080971,0.0003059003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011106335,0.001199012,0.0022013695,0.0005643938,0.000456135,0.000815575,0.0011037599,0.001172077,0.0029650962],"category_scores_gemma":[0.0007172703,0.00059728354,0.001300584,0.00050817104,0.0007444109,0.0006472462,0.00031397454,0.0033280128,0.00076909136],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7300462,0.05789541,0.011613803,0.00075676164,0.0024390004,0.00057707215,0.0003742915,0.0030302554,0.04306946,0.00047771094,0.009887362,0.13983266],"study_design_scores_gemma":[0.62245095,0.3470026,0.020199977,0.000031449832,0.00072385266,0.00042440597,0.00008305976,0.0014673102,0.0027446721,0.00017041762,0.00465939,0.000042034786],"about_ca_topic_score_codex":0.0037550216,"about_ca_topic_score_gemma":0.008336283,"teacher_disagreement_score":0.0037550216,"about_ca_system_score_codex":0.0010569446,"about_ca_system_score_gemma":0.0016353755,"threshold_uncertainty_score":0.009919226},"labels":[],"label_agreement":null},{"id":"W1902804987","doi":"10.1007/s10637-015-0282-y","title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Adverse effect; Pharmacokinetics; Nausea; Vomiting; Dosing; Tyrosine-kinase inhibitor; Gastroenterology; Pharmacology; Internal medicine; Cancer","score_opus":0.035171827927367574,"score_gpt":0.31735924606254523,"score_spread":0.28218741813517767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1902804987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886602,0.003966514,0.000889135,0.0008222197,0.00023654196,0.0017807076,0.0011334945,0.00011232372,0.0023987994],"genre_scores_gemma":[0.9864759,0.0037680322,0.0016537477,0.0011307816,0.00020806538,0.0015233303,0.0025692782,0.0000507283,0.0026201725],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961025,0.0001560387,0.000017486234,0.00007507475,0.000032303324,0.00010889362],"domain_scores_gemma":[0.9993451,0.00012004302,0.00007025545,0.00005921544,0.000040268853,0.00036501375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013448168,0.0013440107,0.0028480212,0.0005504364,0.0005105245,0.0011305027,0.0007872525,0.0012263288,0.0026919497],"category_scores_gemma":[0.0007997326,0.00057690724,0.001915694,0.00058145926,0.0010628651,0.00095912983,0.0003359764,0.0037112846,0.0007105586],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6571305,0.08054183,0.011204926,0.0012953148,0.0025614796,0.00057843165,0.0006290833,0.005708997,0.07147686,0.0008241986,0.007877774,0.16017067],"study_design_scores_gemma":[0.5370297,0.44080082,0.010733819,0.00003789048,0.0007925271,0.00041215267,0.00012610866,0.0017880154,0.0043379697,0.0003486604,0.003555315,0.000036950394],"about_ca_topic_score_codex":0.0015933326,"about_ca_topic_score_gemma":0.0034453769,"teacher_disagreement_score":0.0028480212,"about_ca_system_score_codex":0.0008595515,"about_ca_system_score_gemma":0.0015672895,"threshold_uncertainty_score":0.009005487},"labels":[],"label_agreement":null},{"id":"W1939928011","doi":"10.1023/a:1016253716438","title":"Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642)","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Care Ontario; Procter and Gamble; Eli Lilly and Company","keywords":"Pharmacokinetics; In vivo; Pharmacology; Medicine; Melanoma; Toxicity; In vitro; Cancer; IC50; Apoptosis; Cancer research; Chemistry; Internal medicine; Biology","score_opus":0.03213157658821065,"score_gpt":0.2863443809432163,"score_spread":0.25421280435500565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1939928011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135065,0.0035057764,0.0014257411,0.00025018468,0.000100008285,0.00014092644,0.0006603021,0.0002119725,0.0023544931],"genre_scores_gemma":[0.9957034,0.00095071027,0.00052367843,0.000053533535,0.000057238,0.00010580158,0.00080633507,0.000051307517,0.0017479943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99954695,0.00016958054,0.000019578752,0.000053783348,0.00006281,0.00014735703],"domain_scores_gemma":[0.99946576,0.00016447378,0.00012262724,0.00006614764,0.00004245238,0.00013859713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007824453,0.00062639744,0.0009349755,0.0005811423,0.00030831574,0.00063916034,0.0006594738,0.00073007814,0.0017258461],"category_scores_gemma":[0.0008524071,0.00048548868,0.0004584381,0.0004922527,0.0005582857,0.000668849,0.00016080137,0.0021255638,0.00048357423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10863741,0.02145656,0.0044367635,0.00029866013,0.00032441842,0.00052217935,0.00036779098,0.0074536437,0.7452608,0.0011482295,0.0049982304,0.105095275],"study_design_scores_gemma":[0.010708402,0.22735131,0.023575826,0.00004183765,0.00062106765,0.001301499,0.00017202912,0.013354753,0.7135808,0.00038703746,0.008833585,0.00007188928],"about_ca_topic_score_codex":0.0041649663,"about_ca_topic_score_gemma":0.0039339103,"teacher_disagreement_score":0.0041649663,"about_ca_system_score_codex":0.0011294144,"about_ca_system_score_gemma":0.0008411747,"threshold_uncertainty_score":0.008281469},"labels":[],"label_agreement":null},{"id":"W1964185052","doi":"10.1007/s10637-010-9399-1","title":"A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":295,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Supratek Pharma (Canada)","funders":"","keywords":"Medicine; Population; Response Evaluation Criteria in Solid Tumors; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Doxorubicin; Chemotherapy; Adenocarcinoma; Surgery; Esophagus; Progressive disease; Oncology; Cancer; Clinical trial","score_opus":0.007041558149605497,"score_gpt":0.25788050142822094,"score_spread":0.25083894327861544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964185052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947649,0.0011869333,0.000474349,0.00041070383,0.00013901592,0.0015065705,0.0004893474,0.000048803966,0.0009792768],"genre_scores_gemma":[0.9902954,0.0016796866,0.0013749641,0.00067637354,0.00017657927,0.0018146888,0.001430121,0.00003718285,0.0025149316],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995239,0.00020389017,0.000020584755,0.000086323234,0.000034392593,0.00013082962],"domain_scores_gemma":[0.9994155,0.000120501114,0.00006419541,0.00006261916,0.00004417647,0.0002929547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016388422,0.0017284646,0.0028095318,0.000560575,0.0005252198,0.00101131,0.0008173796,0.0018534889,0.0025388447],"category_scores_gemma":[0.0009597766,0.00074312655,0.0016280536,0.0005184307,0.0011263019,0.0011949689,0.0003505447,0.0040620896,0.0006965021],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6579775,0.14984962,0.0053687086,0.00088841777,0.0014537314,0.00060025643,0.0006845782,0.00434043,0.087441936,0.00054736156,0.003972153,0.086875364],"study_design_scores_gemma":[0.41593158,0.56871015,0.0058939173,0.000018142948,0.00047011964,0.00021706594,0.000094256284,0.0012309451,0.0052421438,0.000118231306,0.0020369913,0.000036500747],"about_ca_topic_score_codex":0.001991031,"about_ca_topic_score_gemma":0.0040821335,"teacher_disagreement_score":0.0028095318,"about_ca_system_score_codex":0.000985028,"about_ca_system_score_gemma":0.0016485214,"threshold_uncertainty_score":0.008667171},"labels":[],"label_agreement":null},{"id":"W1966040155","doi":"10.1007/s10637-007-9044-9","title":"Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Hamilton Health Sciences; University Health Network","funders":"","keywords":"Medicine; Renal cell carcinoma; Nausea; Adverse effect; Internal medicine; Neutropenia; Urology; Vomiting; Clinical trial; Gastroenterology; Oncology; Surgery; Toxicity","score_opus":0.05282090444412633,"score_gpt":0.3459315138132732,"score_spread":0.29311060936914685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966040155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814641,0.005557549,0.0007059319,0.002133833,0.0005165526,0.0027482687,0.002790274,0.00018904649,0.0038944557],"genre_scores_gemma":[0.97596425,0.0059853904,0.0022114597,0.0020382772,0.00032472992,0.002197022,0.003500327,0.000061582345,0.007716934],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970406,0.00014593847,0.000011855546,0.000038150505,0.000034425047,0.00006561635],"domain_scores_gemma":[0.9989579,0.0001240732,0.0001575032,0.00004361543,0.000076808516,0.00064002495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001180169,0.0014576196,0.0018495569,0.0003829045,0.0005316746,0.0009048988,0.00081298995,0.0012008923,0.0050848764],"category_scores_gemma":[0.0010385569,0.00034981422,0.0016571782,0.0004705498,0.0006767842,0.0005953123,0.00030373287,0.0030627674,0.0008014441],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82663995,0.023308322,0.0038931835,0.0013341685,0.00213278,0.00037419534,0.00024771763,0.0023404749,0.016801327,0.0004911016,0.016644431,0.10579242],"study_design_scores_gemma":[0.8268802,0.15906438,0.0070860106,0.00006837435,0.00051187415,0.00033231266,0.00009879418,0.0015058762,0.001363168,0.00025542063,0.0027895481,0.000044040964],"about_ca_topic_score_codex":0.010976864,"about_ca_topic_score_gemma":0.027115984,"teacher_disagreement_score":0.010976864,"about_ca_system_score_codex":0.001693101,"about_ca_system_score_gemma":0.0037082338,"threshold_uncertainty_score":0.02182591},"labels":[],"label_agreement":null},{"id":"W1967210005","doi":"10.1007/s10637-010-9396-4","title":"Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Cetuximab; Toxicity; Medicine; Internal medicine; Pharmacology; Cancer; Colorectal cancer","score_opus":0.015400231313834022,"score_gpt":0.291901193244463,"score_spread":0.276500961930629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967210005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961987,0.0013272845,0.00039320142,0.00014742305,0.00006773972,0.00088402256,0.00033081102,0.00004632983,0.000604499],"genre_scores_gemma":[0.9922397,0.0021954086,0.0014502298,0.00042130722,0.00024453018,0.0011317156,0.000764537,0.000048739348,0.0015038929],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984748,0.0007472693,0.00006872193,0.00030024693,0.0001589962,0.00025001162],"domain_scores_gemma":[0.99618775,0.0012848624,0.000860388,0.00063128676,0.00015419471,0.0008815689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003998481,0.0025647518,0.003349723,0.0010450677,0.0006631125,0.0013894116,0.0015189897,0.0019755834,0.002920506],"category_scores_gemma":[0.0026694033,0.00117585,0.0025543205,0.0012547373,0.0022138592,0.0014740806,0.00045602175,0.005366327,0.0006091122],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65242124,0.21140039,0.011337164,0.00054033706,0.001998743,0.000320392,0.0004172949,0.00350833,0.035741035,0.0001690013,0.0016626039,0.08048349],"study_design_scores_gemma":[0.21022314,0.76484704,0.018031135,0.000027344064,0.0007447976,0.00022992515,0.000060648563,0.0011081963,0.0036837982,0.00012756576,0.0008668343,0.000049621525],"about_ca_topic_score_codex":0.0014792772,"about_ca_topic_score_gemma":0.0023432025,"teacher_disagreement_score":0.003998481,"about_ca_system_score_codex":0.0012047879,"about_ca_system_score_gemma":0.0018676148,"threshold_uncertainty_score":0.021146297},"labels":[],"label_agreement":null},{"id":"W1968618374","doi":"10.1007/s10637-015-0230-x","title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceuticals International; Takeda Oncology","keywords":"Ixazomib; Medicine; Rash; Pharmacodynamics; Multiple myeloma; Pharmacokinetics; Adverse effect; Internal medicine; Proteasome inhibitor; Pharmacology; Gastroenterology; Oncology; Carfilzomib","score_opus":0.07539078866375962,"score_gpt":0.36400187646837306,"score_spread":0.2886110878046134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968618374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920183,0.0037996166,0.00078307214,0.00026452806,0.00005213399,0.00090519205,0.0006015589,0.000105724626,0.0014698064],"genre_scores_gemma":[0.9884901,0.0033503706,0.0021697723,0.0002939875,0.00007042812,0.0007505823,0.0017419255,0.000026695323,0.0031060523],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99979776,0.00007770349,0.000008251155,0.000041855492,0.00003047972,0.000043953623],"domain_scores_gemma":[0.9997528,0.00003157216,0.00006885532,0.000017900524,0.000016060685,0.00011268405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069062476,0.0010358705,0.001080341,0.0002759263,0.00024227488,0.000605679,0.00059352146,0.00055405515,0.002225132],"category_scores_gemma":[0.00036431281,0.00026113255,0.00045088428,0.00032035905,0.0004999352,0.00039558235,0.00021286361,0.0017093477,0.00045909427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2869432,0.07445688,0.01920584,0.0017181052,0.0012189326,0.0014385415,0.000470439,0.008491459,0.35935926,0.0007203213,0.010479997,0.23549704],"study_design_scores_gemma":[0.2538178,0.5877266,0.046139743,0.00013948316,0.00077928713,0.0026919066,0.00009270445,0.0061163856,0.087303594,0.0004928845,0.0146514485,0.000048114256],"about_ca_topic_score_codex":0.00091488997,"about_ca_topic_score_gemma":0.00417344,"teacher_disagreement_score":0.002225132,"about_ca_system_score_codex":0.0011340502,"about_ca_system_score_gemma":0.001248814,"threshold_uncertainty_score":0.008228183},"labels":[],"label_agreement":null},{"id":"W1972337517","doi":"10.1007/s10637-013-0033-x","title":"Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Spleen; Virology; Biology; Virus; Oncolytic virus; Reverse transcriptase; Cancer; Pharmacology; Virotherapy; Immunology; Medicine; RNA; Internal medicine","score_opus":0.03682878076399858,"score_gpt":0.297222366403331,"score_spread":0.2603935856393324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972337517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929255,0.0010346764,0.0044391784,0.00008683133,0.00005950145,0.000049338174,0.00044492885,0.00014030108,0.0008197351],"genre_scores_gemma":[0.9883245,0.0022304137,0.0032343878,0.00008335997,0.00006734807,0.00008925004,0.0005633494,0.00008184523,0.0053254664],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997824,0.00002197596,0.000011006748,0.00007076345,0.000028102937,0.00008578684],"domain_scores_gemma":[0.9995733,0.000060213453,0.00012246592,0.000056618464,0.00006474023,0.00012271601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039040562,0.0008269441,0.0005884831,0.0006175119,0.00021256527,0.0004426012,0.00042925574,0.00045898926,0.0011333601],"category_scores_gemma":[0.00024772674,0.0002746764,0.00042931506,0.00032340628,0.00060056243,0.0010543308,0.00017194528,0.001080289,0.00044808164],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010902151,0.0011960187,0.0008339605,0.00010655643,0.000042743282,0.00016397101,0.00011790492,0.0005609913,0.9720366,0.00032044653,0.00017024405,0.013548319],"study_design_scores_gemma":[0.00019107526,0.009761255,0.0027836973,0.000008028619,0.00010457667,0.00010905347,0.000092224356,0.00162606,0.98422825,0.0000966833,0.000976496,0.000022653203],"about_ca_topic_score_codex":0.0022180397,"about_ca_topic_score_gemma":0.0015015675,"teacher_disagreement_score":0.0022180397,"about_ca_system_score_codex":0.00040638808,"about_ca_system_score_gemma":0.0008895633,"threshold_uncertainty_score":0.0044103265},"labels":[],"label_agreement":null},{"id":"W1974638172","doi":"10.1007/s10637-012-9865-z","title":"REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Baker Hughes (Canada); Oncolytics Biotech (Canada); Alberta Cancer Foundation","funders":"Oncolytics Biotech","keywords":"Medicine; Oncolytic virus; Tolerability; Gastroenterology; Toxicity; Internal medicine; Adverse effect; Clinical trial; Cancer; Progressive disease; Surgery; Disease","score_opus":0.017600910885360137,"score_gpt":0.3095962140356946,"score_spread":0.29199530315033445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974638172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841525,0.0046219183,0.0012677958,0.0012954394,0.0003643759,0.0014814347,0.001552545,0.00033651252,0.0049274606],"genre_scores_gemma":[0.97987914,0.004411222,0.0018486702,0.0012816011,0.00015173029,0.0015438986,0.0032947564,0.00009713045,0.0074919146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980026,0.00006421577,0.0000064150677,0.000040506096,0.000016250788,0.000072357376],"domain_scores_gemma":[0.9996828,0.00007267445,0.000053551877,0.00002846705,0.000013214543,0.00014933331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008365326,0.0015819549,0.0013290916,0.0003707114,0.00031619324,0.0010710704,0.00081966294,0.0011671749,0.0041894987],"category_scores_gemma":[0.0005525703,0.00040172663,0.0012983623,0.00027458003,0.00082713756,0.00068434805,0.0002806235,0.003866246,0.00090026093],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4962568,0.055629477,0.004357738,0.0021133532,0.0021865813,0.0004236121,0.00059164624,0.0068888436,0.13511947,0.0021653299,0.013897796,0.28036943],"study_design_scores_gemma":[0.58699477,0.37410733,0.008500037,0.00011458957,0.0007761572,0.00052509404,0.00016243976,0.0027148118,0.015675899,0.0006934845,0.009659557,0.000075851705],"about_ca_topic_score_codex":0.0016490191,"about_ca_topic_score_gemma":0.003581172,"teacher_disagreement_score":0.0041894987,"about_ca_system_score_codex":0.00078767457,"about_ca_system_score_gemma":0.0010822229,"threshold_uncertainty_score":0.014015257},"labels":[],"label_agreement":null},{"id":"W1975767948","doi":"10.1007/s10637-011-9668-7","title":"A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Chemical synthesis and alkaloids","field":"Chemistry","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Brock University; University of Windsor","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Autophagy; Mitochondrion; Reactive oxygen species; Cell culture; Cytochrome c; Biology; Cancer cell; Programmed cell death; Cancer research; Molecular biology; Chemistry; Cell biology; Biochemistry; Cancer","score_opus":0.015427867166089843,"score_gpt":0.23300123272907783,"score_spread":0.21757336556298798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975767948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914443,0.0016365265,0.0022810108,0.00015777462,0.000048352496,0.00006205091,0.00028038814,0.00007384318,0.004015864],"genre_scores_gemma":[0.9956346,0.00077890133,0.0016175876,0.0000508497,0.000012205557,0.000022315022,0.0002756167,0.000009747875,0.0015981826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994576,0.000007977998,0.000005148341,0.000012500803,0.0000112390935,0.00001742557],"domain_scores_gemma":[0.99994564,0.00000766571,0.000017954553,0.0000060674024,0.000007729408,0.000014878746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084855696,0.00020966028,0.0002248977,0.00017092998,0.0001361469,0.00012649689,0.00038487464,0.00027154214,0.0010964104],"category_scores_gemma":[0.00008621924,0.00010364211,0.00014530854,0.00012541642,0.00017567672,0.00016802739,0.00011392776,0.00034230715,0.00022776451],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022243112,0.00003190166,0.00004685383,0.000048218702,0.000003960619,0.00012365395,0.00001600849,0.00012543556,0.996865,0.00018970683,0.000048083923,0.0022787289],"study_design_scores_gemma":[0.00012216375,0.0018279471,0.001011056,0.0000048331726,0.000020942372,0.0005482665,0.00001433589,0.00038278673,0.99079204,0.000049920305,0.0052187494,0.0000070511214],"about_ca_topic_score_codex":0.00051328965,"about_ca_topic_score_gemma":0.0010239552,"teacher_disagreement_score":0.0010964104,"about_ca_system_score_codex":0.00026469247,"about_ca_system_score_gemma":0.00018647044,"threshold_uncertainty_score":0.0036678314},"labels":[],"label_agreement":null},{"id":"W1976371429","doi":"10.1007/s10637-013-9965-4","title":"A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Gemcitabine; Pharmacokinetics; Medicine; Tolerability; Neutropenia; Pharmacology; Internal medicine; Rash; Gastroenterology; Toxicity; Adverse effect; Chemotherapy","score_opus":0.00475852084442618,"score_gpt":0.22247079158488545,"score_spread":0.21771227074045926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976371429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394387,0.0018017556,0.00046181894,0.00024666684,0.000052407726,0.0015979668,0.0005671084,0.00007714038,0.0012511994],"genre_scores_gemma":[0.9903632,0.0018977704,0.0020074272,0.0005069007,0.00009772691,0.0016384231,0.0017530612,0.000026541085,0.0017089783],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996371,0.00014636677,0.00002321048,0.00007131176,0.000049234008,0.00007268922],"domain_scores_gemma":[0.999572,0.00005135922,0.00010916384,0.00003783006,0.000018353501,0.00021135282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086062343,0.0013179433,0.0021263417,0.00046800874,0.00030819053,0.0009182614,0.0009689614,0.00087391504,0.0027880033],"category_scores_gemma":[0.00054990145,0.00050071825,0.0009411518,0.00052177306,0.0007571529,0.00073483295,0.00038419646,0.002770092,0.00084798783],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5264036,0.10585891,0.011353597,0.0012979533,0.0019871898,0.00067683886,0.000380004,0.005746265,0.12829919,0.00041655987,0.0049597495,0.21262015],"study_design_scores_gemma":[0.35557932,0.6147395,0.0138215395,0.000043468088,0.0005752864,0.00063742435,0.000075109194,0.0017228883,0.00913553,0.00013734406,0.0034973538,0.000035329937],"about_ca_topic_score_codex":0.00086307636,"about_ca_topic_score_gemma":0.0026159524,"teacher_disagreement_score":0.0027880033,"about_ca_system_score_codex":0.0010115071,"about_ca_system_score_gemma":0.0016893174,"threshold_uncertainty_score":0.009326816},"labels":[],"label_agreement":null},{"id":"W1976444729","doi":"10.1007/s10637-006-5730-2","title":"SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; St. Boniface Hospital","funders":"University Health Network","keywords":"Medicine; Colorectal cancer; Chemotherapy; Internal medicine; Neutropenia; Toxicity; Progressive disease; Phases of clinical research; Performance status; Gastroenterology; Cancer; Surgery; Oncology","score_opus":0.1546958686457002,"score_gpt":0.4449759926281748,"score_spread":0.2902801239824746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976444729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750378,0.014670939,0.0002438058,0.0014634277,0.00017439741,0.002382437,0.0022972221,0.000042267817,0.0036877564],"genre_scores_gemma":[0.96446556,0.019827975,0.0018959512,0.001690921,0.00026566023,0.0018477655,0.004293061,0.00003953167,0.0056736213],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99937576,0.0003302577,0.000024952149,0.00006715302,0.00008884834,0.000113035625],"domain_scores_gemma":[0.9989986,0.00013445351,0.00017027682,0.000060064962,0.00015115847,0.0004854947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024208804,0.00088835746,0.0025031308,0.0005009558,0.00077806745,0.0007795358,0.0008802594,0.0010933336,0.0024344283],"category_scores_gemma":[0.0012536664,0.0003574675,0.0013491445,0.00085947814,0.000997083,0.00036502653,0.0003291257,0.00203163,0.00037975961],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7570335,0.022033287,0.017083513,0.0021881864,0.0034722905,0.0002372289,0.0004702888,0.0022229548,0.012078638,0.0004330471,0.010142547,0.17260456],"study_design_scores_gemma":[0.6965433,0.22365169,0.06585277,0.00018471832,0.0024732768,0.0002024086,0.00019774791,0.00079565437,0.001345569,0.00014920549,0.008552668,0.000050962415],"about_ca_topic_score_codex":0.08340346,"about_ca_topic_score_gemma":0.28086564,"teacher_disagreement_score":0.08340346,"about_ca_system_score_codex":0.003276075,"about_ca_system_score_gemma":0.007303103,"threshold_uncertainty_score":0.16583604},"labels":[],"label_agreement":null},{"id":"W1977529605","doi":"10.1007/s10637-014-0066-9","title":"Phase II trial of vorinostat in advanced melanoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Vorinostat; Clinical endpoint; Medicine; Melanoma; Adverse effect; Nausea; Internal medicine; Oncology; Progressive disease; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Chemotherapy; Randomized controlled trial; Cancer research; Histone deacetylase; Histone; Biology","score_opus":0.013002947923047731,"score_gpt":0.2994760520324806,"score_spread":0.2864731041094329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977529605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98486644,0.0043883743,0.00062126614,0.0015092874,0.00056065683,0.0018758063,0.0016901549,0.00014192614,0.0043460866],"genre_scores_gemma":[0.98013616,0.0038574797,0.0010925129,0.0011866586,0.00032416484,0.0017691469,0.0034028494,0.00004898575,0.008182024],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997626,0.00009785001,0.000007948768,0.00003482451,0.00001796728,0.00007879711],"domain_scores_gemma":[0.99956673,0.000073332376,0.000044287106,0.00003409323,0.000017553137,0.0002639398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009829482,0.0014799506,0.0020210855,0.00056644337,0.0005356312,0.0010027732,0.0006998265,0.0011527676,0.0050493916],"category_scores_gemma":[0.0005601037,0.0004722961,0.0012055804,0.0004020216,0.0009770828,0.0008160818,0.00031442926,0.002833804,0.0009922151],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72033656,0.04620254,0.0044542137,0.001211002,0.001155669,0.0006971311,0.0004192819,0.005264089,0.06652183,0.00095622975,0.010345942,0.14243558],"study_design_scores_gemma":[0.5724859,0.40458873,0.008427967,0.00006373781,0.00033146102,0.00036013633,0.00014322653,0.0020770885,0.0057748705,0.00055162085,0.0051593524,0.000035819852],"about_ca_topic_score_codex":0.0019975225,"about_ca_topic_score_gemma":0.0044155098,"teacher_disagreement_score":0.0050493916,"about_ca_system_score_codex":0.0009938901,"about_ca_system_score_gemma":0.0011962986,"threshold_uncertainty_score":0.016891837},"labels":[],"label_agreement":null},{"id":"W1981746443","doi":"10.1007/s10637-011-9678-5","title":"Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Luitpold Pharmaceuticals; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Doxorubicin; Cytotoxicity; Cisplatin; Comet assay; DNA damage; DNA fragmentation; Molecular biology; Cancer research; DNA; Chemistry; Cancer cell; Biology; Pharmacology; In vitro; Cancer; Biochemistry; Apoptosis; Programmed cell death; Chemotherapy; Genetics","score_opus":0.012550214348946445,"score_gpt":0.22081646188326232,"score_spread":0.20826624753431588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981746443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365944,0.0025698922,0.00030264273,0.00020320738,0.00008129276,0.000045038687,0.000594038,0.00009669455,0.0024478368],"genre_scores_gemma":[0.9943784,0.0018466669,0.0004716198,0.00010032826,0.000017573893,0.00006266909,0.0008464213,0.000014985987,0.002261394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981886,0.00003900573,0.000025388481,0.000025862772,0.00003867576,0.000052295178],"domain_scores_gemma":[0.9998783,0.000040778144,0.000015463029,0.000020926529,0.000016827273,0.00002763395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018277726,0.0002995335,0.00078966696,0.00028378243,0.00028578594,0.00036343603,0.00027525364,0.0004937057,0.002167629],"category_scores_gemma":[0.00021600585,0.00026589746,0.00032774766,0.00033898573,0.00022398349,0.00030720312,0.00017076137,0.000856599,0.00042705867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046952344,0.0007352066,0.00053327385,0.0002724,0.00005078405,0.0002489342,0.00013179945,0.0008591728,0.97786945,0.00033811585,0.0010216205,0.013244027],"study_design_scores_gemma":[0.00034403725,0.0037782742,0.008187363,0.000017578457,0.000048521517,0.00026591364,0.00008851957,0.0023207937,0.9814788,0.000073550866,0.0033785147,0.0000181453],"about_ca_topic_score_codex":0.0018370495,"about_ca_topic_score_gemma":0.0031740598,"teacher_disagreement_score":0.002167629,"about_ca_system_score_codex":0.00038601705,"about_ca_system_score_gemma":0.0004294391,"threshold_uncertainty_score":0.007251501},"labels":[],"label_agreement":null},{"id":"W1982150095","doi":"10.1007/s10637-010-9548-6","title":"A novel aminosteroid of the 5α-androstane-3α,17β-diol family induces cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Plant biochemistry and biosynthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier de l'Université Laval","funders":"Canadian Institutes of Health Research","keywords":"Propidium iodide; Apoptosis; Acute promyelocytic leukemia; Cytotoxic T cell; Programmed cell death; Leukemia; Molecular biology; Cell cycle; Flow cytometry; Cell culture; Annexin; Chemistry; Cancer research; Caspase; Cytotoxicity; Biology; Immunology; Biochemistry; Genetics; In vitro; Retinoic acid","score_opus":0.009195888427141058,"score_gpt":0.2070571217329161,"score_spread":0.19786123330577504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982150095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922774,0.004521096,0.00097601756,0.000075378826,0.0000475024,0.00003203023,0.00024311524,0.000056385972,0.0017710227],"genre_scores_gemma":[0.9917241,0.003817323,0.0010080303,0.000077538934,0.000024636474,0.00003435048,0.0007371613,0.000012795382,0.0025640845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994314,0.000009628925,0.0000070421124,0.0000098528035,0.000014391345,0.000015960788],"domain_scores_gemma":[0.9999541,0.000011213684,0.000008088523,0.00000782248,0.0000065875283,0.00001221186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008957968,0.0002853212,0.00033671275,0.00034316748,0.0001984459,0.00019560287,0.00015763259,0.00021358207,0.0010965352],"category_scores_gemma":[0.000070080365,0.000121805024,0.00021736341,0.00028147374,0.00016283807,0.00012351724,0.00013585188,0.0003006072,0.0004119928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050261297,0.000053294767,0.00036545686,0.000052415093,0.0000102959675,0.00028899268,0.000028737733,0.00005366883,0.9950871,0.00008849051,0.00006452955,0.0034044322],"study_design_scores_gemma":[0.00013297606,0.0012869218,0.005105163,0.0000070410706,0.000050214632,0.00093724625,0.00005494666,0.00026272776,0.98614675,0.000064736625,0.0059455917,0.0000057313637],"about_ca_topic_score_codex":0.0004936017,"about_ca_topic_score_gemma":0.00096787227,"teacher_disagreement_score":0.0010965352,"about_ca_system_score_codex":0.00020542368,"about_ca_system_score_gemma":0.00017671243,"threshold_uncertainty_score":0.0036683083},"labels":[],"label_agreement":null},{"id":"W1983086187","doi":"10.1007/s10637-005-2905-1","title":"Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Camptothecin; Lethargy; Vomiting; Toxicity; Nausea; Pharmacokinetics; Diarrhea; Pharmacology; Gastroenterology; Anesthesia; Internal medicine; Chemistry","score_opus":0.01063012803762387,"score_gpt":0.27958224717583585,"score_spread":0.268952119138212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983086187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596894,0.00093622453,0.0006286725,0.00026811773,0.000067816065,0.0005384929,0.00048406757,0.000091666174,0.0010160417],"genre_scores_gemma":[0.9955596,0.00085596775,0.00092036003,0.00024467777,0.000082775034,0.00042978048,0.00082685763,0.000039957824,0.0010400569],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996934,0.0001228673,0.000009496816,0.000056672157,0.00003958661,0.000078016055],"domain_scores_gemma":[0.99942845,0.00009649596,0.00011374991,0.00006896031,0.000027012717,0.00026524282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066268706,0.0012216775,0.0020358078,0.00044331438,0.00046801817,0.00077231706,0.00067172037,0.00086356717,0.0011482501],"category_scores_gemma":[0.00091478537,0.00065749104,0.0009271499,0.0006245518,0.0011026647,0.0007192125,0.00023386764,0.0033634496,0.00041018697],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48736936,0.07657946,0.009925226,0.00050446106,0.0011449482,0.0006188398,0.0007559592,0.011233008,0.23910964,0.0010343455,0.006746307,0.16497852],"study_design_scores_gemma":[0.28223574,0.64513,0.035321917,0.000026753165,0.00068164605,0.00091850857,0.0001435855,0.0061812685,0.022947177,0.00041286284,0.0059274537,0.00007318091],"about_ca_topic_score_codex":0.002678726,"about_ca_topic_score_gemma":0.0029538346,"teacher_disagreement_score":0.002678726,"about_ca_system_score_codex":0.0010473961,"about_ca_system_score_gemma":0.0016235536,"threshold_uncertainty_score":0.007599473},"labels":[],"label_agreement":null},{"id":"W1983180167","doi":"10.1007/s10637-009-9367-9","title":"Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Pharmaceuticals Bayer","keywords":"Sorafenib; Medicine; Discontinuation; Rash; Adverse effect; Placebo; Randomized controlled trial; Internal medicine; Soft tissue sarcoma; Nausea; Surgery; Sarcoma; Tolerability; Oncology; Soft tissue; Pathology; Hepatocellular carcinoma","score_opus":0.011751264357806945,"score_gpt":0.278792244268608,"score_spread":0.26704097991080106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983180167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99749243,0.00094014045,0.00020954116,0.0002973095,0.00004499627,0.00021782746,0.00042225103,0.0000120698805,0.00036349302],"genre_scores_gemma":[0.9969708,0.00048488457,0.0002838889,0.00026360428,0.00010331451,0.00027442968,0.0012907796,0.000008523504,0.00031983724],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989221,0.00061829813,0.00007715022,0.00016877791,0.00006266098,0.00015107427],"domain_scores_gemma":[0.99797744,0.0007390006,0.0004982159,0.0002496151,0.00013285106,0.00040285548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030736348,0.0014372789,0.002837091,0.00031327488,0.0005908095,0.0011185745,0.00054503477,0.0007716943,0.0026434413],"category_scores_gemma":[0.0029631418,0.00040096065,0.0024406153,0.0004617282,0.0008697672,0.001075305,0.00039181852,0.0021637536,0.00039313326],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8904697,0.004307212,0.046113025,0.0004762575,0.0033957725,0.00051901484,0.00029020372,0.0012788364,0.0107233245,0.00027469225,0.0024983445,0.039653663],"study_design_scores_gemma":[0.7366465,0.13512096,0.10764589,0.000088570545,0.006369886,0.0015845189,0.00031255663,0.0029225522,0.0030436942,0.0011795696,0.0049908436,0.00009460043],"about_ca_topic_score_codex":0.00032542716,"about_ca_topic_score_gemma":0.00086163764,"teacher_disagreement_score":0.0030736348,"about_ca_system_score_codex":0.0005893318,"about_ca_system_score_gemma":0.00089366833,"threshold_uncertainty_score":0.01625514},"labels":[],"label_agreement":null},{"id":"W1984395407","doi":"10.1023/b:drug.0000006171.54078.3d","title":"The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal","funders":"","keywords":"Plasmin; Plasminogen activator; Urokinase; Angiogenesis; Tissue plasminogen activator; Chemistry; In vitro; Stimulation; T-plasminogen activator; Fibrinolysis; Activator (genetics); Pharmacology; Biochemistry; Enzyme; Biology; Receptor; Endocrinology; Cancer research; Internal medicine; Medicine","score_opus":0.0133581378657629,"score_gpt":0.24500450344369587,"score_spread":0.23164636557793297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984395407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96208274,0.021008512,0.006117177,0.00062840094,0.00018009207,0.00006524288,0.00045109342,0.00018183098,0.009285008],"genre_scores_gemma":[0.98221636,0.007899136,0.0033891888,0.00018074371,0.00009972539,0.000038161492,0.0006888921,0.00002602023,0.0054616923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998524,0.000030729945,0.0000074960385,0.00002035997,0.00004210617,0.000046910824],"domain_scores_gemma":[0.99989104,0.000043330157,0.000023603332,0.0000072595117,0.000007734405,0.000026961172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001500782,0.00042085155,0.00028332934,0.00033020152,0.00013257805,0.00047668625,0.00025435688,0.00031053057,0.0028064142],"category_scores_gemma":[0.0002375295,0.0001911342,0.0002353305,0.00020755116,0.00020641008,0.00028009506,0.00022971972,0.0008561413,0.0008752534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006836165,0.00012114538,0.00037107515,0.00008210429,0.000012760118,0.0002512827,0.000018740335,0.00011170742,0.9794592,0.0006480129,0.0003462337,0.017894123],"study_design_scores_gemma":[0.00011414975,0.00082525826,0.003071754,0.0000070913256,0.0000149080015,0.0010217745,0.000015915864,0.0005026509,0.98611623,0.00014951393,0.008155034,0.000005746724],"about_ca_topic_score_codex":0.0003209971,"about_ca_topic_score_gemma":0.0002598446,"teacher_disagreement_score":0.0028064142,"about_ca_system_score_codex":0.00028468916,"about_ca_system_score_gemma":0.00017601659,"threshold_uncertainty_score":0.009388447},"labels":[],"label_agreement":null},{"id":"W1985731766","doi":"10.1007/s10637-009-9375-9","title":"Sphingosine-1-phosphate: a potential therapeutic agent against human breast cancer","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Cancer Research Society","keywords":"Sphingosine; Sphingosine kinase 1; Sphingosine-1-phosphate; Docetaxel; Sphingosine kinase; Breast cancer; Apoptosis; Pharmacology; Cancer research; Cancer; Cytotoxicity; Medicine; Systemic administration; Cancer cell; Kinase; Internal medicine; Chemistry; Biology; Cell biology; In vitro; Receptor; Biochemistry; In vivo","score_opus":0.011669850574289218,"score_gpt":0.2609885731992294,"score_spread":0.2493187226249402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985731766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5919272,0.33115757,0.007822847,0.010064468,0.0013921262,0.0005283834,0.0020809113,0.00041699392,0.054609593],"genre_scores_gemma":[0.8029369,0.1701079,0.005029058,0.0010736599,0.00057063205,0.00019025923,0.0010163259,0.000026420685,0.019048722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999603,0.000011359461,0.0000028553254,0.000005494931,0.000007898601,0.000012126023],"domain_scores_gemma":[0.9999616,0.000010393923,0.0000062308104,0.0000030238175,0.0000061642595,0.000012619635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002685023,0.0003562837,0.00026611306,0.0005595757,0.00026919617,0.00036237945,0.00026993148,0.0003953661,0.002396749],"category_scores_gemma":[0.00014307312,0.00012271518,0.00013830326,0.0003655717,0.0002234969,0.00034902227,0.00026533628,0.0006465856,0.00070474035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044202073,0.0010887219,0.0020098232,0.0013144679,0.0000895864,0.0020176817,0.00017093992,0.0014509953,0.59107107,0.009792037,0.009246686,0.37732783],"study_design_scores_gemma":[0.0018132052,0.008110269,0.0063495734,0.00016319405,0.00037380686,0.004522352,0.00017062595,0.0017158806,0.67131776,0.0030497536,0.30236873,0.000044909364],"about_ca_topic_score_codex":0.0005684984,"about_ca_topic_score_gemma":0.0012495136,"teacher_disagreement_score":0.002396749,"about_ca_system_score_codex":0.0003248354,"about_ca_system_score_gemma":0.00042674167,"threshold_uncertainty_score":0.008017957},"labels":[],"label_agreement":null},{"id":"W1986001121","doi":"10.1007/s10637-012-9899-2","title":"Clinical trial design in biosimilar drug development","year":2012,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Biosimilar; Clinical trial; Drug development; Immunogenicity; Medicine; Drug; Risk analysis (engineering); Pharmacology; Intensive care medicine; Drug approval; Immune system; Immunology; Internal medicine","score_opus":0.2911499705476818,"score_gpt":0.4276049626942675,"score_spread":0.13645499214658569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986001121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001732148,0.99432015,0.0016126913,0.0015394426,0.00075935555,0.00006441405,0.000029517634,0.0000136765875,0.0014875197],"genre_scores_gemma":[0.0060847756,0.9797968,0.0046361727,0.004938341,0.003066033,0.00027935405,0.00011402688,0.000016020113,0.0010683788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931584,0.004299282,0.00069989654,0.00052448,0.0011616101,0.00015635781],"domain_scores_gemma":[0.9543002,0.039067287,0.0031930683,0.0006067752,0.0020907766,0.00074181496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020420033,0.0012787514,0.0039260318,0.002243788,0.0003400265,0.002487805,0.0023971186,0.0033431754,0.007499251],"category_scores_gemma":[0.027480057,0.00057727133,0.0012220971,0.0021557608,0.0024682789,0.0019857055,0.0013188632,0.0043623615,0.001706759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006781363,0.00016357446,0.0002537749,0.021151304,0.00021105538,0.00016790543,0.000053143962,0.00058286206,0.0005661142,0.008367336,0.025214463,0.9425903],"study_design_scores_gemma":[0.002034472,0.0016960354,0.002188242,0.037468392,0.0013215471,0.0020933656,0.00011655196,0.0012726496,0.001588835,0.02971198,0.92042863,0.00007944281],"about_ca_topic_score_codex":0.00055459037,"about_ca_topic_score_gemma":0.0011619261,"teacher_disagreement_score":0.97958,"about_ca_system_score_codex":0.0018982178,"about_ca_system_score_gemma":0.00413442,"threshold_uncertainty_score":0.10799271},"labels":[],"label_agreement":null},{"id":"W1987291688","doi":"10.1007/s10637-010-9431-5","title":"Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; Cancer Research UK","keywords":"Carbamate; Potency; Chemistry; Epidermal growth factor; Biochemistry; DNA; Intracellular; Molecular biology; Stereochemistry; In vitro; Biology; Receptor","score_opus":0.008599591222095335,"score_gpt":0.21366069975280813,"score_spread":0.2050611085307128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987291688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774724,0.00042724522,0.0009342476,0.00002685497,0.00000776203,0.000016944019,0.00014186985,0.00001597551,0.00068180973],"genre_scores_gemma":[0.99805826,0.0001793052,0.00065152696,0.000012897336,0.0000040976724,0.000012180596,0.00020337504,0.000004657263,0.000873813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998865,0.000018391976,0.000008363223,0.000017714401,0.000047700065,0.000021333317],"domain_scores_gemma":[0.99986887,0.000052406736,0.000030002926,0.000011427862,0.000019225747,0.000018084755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018427045,0.0001601483,0.00013071831,0.0001328386,0.000066192064,0.00014079096,0.0001250206,0.00023439559,0.0010125055],"category_scores_gemma":[0.00027451696,0.0000727631,0.00012266815,0.0001237463,0.00012333081,0.00013401521,0.000051575185,0.0002406991,0.00018912916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008294941,0.000021883112,0.00011884856,0.000007677088,0.0000020657226,0.000011973211,0.0000067563474,0.000057419584,0.9989165,0.000018641837,0.000014752505,0.0007404455],"study_design_scores_gemma":[0.000008959435,0.00037932492,0.0009688679,5.263292e-7,0.0000040127047,0.00003987658,0.0000031024429,0.00060339394,0.9977627,0.000004249058,0.00022364521,0.0000014034187],"about_ca_topic_score_codex":0.00032668488,"about_ca_topic_score_gemma":0.00040907657,"teacher_disagreement_score":0.0010125055,"about_ca_system_score_codex":0.00012587961,"about_ca_system_score_gemma":0.00007530341,"threshold_uncertainty_score":0.0033871531},"labels":[],"label_agreement":null},{"id":"W1987338076","doi":"10.1007/s10637-012-9901-z","title":"Characterization of a membrane-active anti-tumor agent, UA8967","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"National Cancer Institute; National Institutes of Health; University of Arizona Cancer Center","keywords":"Medicine","score_opus":0.02169782672767152,"score_gpt":0.23911225117782303,"score_spread":0.21741442445015152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987338076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870618,0.0023024704,0.0059664007,0.00006011318,0.000019997646,0.000074743024,0.00028628306,0.00005550882,0.004172562],"genre_scores_gemma":[0.9912322,0.00087598513,0.0037160784,0.000034954093,0.0000049959935,0.000026484415,0.00042445707,0.000030107207,0.0036546732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999199,0.000012442913,0.0000045680636,0.000012471615,0.000034797282,0.000015858219],"domain_scores_gemma":[0.99995387,0.000013152275,0.000009200235,0.0000041041008,0.000011943837,0.000007832085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113976756,0.00016349276,0.0001571423,0.00021801122,0.00013271174,0.00017054155,0.00015569691,0.00024050845,0.0013461064],"category_scores_gemma":[0.00017340355,0.00010699474,0.00012930552,0.00014397706,0.00010781223,0.00018468611,0.00008880858,0.00021520494,0.00053465465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005761761,0.000024186415,0.000086180735,0.000024117682,0.0000031546094,0.000034085544,0.000018986415,0.00006821509,0.99709487,0.00006842384,0.000040392293,0.002479682],"study_design_scores_gemma":[0.000004152889,0.00020807692,0.00080191967,0.0000027339768,0.000006140957,0.00008154682,0.000010949819,0.00052469614,0.9966395,0.000009014655,0.0017091873,0.0000020612358],"about_ca_topic_score_codex":0.0008089022,"about_ca_topic_score_gemma":0.0007631828,"teacher_disagreement_score":0.0013461064,"about_ca_system_score_codex":0.00011632028,"about_ca_system_score_gemma":0.00017206336,"threshold_uncertainty_score":0.0045031905},"labels":[],"label_agreement":null},{"id":"W1988476175","doi":"10.1007/s10637-014-0113-6","title":"Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Posterior reversible encephalopathy syndrome; Sunitinib; Bevacizumab; Colorectal cancer; Peripheral edema; Pathology; Adverse effect; Magnetic resonance imaging; Radiology; Internal medicine; Cancer; Chemotherapy","score_opus":0.024869257835693874,"score_gpt":0.26272831302886096,"score_spread":0.23785905519316708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988476175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606645,0.00701992,0.0030049793,0.008149496,0.00050163793,0.00026526942,0.0005208139,0.00032486397,0.019548493],"genre_scores_gemma":[0.9954384,0.0012862268,0.00057457905,0.0012267667,0.00041898244,0.000016946924,0.00013406701,0.000018540875,0.0008854975],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996363,0.000051302846,0.000052081094,0.000080184254,0.00006369672,0.000116408],"domain_scores_gemma":[0.9986651,0.00046481422,0.00027460812,0.000089955174,0.00009053058,0.0004150494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002967103,0.001675443,0.0012412813,0.0015597942,0.0018811828,0.0009982269,0.0012753002,0.003736819,0.0019799466],"category_scores_gemma":[0.0029479295,0.00077066506,0.0014853234,0.0011687301,0.0012438353,0.001212201,0.0007299143,0.0036065318,0.00056567317],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012523109,0.00002270365,0.0039848606,0.00002789198,0.0000141573755,0.9943046,0.000042838135,0.00006468822,0.0005194048,0.0000788786,0.00014980581,0.0006649895],"study_design_scores_gemma":[0.000060478644,0.00022578763,0.009820877,0.000017924536,0.0000808749,0.98761046,0.000074591546,0.0005948812,0.0007567524,0.00018841423,0.00055204274,0.000016984226],"about_ca_topic_score_codex":0.004978746,"about_ca_topic_score_gemma":0.006323101,"teacher_disagreement_score":0.004978746,"about_ca_system_score_codex":0.0020057915,"about_ca_system_score_gemma":0.0013921851,"threshold_uncertainty_score":0.01455307},"labels":[],"label_agreement":null},{"id":"W1988711151","doi":"10.1007/s10637-015-0245-3","title":"Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Pharmacokinetics; Cmax; Feeding tube; Tyrosine-kinase inhibitor; Pharmacology; Internal medicine; Oncology; Gastroenterology; Cancer; Surgery","score_opus":0.01691844029429995,"score_gpt":0.28355555763398604,"score_spread":0.2666371173396861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988711151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983499,0.0007146007,0.00012207995,0.000068710324,0.000010533321,0.000017845667,0.00012705752,0.000009669543,0.00057961704],"genre_scores_gemma":[0.9991922,0.00024245113,0.00010074505,0.00007658784,0.000014688872,0.000010536751,0.00015737211,0.0000034331422,0.00020197942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977916,0.000056541787,0.000015711841,0.000051773262,0.000060124163,0.00003668715],"domain_scores_gemma":[0.9994917,0.00012003807,0.00021025047,0.000019532445,0.00005152306,0.00010698279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033356738,0.00019387974,0.00051174493,0.00025742874,0.00022004715,0.0007130957,0.00019377995,0.00037281963,0.0007423271],"category_scores_gemma":[0.0017143323,0.00017504784,0.0004009733,0.00039157993,0.00021934813,0.00053461565,0.00018339,0.0007974758,0.00013445475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04136392,0.0013608078,0.8639056,0.00018129151,0.000876442,0.0013471927,0.00038264695,0.0016919619,0.022966295,0.00020908438,0.0010991981,0.06461555],"study_design_scores_gemma":[0.0009312764,0.014677048,0.9663647,0.000031291536,0.0007943721,0.0020570692,0.00038063206,0.00578278,0.0061256774,0.00019611449,0.0026196737,0.000039419847],"about_ca_topic_score_codex":0.0026672196,"about_ca_topic_score_gemma":0.0035528855,"teacher_disagreement_score":0.0026672196,"about_ca_system_score_codex":0.0008451214,"about_ca_system_score_gemma":0.0005649361,"threshold_uncertainty_score":0.006131828},"labels":[],"label_agreement":null},{"id":"W1989987919","doi":"10.1007/s10637-006-5938-1","title":"Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pyrogenesis (Canada); Queen's University; London Health Sciences Centre; Hôpital Notre-Dame; Princess Margaret Cancer Centre; University Health Network; Queen Elizabeth II Health Sciences Centre","funders":"National Cancer Institute; Medical Research Council; University Health Network","keywords":"Clinical trial; Medicine; Renal cell carcinoma; Cancer; Phases of clinical research; Drug; Oncology; Cancer drugs; Internal medicine; Pharmacology","score_opus":0.03687109437820722,"score_gpt":0.32023486744838175,"score_spread":0.2833637730701745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989987919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904612,0.0028882187,0.00048192168,0.0012119011,0.00024823792,0.0014030152,0.0011753723,0.000093200964,0.0020370244],"genre_scores_gemma":[0.9864429,0.0033345285,0.0015435631,0.0010815605,0.00023827484,0.0015336272,0.0020214901,0.000045649966,0.0037583527],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99956816,0.00020011111,0.000014944946,0.00006471273,0.000040861167,0.00011118598],"domain_scores_gemma":[0.9991474,0.00016950628,0.00012658477,0.00005809589,0.0000482343,0.00045007034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013322663,0.0018169691,0.0030205601,0.00063152023,0.00062484597,0.0010896174,0.0013060706,0.0017690884,0.0032572327],"category_scores_gemma":[0.0010948965,0.0006367384,0.0014934685,0.0007117324,0.0011476185,0.00083144184,0.00035734737,0.0036234842,0.0006589172],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78984463,0.041825254,0.0076830382,0.00067955704,0.0014070078,0.0003779665,0.00036916003,0.0048710634,0.035112895,0.00063071214,0.0072279857,0.10997083],"study_design_scores_gemma":[0.67266107,0.30760252,0.010687843,0.00003316238,0.0004255932,0.0002170695,0.00010199236,0.0017670512,0.003509206,0.0003032532,0.0026479315,0.000043374625],"about_ca_topic_score_codex":0.00682263,"about_ca_topic_score_gemma":0.018498456,"teacher_disagreement_score":0.00682263,"about_ca_system_score_codex":0.0017821031,"about_ca_system_score_gemma":0.0027373924,"threshold_uncertainty_score":0.013565779},"labels":[],"label_agreement":null},{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","score_opus":0.04450204486330388,"score_gpt":0.35368284050258053,"score_spread":0.30918079563927664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991064094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902872,0.0021864932,0.0004868018,0.0016378998,0.00021906037,0.001966073,0.0015347266,0.0000851699,0.0015964721],"genre_scores_gemma":[0.982081,0.0020807402,0.0030254417,0.0019847539,0.0003998995,0.002794288,0.004107604,0.0000601386,0.0034660918],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992229,0.00047631576,0.000019604648,0.00010268879,0.000056844907,0.00012161576],"domain_scores_gemma":[0.9982173,0.00034381112,0.00020337233,0.00014029833,0.000084412575,0.0010108034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028336707,0.0015708003,0.0026939875,0.00049303693,0.0006540555,0.0010912172,0.0008866705,0.0013962561,0.0043300255],"category_scores_gemma":[0.0021078626,0.0005098826,0.0016442343,0.00040618106,0.0010105136,0.0009995264,0.00067156384,0.0040880814,0.0007262782],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7696248,0.038794443,0.007842019,0.0008819663,0.002016834,0.0003782269,0.00033958064,0.0033541608,0.019117737,0.00061504566,0.013020002,0.14401515],"study_design_scores_gemma":[0.85051966,0.13538787,0.008335232,0.000023602222,0.00037854057,0.0002796304,0.00006251864,0.0011541792,0.0012603209,0.00034485172,0.0022240428,0.000029560966],"about_ca_topic_score_codex":0.0013021487,"about_ca_topic_score_gemma":0.0027016387,"teacher_disagreement_score":0.0043300255,"about_ca_system_score_codex":0.0010327095,"about_ca_system_score_gemma":0.0021962905,"threshold_uncertainty_score":0.014986038},"labels":[],"label_agreement":null},{"id":"W1991265164","doi":"10.1007/s10637-010-9456-9","title":"A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; St. Joseph’s Healthcare Hamilton; St Joseph's Health Care; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Causality (physics); Clinical trial; Attribution; Thematic analysis; Objectivity (philosophy); Medicine; Psychology; Qualitative research; Medical education; Internal medicine; Social psychology; Epistemology","score_opus":0.8588413857350846,"score_gpt":0.7504655684450426,"score_spread":0.10837581729004198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991265164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9211769,0.002391244,0.03846183,0.018741092,0.00043132564,0.005744631,0.0009107196,0.00009615551,0.012046121],"genre_scores_gemma":[0.98170346,0.0009108198,0.009150526,0.0027780517,0.00007506407,0.004059435,0.0001646058,0.000037890826,0.0011201449],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.7077878,0.26685348,0.00896287,0.0034398993,0.008529017,0.004426866],"domain_scores_gemma":[0.120260604,0.82202613,0.028047195,0.008166765,0.01595724,0.00554215],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2182499,0.000649208,0.0013441074,0.0048929523,0.01409805,0.0053804833,0.0035363485,0.003395886,0.00549747],"category_scores_gemma":[0.54217345,0.0011453365,0.0011572135,0.0040800385,0.010054509,0.0083463015,0.009375263,0.006206758,0.00039661376],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090138626,0.0004935867,0.020980952,0.0018652424,0.00011366165,0.0005230593,0.9418625,0.00031009794,0.00026908086,0.007774564,0.0018728551,0.023033075],"study_design_scores_gemma":[0.00046899635,0.000819312,0.01186699,0.002673937,0.00014748474,0.0004599385,0.95551354,0.001410345,0.0007717819,0.011361804,0.014374417,0.00013135189],"about_ca_topic_score_codex":0.0105793495,"about_ca_topic_score_gemma":0.011184352,"teacher_disagreement_score":0.7817501,"about_ca_system_score_codex":0.019697078,"about_ca_system_score_gemma":0.03316499,"threshold_uncertainty_score":0.96403706},"labels":[],"label_agreement":null},{"id":"W1991823030","doi":"10.1007/s10637-007-9066-3","title":"A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Pancreatic carcinoma; Medicine; Internal medicine; Phases of clinical research; Oncology; Deoxycytidine; Chemotherapy; Pancreatic cancer; Cancer","score_opus":0.025480800549538923,"score_gpt":0.338689633946706,"score_spread":0.31320883339716704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991823030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912049,0.0026932962,0.0004509396,0.00086994027,0.00021960952,0.0014444551,0.00075377006,0.00007456341,0.0022884274],"genre_scores_gemma":[0.98381454,0.0035281223,0.0016142188,0.0016490858,0.00029591104,0.0019236836,0.0027029274,0.00005104682,0.0044203787],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995353,0.00026906753,0.000015767984,0.000057926714,0.000033402765,0.000088643465],"domain_scores_gemma":[0.9988808,0.00024996544,0.00016356015,0.00008916627,0.000045872035,0.00057061104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018906388,0.0016349085,0.0017685243,0.0005353982,0.00045608456,0.00092996116,0.0011998735,0.0017584455,0.00411834],"category_scores_gemma":[0.0011409541,0.00069616496,0.0014418069,0.0005692803,0.0010816364,0.00087203144,0.00042426615,0.0039559184,0.00079652306],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82563365,0.05340433,0.0041019665,0.00063616555,0.0012795073,0.00047407145,0.0003251249,0.0025259191,0.028646275,0.00049907144,0.006496603,0.07597728],"study_design_scores_gemma":[0.79195803,0.19695747,0.0048091765,0.000022464134,0.00029861994,0.00028771348,0.000062331914,0.00077289063,0.0023234652,0.00018362157,0.0023008166,0.000023388071],"about_ca_topic_score_codex":0.0017396468,"about_ca_topic_score_gemma":0.003355467,"teacher_disagreement_score":0.00411834,"about_ca_system_score_codex":0.000875675,"about_ca_system_score_gemma":0.0014221626,"threshold_uncertainty_score":0.013777256},"labels":[],"label_agreement":null},{"id":"W1995930791","doi":"10.1007/s10637-014-0171-9","title":"A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Norris Cotton Cancer Center; Bristol-Myers Squibb","keywords":"Medicine; Pharmacokinetics; Mucositis; Neutropenia; Pharmacology; Toxicity; Epothilone; Folate receptor; Cancer; Dosing; Internal medicine; Oncology; Cancer cell; Chemistry","score_opus":0.016924110530593332,"score_gpt":0.3168864988068077,"score_spread":0.29996238827621435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995930791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306846,0.0012414934,0.0016602881,0.00027784143,0.000052753378,0.00104143,0.0011421761,0.000121272446,0.0013941803],"genre_scores_gemma":[0.9917663,0.0014297423,0.001872041,0.00046548108,0.0000802476,0.0006320296,0.0015659676,0.00006605162,0.002122061],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996511,0.00015085557,0.000012644021,0.000079566365,0.000054145617,0.00005176164],"domain_scores_gemma":[0.99959964,0.000056506786,0.000092919305,0.00005640874,0.000032434047,0.00016209263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085245335,0.00095959747,0.001267621,0.00038524703,0.0004696245,0.0007699017,0.00051631976,0.00093247916,0.0027791217],"category_scores_gemma":[0.00081403105,0.00052967056,0.000996107,0.0003814057,0.00077035744,0.00066339,0.00021569035,0.00216265,0.0006120011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47791424,0.055773064,0.008202609,0.00059061113,0.0019939323,0.00059124484,0.00048646695,0.00558628,0.30485502,0.0008167805,0.006799426,0.1363903],"study_design_scores_gemma":[0.20110443,0.6941885,0.035732724,0.00005240523,0.0018880832,0.0013186045,0.00016504568,0.0055718566,0.046980865,0.0006527798,0.01224267,0.00010209671],"about_ca_topic_score_codex":0.0021071837,"about_ca_topic_score_gemma":0.0035050174,"teacher_disagreement_score":0.0027791217,"about_ca_system_score_codex":0.00096146384,"about_ca_system_score_gemma":0.0015141215,"threshold_uncertainty_score":0.0092971325},"labels":[],"label_agreement":null},{"id":"W1996453449","doi":"10.1007/s10637-010-9554-8","title":"Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Topoisomerase; K562 cells; Apoptosis; Molecular biology; Biology; Etoposide; DNA fragmentation; Leukemia; DNA; Biochemistry; Programmed cell death; Immunology; Genetics","score_opus":0.010398452731451124,"score_gpt":0.24502683942644496,"score_spread":0.23462838669499383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996453449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9496691,0.025743801,0.0043530003,0.00035814164,0.00015397927,0.00018397158,0.0011652539,0.00046746747,0.017905144],"genre_scores_gemma":[0.9837135,0.010695489,0.0015932585,0.00012247683,0.00003313613,0.000039416533,0.0009059769,0.00002293159,0.0028737667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996066,0.0000080053505,0.0000036600934,0.000008740991,0.000008082653,0.000010831453],"domain_scores_gemma":[0.999977,0.0000029959633,0.0000064033643,0.0000029364865,0.0000027550245,0.0000078443245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007430348,0.00034979923,0.0002463021,0.0003007729,0.00011313562,0.00014982712,0.0001954692,0.00012783034,0.0008688606],"category_scores_gemma":[0.00006742287,0.00009043203,0.00008906105,0.00014891358,0.00013430201,0.00011179414,0.00012066058,0.00025000935,0.000287721],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060783396,0.000061607665,0.00032771393,0.0001525795,0.000017027423,0.00015719862,0.000021143935,0.00029341102,0.9757391,0.00045114354,0.00052408985,0.021647131],"study_design_scores_gemma":[0.00016423601,0.0012216915,0.0033319814,0.00001118921,0.00003970636,0.00047852282,0.000013170891,0.00048992556,0.9764772,0.000058891204,0.0177037,0.000009842364],"about_ca_topic_score_codex":0.0009128594,"about_ca_topic_score_gemma":0.0014414473,"teacher_disagreement_score":0.0009128594,"about_ca_system_score_codex":0.00029979093,"about_ca_system_score_gemma":0.00016938637,"threshold_uncertainty_score":0.0029066205},"labels":[],"label_agreement":null},{"id":"W1996463727","doi":"10.1007/s10637-012-9832-8","title":"Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; BC Cancer Agency; University of British Columbia","funders":"University of British Columbia; British Columbia Innovation Council","keywords":"Topotecan; Pharmacokinetics; Pharmacology; Liposome; Camptothecin; In vivo; Ovarian cancer; Irinotecan; Bioavailability; Drug; Chemistry; Medicine; Doxorubicin; Pharmacodynamics; Chemotherapy; Cancer; Internal medicine; Biochemistry; Biology","score_opus":0.046230400316462986,"score_gpt":0.32016301409947817,"score_spread":0.2739326137830152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996463727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94217837,0.01092577,0.026315037,0.0014626982,0.00044695454,0.00056166615,0.00070440455,0.00045486933,0.016950397],"genre_scores_gemma":[0.98434794,0.0026038382,0.00672366,0.0002342279,0.00003936131,0.00007914308,0.00030947346,0.000037730286,0.0056247516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999174,0.000011539854,0.0000046521645,0.000017738615,0.000029954092,0.000018810244],"domain_scores_gemma":[0.9999609,0.000007956944,0.0000062996482,0.000002406358,0.000007092619,0.000015399537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015523497,0.00022074248,0.00015721394,0.00026692107,0.00018939046,0.0003080795,0.00023293498,0.0005431398,0.0016482609],"category_scores_gemma":[0.00017369346,0.000099764075,0.00013450425,0.00014354975,0.00018069216,0.00028567913,0.00021402484,0.0004931737,0.00034146218],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008688694,0.00016579666,0.00012991072,0.00019719264,0.00002535506,0.0001855146,0.000021188847,0.0005543177,0.9636009,0.0005957451,0.0013425465,0.032312673],"study_design_scores_gemma":[0.0002718339,0.00090900995,0.0014206166,0.0000151497825,0.000059524195,0.0007402006,0.000017550907,0.0024587559,0.9811581,0.00009401606,0.01283482,0.000020465735],"about_ca_topic_score_codex":0.0019367499,"about_ca_topic_score_gemma":0.0017592233,"teacher_disagreement_score":0.0019367499,"about_ca_system_score_codex":0.00042668614,"about_ca_system_score_gemma":0.0007297116,"threshold_uncertainty_score":0.005513966},"labels":[],"label_agreement":null},{"id":"W1997853067","doi":"10.1007/s10637-007-9097-9","title":"A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Queen's University; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Melanoma; Neutropenia; Adverse effect; Toxicity; Clinical trial; Internal medicine; Phases of clinical research; Cancer; Pharmacokinetics; Chemotherapy; Surgery; Oncology; Gastroenterology; Cancer research","score_opus":0.08669226906530368,"score_gpt":0.38267614061835153,"score_spread":0.29598387155304784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997853067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97462976,0.0073090913,0.0006814944,0.0024182084,0.0005669715,0.0034389442,0.0038076777,0.0001820801,0.006965789],"genre_scores_gemma":[0.9724955,0.0059337392,0.0017217633,0.0026331309,0.00044256466,0.0026251301,0.0057773525,0.00006185903,0.008309139],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99951494,0.000223639,0.00001381872,0.000067499874,0.00004282479,0.00013738086],"domain_scores_gemma":[0.9991818,0.00008904144,0.00011622055,0.000052231066,0.00005251141,0.00050816336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017495896,0.0022205485,0.0027025717,0.00043340627,0.0006514749,0.0012357815,0.0010927052,0.0017658166,0.005170634],"category_scores_gemma":[0.0009803823,0.00063229504,0.0019291083,0.0005635969,0.0011142663,0.00084393524,0.00035327554,0.0043679094,0.0013598845],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8258075,0.02431648,0.005841695,0.0012278488,0.0024309459,0.0003746024,0.00026693105,0.0028091322,0.018202595,0.00056592707,0.016437693,0.10171862],"study_design_scores_gemma":[0.83637977,0.1476073,0.00854144,0.0000514484,0.00063588313,0.0002597553,0.000067758185,0.0009842357,0.0010137741,0.00025435784,0.004167975,0.00003624082],"about_ca_topic_score_codex":0.008539056,"about_ca_topic_score_gemma":0.027073314,"teacher_disagreement_score":0.9914609,"about_ca_system_score_codex":0.0018986904,"about_ca_system_score_gemma":0.0030262894,"threshold_uncertainty_score":0.017297506},"labels":[],"label_agreement":null},{"id":"W2000023204","doi":"10.1007/s10637-010-9570-8","title":"A phase I study of temsirolimus and metformin in advanced solid tumours","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Temsirolimus; Metformin; Medicine; Internal medicine; Maximum tolerated dose; Toxicity; Cancer; Limiting; Gastroenterology; Discovery and development of mTOR inhibitors","score_opus":0.012043021149741137,"score_gpt":0.30803073724029995,"score_spread":0.2959877160905588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000023204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904417,0.0035579044,0.0006423311,0.00064462685,0.00025345484,0.0017668944,0.0009600356,0.00007284367,0.0016603161],"genre_scores_gemma":[0.9823278,0.004545188,0.0026312068,0.0009162131,0.00025536027,0.0027838282,0.0024971145,0.000059754966,0.003983505],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995022,0.0002132948,0.000023784442,0.00008626029,0.000048888454,0.00012561108],"domain_scores_gemma":[0.99941254,0.000088055036,0.000078706296,0.00006723086,0.000032444434,0.0003210716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017676878,0.0013935799,0.003019271,0.0008107511,0.0006202308,0.00112226,0.0011574466,0.0015921345,0.0031586918],"category_scores_gemma":[0.0006609345,0.00079674355,0.0018843828,0.00074693596,0.00116067,0.0012105221,0.00043403308,0.0035474605,0.00067882997],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6860719,0.095463336,0.0047280206,0.001106031,0.0024991534,0.0003799312,0.00038233527,0.005567672,0.094691694,0.0010098474,0.00521369,0.1028864],"study_design_scores_gemma":[0.48053092,0.49772558,0.005867115,0.000033268992,0.0007449933,0.00031030408,0.00009531022,0.0010955016,0.0087164985,0.0002802798,0.0045484314,0.000051744206],"about_ca_topic_score_codex":0.0015752871,"about_ca_topic_score_gemma":0.0042900774,"teacher_disagreement_score":0.0031586918,"about_ca_system_score_codex":0.0010681165,"about_ca_system_score_gemma":0.002152994,"threshold_uncertainty_score":0.01056689},"labels":[],"label_agreement":null},{"id":"W2000123112","doi":"10.1023/b:drug.0000026258.02846.1c","title":"Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"National Cancer Institute; McGill University","keywords":"Nausea; Medicine; Gastroenterology; Internal medicine; Vomiting; Diarrhea; Melanoma; Progressive disease; Anorexia; Toxicity; Regimen; Phases of clinical research; Surgery; Chemotherapy; Cancer research","score_opus":0.021077545427093294,"score_gpt":0.2726131858557945,"score_spread":0.25153564042870125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000123112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131244,0.003414681,0.00047396348,0.00068380457,0.00023075708,0.00091064797,0.0006205802,0.00007181702,0.0022812635],"genre_scores_gemma":[0.9884322,0.0031430451,0.00082257675,0.0005568094,0.00020184636,0.0010595034,0.001235714,0.000027116504,0.0045210924],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976486,0.00009641721,0.0000071964173,0.000032153584,0.000019451445,0.000079964615],"domain_scores_gemma":[0.9995629,0.00008820092,0.000052606385,0.000034921104,0.000020486501,0.00024091013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009792295,0.0012901317,0.0018317263,0.0004425451,0.0004952002,0.00076721126,0.00081089785,0.0011282499,0.002803592],"category_scores_gemma":[0.0007221702,0.0004698168,0.0009505878,0.0003532533,0.0009513634,0.0007432466,0.00023667135,0.0027637463,0.0005181325],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72720486,0.05093186,0.004622452,0.0010118576,0.0011736153,0.00059143885,0.00043975585,0.0045439834,0.07544234,0.00091304205,0.0064801304,0.12664461],"study_design_scores_gemma":[0.47452325,0.4989129,0.011687991,0.000060815128,0.0004068326,0.0004321541,0.0001515262,0.0020079294,0.007267707,0.0004853298,0.0040230653,0.000040459752],"about_ca_topic_score_codex":0.0020406311,"about_ca_topic_score_gemma":0.0049794125,"teacher_disagreement_score":0.002803592,"about_ca_system_score_codex":0.0008702683,"about_ca_system_score_gemma":0.0009450795,"threshold_uncertainty_score":0.00937897},"labels":[],"label_agreement":null},{"id":"W2000249294","doi":"10.1007/s10637-007-9056-5","title":"Silencing of endo-exonuclease expression sensitizes mouse B16F10 melanoma cells to DNA damaging agents","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Paraza Pharma (Canada); McGill University; Montreal General Hospital","funders":"National Cancer Institute; Cancer Research Society","keywords":"Exonuclease; Molecular biology; Transfection; Nuclease; Chemistry; Gene silencing; DNA damage; DNA; DNA repair; Cisplatin; Biology; Cancer research; Biochemistry; Gene; DNA polymerase; Genetics","score_opus":0.011602185164888488,"score_gpt":0.2417345264299355,"score_spread":0.23013234126504703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000249294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931317,0.001449755,0.0030967006,0.00015517828,0.000049849852,0.00004429169,0.00023966297,0.0001527595,0.0016801294],"genre_scores_gemma":[0.9925189,0.0010352674,0.0016307029,0.00006055526,0.00000966411,0.000033302706,0.0002549744,0.000036312013,0.0044203578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981636,0.0000270315,0.000019744934,0.000036995138,0.000051771432,0.000048090937],"domain_scores_gemma":[0.9998424,0.000041926156,0.000045172616,0.000028423847,0.000014653043,0.000027430577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001902656,0.0004726861,0.0003072359,0.0003042528,0.000121623736,0.00033474708,0.00023829757,0.00041218605,0.0014214795],"category_scores_gemma":[0.00013013167,0.00029201023,0.0002641026,0.00015032454,0.00027207832,0.0002038106,0.00014888291,0.00072126405,0.00044773796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023068635,0.00000990775,0.000036462705,0.00000780493,0.0000018344281,0.000014681968,0.0000035359626,0.000018096318,0.99961734,0.000031413638,0.000009997635,0.00022579651],"study_design_scores_gemma":[0.000005620854,0.00010308272,0.0007239891,0.0000017915336,0.0000049024425,0.00006113568,0.0000072950033,0.00018202896,0.9983845,0.00001388418,0.0005106689,0.0000011419654],"about_ca_topic_score_codex":0.0008491211,"about_ca_topic_score_gemma":0.0017663344,"teacher_disagreement_score":0.0014214795,"about_ca_system_score_codex":0.0002938064,"about_ca_system_score_gemma":0.00017989913,"threshold_uncertainty_score":0.004755318},"labels":[],"label_agreement":null},{"id":"W2004766935","doi":"10.1007/s10637-010-9391-9","title":"LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Calgary Laboratory Services; University of Calgary","keywords":"Western blot; Molecular biology; Cell growth; Growth inhibition; Cell culture; Chemistry; Inhibitory postsynaptic potential; Flow cytometry; Trypan blue; Cell; Biology; Biochemistry; Endocrinology","score_opus":0.013771277549352775,"score_gpt":0.2527174040191496,"score_spread":0.23894612646979682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004766935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822827,0.008682608,0.004417505,0.00023388921,0.00006302203,0.00010448418,0.0006308502,0.00016392318,0.0034210137],"genre_scores_gemma":[0.9861221,0.0048808125,0.004025546,0.000069239955,0.000016674136,0.000049193673,0.0010745773,0.000021446082,0.003740488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999541,0.000007759873,0.0000046502328,0.000007514001,0.000012432759,0.000013516576],"domain_scores_gemma":[0.9999682,0.000005903985,0.000007765505,0.0000035610929,0.0000046106434,0.0000099261915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010624594,0.0002720773,0.00037332,0.0002881973,0.000149598,0.00021323819,0.00024695275,0.00018731116,0.00082064106],"category_scores_gemma":[0.00007108262,0.00011770687,0.000175132,0.00021575596,0.00018329911,0.00019761678,0.00011786894,0.0004086956,0.00026069523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007591186,0.00008015085,0.00046156888,0.00011347676,0.000017848117,0.0001968328,0.00001678826,0.00023087196,0.9840726,0.0001309487,0.0002491802,0.0136706],"study_design_scores_gemma":[0.00011781487,0.001077121,0.002672548,0.0000041268636,0.000030236622,0.0009190086,0.00001691801,0.00057162705,0.9887666,0.00002299467,0.005794322,0.0000065274826],"about_ca_topic_score_codex":0.00073702424,"about_ca_topic_score_gemma":0.002186603,"teacher_disagreement_score":0.00082064106,"about_ca_system_score_codex":0.00032559532,"about_ca_system_score_gemma":0.00027617265,"threshold_uncertainty_score":0.0027453303},"labels":[],"label_agreement":null},{"id":"W2006721545","doi":"10.1007/s10637-005-1439-x","title":"A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pharmacokinetics; Paclitaxel; Medicine; Neutropenia; Pharmacology; Toxicity; P-glycoprotein; Chemotherapy; Febrile neutropenia; Internal medicine; Multiple drug resistance; Antibiotics; Chemistry","score_opus":0.008409667718402071,"score_gpt":0.2599263105277969,"score_spread":0.25151664280939484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006721545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995783,0.0010255632,0.00049832795,0.0003255513,0.00008950373,0.00050070934,0.0004837331,0.00007754957,0.0012161112],"genre_scores_gemma":[0.9942508,0.0012624082,0.0012356815,0.00034610738,0.00014645651,0.00043277847,0.0009754995,0.00004884079,0.0013013502],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99949384,0.00025334634,0.000019638672,0.0000801963,0.00004749263,0.00010543285],"domain_scores_gemma":[0.9991561,0.00022084822,0.00013316012,0.00009232895,0.000035911824,0.0003616262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010390091,0.0011365224,0.0022915734,0.00053154485,0.0005821826,0.0011050012,0.0007688111,0.0009829988,0.0021731085],"category_scores_gemma":[0.0014798443,0.000788252,0.0014558426,0.0007809842,0.001158558,0.0011590972,0.00026377043,0.0044385875,0.0005159447],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6383714,0.09939995,0.0117959855,0.00052540423,0.0014969284,0.00083242595,0.00068281544,0.005796608,0.089699,0.00071773364,0.0058878157,0.14479399],"study_design_scores_gemma":[0.3194932,0.63478506,0.02425885,0.000028121867,0.00079772074,0.0010148378,0.00014572308,0.0044172746,0.010499336,0.00031902848,0.0041577364,0.00008315143],"about_ca_topic_score_codex":0.0018188709,"about_ca_topic_score_gemma":0.003820023,"teacher_disagreement_score":0.0022915734,"about_ca_system_score_codex":0.0011319654,"about_ca_system_score_gemma":0.0019073025,"threshold_uncertainty_score":0.008213043},"labels":[],"label_agreement":null},{"id":"W2007480962","doi":"10.1007/s10637-013-9974-3","title":"Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research; University of Texas at El Paso; Canada Research Chairs; University Health Network","keywords":"Docetaxel; Cyclophosphamide; Medicine; Chemotherapy; Pharmacology; Oncology; Drug resistance; Bevacizumab; Nitrogen mustard; Internal medicine; Biology","score_opus":0.014270792231690093,"score_gpt":0.29993228244452186,"score_spread":0.28566149021283177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007480962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99597067,0.00091635966,0.0009464512,0.000132945,0.000052342297,0.00017989501,0.00044779282,0.000085807675,0.0012677007],"genre_scores_gemma":[0.99595094,0.0005177097,0.0007097655,0.000047495054,0.00002859227,0.00015918692,0.0006176923,0.000032076958,0.0019364218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933547,0.0001960425,0.000052850744,0.00008757025,0.00011343548,0.00021459471],"domain_scores_gemma":[0.9993948,0.00017350841,0.00012561842,0.00009743908,0.000075051474,0.00013362821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008218114,0.00057289784,0.0009192085,0.0007201974,0.0002656299,0.0004596909,0.0006027194,0.0005085446,0.0029401206],"category_scores_gemma":[0.0006996745,0.00030096076,0.0005102713,0.00043633732,0.00045152404,0.00059275713,0.00022682115,0.0019087855,0.0005186818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00891532,0.011519536,0.0022327476,0.00016622955,0.000109507935,0.00016531655,0.00015864745,0.0018784843,0.9560029,0.00079004833,0.0011243242,0.01693691],"study_design_scores_gemma":[0.0011095481,0.11393351,0.014130543,0.000021730963,0.00022409693,0.00084670464,0.00013773216,0.006234635,0.858459,0.00026122018,0.0046061585,0.000035175817],"about_ca_topic_score_codex":0.0009997003,"about_ca_topic_score_gemma":0.00094297435,"teacher_disagreement_score":0.0029401206,"about_ca_system_score_codex":0.0006753503,"about_ca_system_score_gemma":0.00037925836,"threshold_uncertainty_score":0.00983566},"labels":[],"label_agreement":null},{"id":"W2007695631","doi":"10.1007/s10637-013-9990-3","title":"Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"National Institutes of Health; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust; GlaxoSmithKline; Amgen","keywords":"Medicine; Irinotecan; Oxaliplatin; Colorectal cancer; Toxicity; Internal medicine; Gastroenterology; Phases of clinical research; Surgery; Cancer; Progression-free survival; Dexamethasone; Chemotherapy","score_opus":0.01849474570922308,"score_gpt":0.27944620998014535,"score_spread":0.26095146427092225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007695631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98377824,0.01029856,0.00019605143,0.0011412052,0.00017150702,0.00033551722,0.0010835062,0.000063396445,0.0029320484],"genre_scores_gemma":[0.98634166,0.007499316,0.00043517578,0.00094099366,0.00018158091,0.00023900226,0.0019749305,0.000020029818,0.0023673335],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997794,0.00011479196,0.000009194613,0.00003003737,0.000022677334,0.000043911925],"domain_scores_gemma":[0.9994271,0.0001520663,0.00012582046,0.000040300398,0.000025074422,0.00022970064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008360206,0.00082270184,0.0012074503,0.00025719887,0.0001948696,0.0008606115,0.000668993,0.0005787255,0.0027744398],"category_scores_gemma":[0.0009300701,0.00020852909,0.0009309899,0.00040801242,0.0004841794,0.0006601655,0.00022358898,0.0025241433,0.0004644576],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7803997,0.007353323,0.011276181,0.0016577947,0.00313652,0.00033799905,0.00016542057,0.002228694,0.016511481,0.000364264,0.0056847115,0.17088394],"study_design_scores_gemma":[0.7545888,0.18128665,0.048369817,0.00016889552,0.0028501202,0.00064691255,0.0001366261,0.0017017758,0.003501449,0.00042920993,0.006250416,0.00006928695],"about_ca_topic_score_codex":0.0011184323,"about_ca_topic_score_gemma":0.0033856507,"teacher_disagreement_score":0.0027744398,"about_ca_system_score_codex":0.0006513281,"about_ca_system_score_gemma":0.00075142743,"threshold_uncertainty_score":0.0092814565},"labels":[],"label_agreement":null},{"id":"W2011261264","doi":"10.1007/s10637-013-9979-y","title":"Ring-substituted analogs of 3,3′-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and –independent prostate cancer cells","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Synthesis of Indole Derivatives","field":"Chemistry","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; Armand Frappier Museum; Institut National de la Recherche Scientifique","funders":"Canadian Institutes of Health Research","keywords":"LNCaP; Propidium iodide; Apoptosis; Programmed cell death; Cancer research; Prostate cancer; Caspase; Cell growth; Biology; Chemistry; Internal medicine; Molecular biology; Cancer; Biochemistry; Medicine","score_opus":0.015218121862387147,"score_gpt":0.23283804644190056,"score_spread":0.21761992457951343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011261264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98417956,0.0021178424,0.0053553935,0.00011009994,0.00004567031,0.000050107294,0.00024984908,0.00013149646,0.007760056],"genre_scores_gemma":[0.9953252,0.0007425471,0.0017042528,0.000042563046,0.000007316588,0.000024130091,0.00019182538,0.000010472676,0.0019516438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999304,0.000014962814,0.000004948793,0.000011001923,0.000015856085,0.000022746694],"domain_scores_gemma":[0.9999447,0.000012317011,0.000015606194,0.000008221597,0.0000055895744,0.000013522843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012650884,0.00016854182,0.00012612376,0.0001269895,0.000104318126,0.00010240555,0.00029264373,0.00014312743,0.0013945013],"category_scores_gemma":[0.00008387478,0.00010041174,0.00012374925,0.00011968163,0.00011632417,0.0001494349,0.00009269633,0.00038851012,0.00025129458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022111669,0.000043296895,0.00007538198,0.00003735282,0.0000037688794,0.00006127184,0.000019939805,0.00017053622,0.9965713,0.00032013928,0.00007550795,0.0024004402],"study_design_scores_gemma":[0.000033615164,0.0005761485,0.00071347936,0.0000030423773,0.0000059680465,0.00011893868,0.000010409192,0.0006227886,0.9960957,0.00004536712,0.0017720283,0.00000253945],"about_ca_topic_score_codex":0.00026211384,"about_ca_topic_score_gemma":0.00064867735,"teacher_disagreement_score":0.0013945013,"about_ca_system_score_codex":0.00024499264,"about_ca_system_score_gemma":0.00014082265,"threshold_uncertainty_score":0.0046650767},"labels":[],"label_agreement":null},{"id":"W2013709636","doi":"10.1007/s10637-013-0001-5","title":"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Oral health in cancer treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Internal medicine; Pharmacokinetics; Pharmacology; Neutropenia; Rash; Gastroenterology; Oncology; Toxicity","score_opus":0.014508266352405094,"score_gpt":0.29920246697569053,"score_spread":0.28469420062328543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013709636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390984,0.0014014695,0.00051405374,0.00033586175,0.00008434196,0.0019173939,0.0005242583,0.000065306755,0.0012475507],"genre_scores_gemma":[0.99213684,0.0009912978,0.0016942326,0.0005997861,0.0001158329,0.0018023474,0.0014490939,0.000021808197,0.001188878],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99946636,0.00023072795,0.000042464188,0.00009426187,0.000066842695,0.000099407625],"domain_scores_gemma":[0.999313,0.00008724877,0.00012152401,0.00006996409,0.00004226807,0.00036597328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013347097,0.0012676017,0.0022125419,0.00046338516,0.00041625992,0.0008190469,0.00085317454,0.0009827056,0.0029102627],"category_scores_gemma":[0.0006605507,0.0006071945,0.0011588664,0.0004955518,0.00086670165,0.00071700686,0.00038791244,0.002911738,0.001030194],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5706529,0.12127779,0.017761556,0.0009933236,0.0022796406,0.00069098995,0.0005196876,0.0053128465,0.14476666,0.0003538865,0.0048752488,0.1305155],"study_design_scores_gemma":[0.37645078,0.5950996,0.01522719,0.00003163366,0.00046886923,0.00056513026,0.00007970179,0.0015695053,0.0070412564,0.00014230295,0.0032903168,0.000033721804],"about_ca_topic_score_codex":0.0007549436,"about_ca_topic_score_gemma":0.0017891957,"teacher_disagreement_score":0.0029102627,"about_ca_system_score_codex":0.0010268218,"about_ca_system_score_gemma":0.002013037,"threshold_uncertainty_score":0.009735763},"labels":[],"label_agreement":null},{"id":"W2014271351","doi":"10.1007/s10637-006-9021-8","title":"A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peroxisome Proliferator-Activated Receptors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Irinotecan; Medicine; Pharmacology; Pharmacokinetics; Tolerability; Active metabolite; SN-38; Chemotherapy; Oral administration; Internal medicine; Cancer; Adverse effect; Colorectal cancer","score_opus":0.007061497655436181,"score_gpt":0.23943923806344042,"score_spread":0.23237774040800424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014271351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041045,0.0027284743,0.0007033474,0.00078903156,0.00023240209,0.0018326383,0.0009274605,0.0001540798,0.0022221403],"genre_scores_gemma":[0.9867775,0.0035652546,0.001580797,0.00064984604,0.0002451606,0.0019037878,0.0017826222,0.00007621037,0.0034188488],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99930286,0.0003137617,0.000029425542,0.0001220055,0.000052114883,0.00017986144],"domain_scores_gemma":[0.99913627,0.00017601112,0.00010404522,0.00010621213,0.000040975105,0.00043640716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001273975,0.0020502254,0.0050895824,0.000813722,0.0008162129,0.001650843,0.0013120082,0.001875755,0.0039789747],"category_scores_gemma":[0.000994657,0.0011009135,0.002360504,0.0008507801,0.0018749072,0.0014727435,0.00054352713,0.0060010892,0.0013155413],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75272435,0.07927698,0.004449694,0.0011229707,0.0020797667,0.0006584376,0.0004955235,0.0043281643,0.05121598,0.0005429065,0.003982676,0.09912254],"study_design_scores_gemma":[0.49432686,0.49102002,0.0050680647,0.000027717479,0.000592428,0.000436667,0.00009449127,0.0011633876,0.004466124,0.00016106405,0.0025957348,0.000047509977],"about_ca_topic_score_codex":0.0025430033,"about_ca_topic_score_gemma":0.004473221,"teacher_disagreement_score":0.0050895824,"about_ca_system_score_codex":0.0015153548,"about_ca_system_score_gemma":0.0025838176,"threshold_uncertainty_score":0.013310969},"labels":[],"label_agreement":null},{"id":"W2014952173","doi":"10.1007/s10637-007-9098-8","title":"Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Neutropenia; Leukopenia; Chemotherapy; Internal medicine; Gastroenterology; Head and neck squamous-cell carcinoma; Adverse effect; Phases of clinical research; Oncology; Surgery; Head and neck cancer; Radiation therapy","score_opus":0.020606124122446463,"score_gpt":0.2880066215949376,"score_spread":0.26740049747249117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014952173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990311,0.0029762667,0.00044355317,0.00042791467,0.00017582587,0.0016186143,0.0012133062,0.00007433188,0.0027591991],"genre_scores_gemma":[0.98470783,0.003603151,0.0009375974,0.0005778497,0.00015466101,0.0019084133,0.0030014967,0.00004142128,0.0050674104],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996798,0.00012724508,0.0000110864385,0.000044614433,0.000027638427,0.00010958808],"domain_scores_gemma":[0.999579,0.00006464891,0.000059430047,0.000042973068,0.000036455815,0.00021743086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011650693,0.0014695115,0.0025012814,0.0005345359,0.0005475437,0.00097450835,0.0010602954,0.0012082567,0.0035482815],"category_scores_gemma":[0.0005826051,0.0005161736,0.0013272738,0.0005333325,0.0009641299,0.00074508117,0.0003053958,0.002942344,0.00075724244],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58853143,0.07078668,0.013066438,0.0020154163,0.0025830846,0.00089355453,0.0009045352,0.009076698,0.093644105,0.0011606489,0.012976037,0.20436147],"study_design_scores_gemma":[0.33902758,0.6165889,0.016551485,0.00008975224,0.00093773694,0.00089699065,0.0003542178,0.003079616,0.014357911,0.00045964346,0.00759211,0.00006407144],"about_ca_topic_score_codex":0.003620065,"about_ca_topic_score_gemma":0.008560816,"teacher_disagreement_score":0.003620065,"about_ca_system_score_codex":0.0013144417,"about_ca_system_score_gemma":0.0019322583,"threshold_uncertainty_score":0.011870205},"labels":[],"label_agreement":null},{"id":"W2015395716","doi":"10.1007/s10637-013-0024-y","title":"Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of California, Davis; Celgene; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Paclitaxel; Progressive disease; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cisplatin","score_opus":0.01173629540340306,"score_gpt":0.31101612161331627,"score_spread":0.2992798262099132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015395716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880874,0.0025010242,0.0005207368,0.001410808,0.00038617797,0.0021071746,0.0015166521,0.00011429189,0.0033557133],"genre_scores_gemma":[0.9831508,0.0028342062,0.0014872047,0.0013266243,0.00029350672,0.002306558,0.0027935677,0.000051661762,0.0057559204],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996989,0.00012529086,0.000011036941,0.00006501739,0.000016456714,0.00008328645],"domain_scores_gemma":[0.9994816,0.0000839565,0.00006716411,0.000041098356,0.000023278466,0.00030292053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011446571,0.0017750468,0.002296892,0.00049316575,0.00050864957,0.0012767488,0.0010004296,0.0013533217,0.005657156],"category_scores_gemma":[0.00086593605,0.00063845044,0.0014747193,0.00044697424,0.001227684,0.001350142,0.00044140185,0.003920261,0.0010768592],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88456064,0.035886955,0.0023058697,0.0005105214,0.0010938756,0.00015890431,0.0001943708,0.003086941,0.014997562,0.00042230656,0.0040281466,0.052753925],"study_design_scores_gemma":[0.7991477,0.19122869,0.004352961,0.000028663355,0.00035798608,0.00012255307,0.0000697489,0.0010531901,0.0013850632,0.00028270512,0.0019503363,0.000020460448],"about_ca_topic_score_codex":0.0016500776,"about_ca_topic_score_gemma":0.0040879105,"teacher_disagreement_score":0.005657156,"about_ca_system_score_codex":0.0012544565,"about_ca_system_score_gemma":0.0014947314,"threshold_uncertainty_score":0.01892513},"labels":[],"label_agreement":null},{"id":"W2015941325","doi":"10.1007/s10637-010-9494-3","title":"Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Cisplatin; Cytoplasm; Liposome; Chemistry; DNA; Cancer cell; Intracellular; Cytotoxicity; Cancer research; Pharmacology; Molecular biology; Biochemistry; Biology; Colorectal cancer; Cancer; Chemotherapy; In vitro","score_opus":0.02019884188833627,"score_gpt":0.24187397622232024,"score_spread":0.22167513433398398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015941325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427754,0.0021501433,0.0012529965,0.000080427475,0.00003016856,0.000015738624,0.00030188146,0.000027936767,0.0018631736],"genre_scores_gemma":[0.9944495,0.0007848012,0.0009577102,0.000027324075,0.000007027087,0.000016782275,0.00029422189,0.000010067527,0.0034525935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998907,0.000024463023,0.000011697984,0.00002798757,0.00002389317,0.000021331818],"domain_scores_gemma":[0.9999162,0.000027945956,0.000014825759,0.000008060994,0.000022583761,0.000010462567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016444303,0.00015900042,0.00019732043,0.00015703864,0.00016026577,0.00022533642,0.00013892674,0.00023429081,0.0010488364],"category_scores_gemma":[0.00013344227,0.00013839641,0.00012585598,0.00024984326,0.0002079967,0.0002461575,0.00008054025,0.00029779034,0.00022434235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038831533,0.00003058328,0.00030087592,0.00007852635,0.000006627984,0.00005282901,0.000049574857,0.00014185722,0.9974215,0.00010557015,0.000037516547,0.0013861334],"study_design_scores_gemma":[0.000024679573,0.00059661444,0.0057195807,0.000004816073,0.000028211041,0.00013489963,0.00006289206,0.0012881489,0.99085885,0.000019778088,0.0012558401,0.0000056915396],"about_ca_topic_score_codex":0.004335374,"about_ca_topic_score_gemma":0.0029046861,"teacher_disagreement_score":0.004335374,"about_ca_system_score_codex":0.0003243845,"about_ca_system_score_gemma":0.00023261075,"threshold_uncertainty_score":0.008620262},"labels":[],"label_agreement":null},{"id":"W2016664719","doi":"10.1007/s10637-008-9193-5","title":"Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Paclitaxel; Neutropenia; Pharmacokinetics; Febrile neutropenia; Mesothelioma; Pharmacology; Toxicity; Internal medicine; Chemotherapy; Oncology; Cisplatin; Pathology","score_opus":0.11158738678637896,"score_gpt":0.3833905561850204,"score_spread":0.2718031693986414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016664719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978466,0.0009785518,0.00026849154,0.00008644771,0.000040501156,0.00027576237,0.00012366516,0.000019715695,0.00036032128],"genre_scores_gemma":[0.99561715,0.0018790499,0.0007435256,0.00011065106,0.00022598189,0.0002397032,0.00023019078,0.000038369737,0.00091537554],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9983923,0.00082188763,0.00010324704,0.0002659846,0.00015626621,0.00026041846],"domain_scores_gemma":[0.9968041,0.0015271301,0.00040571066,0.00042495978,0.00012026801,0.00071782275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026576386,0.0019162028,0.0045432127,0.0020100954,0.0010024995,0.0012442974,0.0020147027,0.0020870594,0.0026729146],"category_scores_gemma":[0.003043759,0.0010600995,0.0023690194,0.0019113863,0.0024947964,0.002059353,0.00062602834,0.0034257176,0.0005060551],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73880666,0.13210309,0.004746203,0.0006138748,0.0015735229,0.0005094768,0.00059342553,0.0036192115,0.05277064,0.00025925893,0.00047002197,0.06393467],"study_design_scores_gemma":[0.11244448,0.8556972,0.008194427,0.000029670575,0.0012873784,0.00034132763,0.00019370648,0.001515424,0.019085027,0.00013542961,0.0010147302,0.000061155195],"about_ca_topic_score_codex":0.0026201224,"about_ca_topic_score_gemma":0.0026973842,"teacher_disagreement_score":0.0045432127,"about_ca_system_score_codex":0.0013577854,"about_ca_system_score_gemma":0.0016302677,"threshold_uncertainty_score":0.014055073},"labels":[],"label_agreement":null},{"id":"W2019711560","doi":"10.1007/s10637-006-9002-y","title":"A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TransCanada (Canada); Royal Victoria Hospital; BC Cancer Agency; CancerCare Manitoba; University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Tolerability; Nausea; Vomiting; Chemotherapy; Doxorubicin; Melanoma; Internal medicine; Phases of clinical research; Oncology; Gastroenterology; Surgery; Adverse effect","score_opus":0.02426473383952529,"score_gpt":0.27331842390370087,"score_spread":0.24905369006417558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019711560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442613,0.0013320037,0.0005118571,0.00055444293,0.00012751464,0.0013388817,0.0004809156,0.000047911835,0.0011802351],"genre_scores_gemma":[0.98994,0.0022257254,0.0013705348,0.0007453821,0.00018617055,0.00157403,0.00096101506,0.000033445296,0.0029636517],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999622,0.00015928,0.000014268124,0.00007515737,0.00003490246,0.00009430011],"domain_scores_gemma":[0.99937683,0.00012625102,0.0000738904,0.00005115759,0.00003542312,0.0003365882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013871038,0.0016399373,0.0028245342,0.0005238758,0.00054600945,0.0009149235,0.0006993285,0.0013675824,0.003173476],"category_scores_gemma":[0.00081483397,0.0007721555,0.001288437,0.00041009978,0.0012012533,0.0011983116,0.00034228349,0.0033221564,0.0009822404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5842968,0.13893546,0.013147836,0.0013589181,0.001475382,0.0009753959,0.0010305448,0.0038160044,0.11841218,0.00048191746,0.0048715943,0.13119793],"study_design_scores_gemma":[0.41843998,0.5607365,0.011352338,0.00003193161,0.00041778124,0.00040550402,0.00014793935,0.0014018457,0.004265896,0.00018107801,0.0025748466,0.000044332435],"about_ca_topic_score_codex":0.0012984291,"about_ca_topic_score_gemma":0.0034024834,"teacher_disagreement_score":0.003173476,"about_ca_system_score_codex":0.0008735491,"about_ca_system_score_gemma":0.0012099613,"threshold_uncertainty_score":0.0106163025},"labels":[],"label_agreement":null},{"id":"W2019787838","doi":"10.1007/s10637-011-9769-3","title":"Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Imatinib; Imatinib mesylate; Renal function; Creatinine; Discontinuation; Urology; Pharmacology; Internal medicine; Dosing; Gastroenterology","score_opus":0.03023631602534122,"score_gpt":0.2436660946716437,"score_spread":0.2134297786463025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019787838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811648,0.0019278342,0.0005826587,0.005600222,0.00031582528,0.000080397265,0.000209186,0.00008187679,0.010037089],"genre_scores_gemma":[0.99608624,0.0006917192,0.0003405006,0.0014513638,0.0004997282,0.000009572038,0.00010784256,0.000013220665,0.0007997981],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9995776,0.00005726907,0.000056853427,0.0000825581,0.000059932416,0.00016580128],"domain_scores_gemma":[0.99855596,0.0004940332,0.0002078723,0.00005232025,0.00005931557,0.0006305333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032768832,0.0010608869,0.0011250183,0.0017277612,0.002600803,0.0014852689,0.0010365963,0.0037439049,0.0025135118],"category_scores_gemma":[0.0025005452,0.00068597466,0.0015241383,0.001133548,0.001083628,0.0013129889,0.0009014996,0.004169811,0.0005724977],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051443256,0.00027822226,0.037889097,0.00002430203,0.000044644934,0.95760137,0.00013592733,0.00018207794,0.0010893955,0.00018132088,0.00033627677,0.0017229344],"study_design_scores_gemma":[0.0001303064,0.0013026434,0.06400007,0.000031189542,0.00014894761,0.9297424,0.00050127786,0.00147244,0.0012012296,0.00033487784,0.0010941541,0.000040404437],"about_ca_topic_score_codex":0.0036010786,"about_ca_topic_score_gemma":0.0050054677,"teacher_disagreement_score":0.0037439049,"about_ca_system_score_codex":0.0016835588,"about_ca_system_score_gemma":0.0014944297,"threshold_uncertainty_score":0.0122151375},"labels":[],"label_agreement":null},{"id":"W2019837162","doi":"10.1007/s10637-014-0169-3","title":"A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Bevacizumab; Mucositis; Discontinuation; Internal medicine; Interim analysis; Gastroenterology; Sorafenib; Hepatocellular carcinoma; Phases of clinical research; Clinical endpoint; Progression-free survival; Surgery; Toxicity; Clinical trial; Chemotherapy; Discovery and development of mTOR inhibitors","score_opus":0.0276207536430723,"score_gpt":0.24154964911411808,"score_spread":0.21392889547104577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019837162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335444,0.0025710065,0.00032965705,0.0009857598,0.0002455466,0.0007153327,0.0004340639,0.00006533515,0.0012988795],"genre_scores_gemma":[0.99227226,0.0019398539,0.0010244547,0.00079430494,0.00023309022,0.00093988684,0.0013587446,0.000021855962,0.0014155122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995666,0.00023361655,0.000024288353,0.00007042418,0.000027202701,0.00007783235],"domain_scores_gemma":[0.99934345,0.00013266661,0.00009595168,0.000050079725,0.00003364054,0.00034427922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014175687,0.0012152293,0.0026436097,0.0004256376,0.00037342714,0.00089620764,0.0005316189,0.0008900889,0.0030239439],"category_scores_gemma":[0.0011305301,0.0005093274,0.0014642669,0.00047679557,0.0008599869,0.0011052901,0.00041975372,0.0030152933,0.00062111515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9023845,0.014686239,0.0040771924,0.00052552373,0.0016300428,0.00014637536,0.00014047706,0.0019043732,0.011556987,0.00020711764,0.002466123,0.060275003],"study_design_scores_gemma":[0.82149166,0.16712557,0.0066777365,0.000026597581,0.00060300017,0.00013836009,0.00006488525,0.0010834953,0.0010256127,0.00017754,0.0015617568,0.000023744078],"about_ca_topic_score_codex":0.001009964,"about_ca_topic_score_gemma":0.002691306,"teacher_disagreement_score":0.0030239439,"about_ca_system_score_codex":0.00089262024,"about_ca_system_score_gemma":0.0013084225,"threshold_uncertainty_score":0.0101161},"labels":[],"label_agreement":null},{"id":"W2020555572","doi":"10.1007/s10637-013-0055-4","title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"U.S. Food and Drug Administration; GlaxoSmithKline","keywords":"Lapatinib; Pharmacokinetics; Cmax; Medicine; Meal; Tolerability; Pharmacology; Internal medicine; Gastroenterology; Adverse effect; Cancer; Breast cancer; Trastuzumab","score_opus":0.0052637587914176305,"score_gpt":0.2631291230371833,"score_spread":0.25786536424576567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020555572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987804,0.00056636095,0.00007875079,0.000085005806,0.000024552375,0.000012627709,0.000098239296,0.000017864397,0.00033609965],"genre_scores_gemma":[0.9990482,0.00019457894,0.00013590355,0.000091420414,0.000021301877,0.000015261805,0.00015343247,0.000010519128,0.00032941508],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996501,0.00016694798,0.00002105343,0.000050710252,0.000034079425,0.000077024066],"domain_scores_gemma":[0.9993087,0.00033679223,0.00010330377,0.00005114815,0.00003565714,0.00016441061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005940526,0.00039432032,0.0011199681,0.0001663129,0.00023486045,0.0005601539,0.00020936722,0.00045072852,0.0015305337],"category_scores_gemma":[0.0020194144,0.0002588397,0.00069188233,0.00023529663,0.00036056683,0.00087843114,0.0003010279,0.0015819503,0.00020396165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79473215,0.0046098167,0.042606685,0.00019173225,0.001665085,0.00034463263,0.00027181063,0.0033293809,0.04779743,0.00016860761,0.0014158384,0.102866895],"study_design_scores_gemma":[0.037927918,0.26512876,0.62819934,0.00007351681,0.0035762833,0.0012050767,0.0008968056,0.016708972,0.040217426,0.00063920347,0.0051955134,0.00023126396],"about_ca_topic_score_codex":0.0015040439,"about_ca_topic_score_gemma":0.0023385542,"teacher_disagreement_score":0.0015305337,"about_ca_system_score_codex":0.0005985535,"about_ca_system_score_gemma":0.00048639072,"threshold_uncertainty_score":0.0051200986},"labels":[],"label_agreement":null},{"id":"W2021908659","doi":"10.1007/s10637-005-2903-3","title":"An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada); Ontario Institute for Cancer Research; Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Pharmacokinetics; Medicine; Doxorubicin; Tolerability; Dosing; Pharmacology; Toxicity; Chemotherapy; Stomatitis; Internal medicine; Adverse effect","score_opus":0.011232256567179634,"score_gpt":0.27975450958306297,"score_spread":0.26852225301588334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021908659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294347,0.0015373838,0.000965388,0.0005676582,0.00013137286,0.0010359962,0.0008361768,0.00018516526,0.0017972499],"genre_scores_gemma":[0.9900926,0.0017105655,0.0021499805,0.00042174401,0.00009608997,0.00087258476,0.0015372533,0.00007851929,0.0030407659],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99950194,0.00020567399,0.000015733904,0.00007685212,0.000061989434,0.00013787679],"domain_scores_gemma":[0.99921453,0.00011574454,0.0001351911,0.000083422856,0.000032034663,0.0004190011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011947743,0.0016820488,0.0024150328,0.00082723686,0.0005266442,0.001064946,0.001323553,0.0011690184,0.0028618101],"category_scores_gemma":[0.0011954198,0.0008791722,0.0009795938,0.00093842804,0.0012282559,0.0010035067,0.00042123866,0.005231677,0.00085624895],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.417905,0.15449405,0.0073433174,0.0006251097,0.0014685647,0.0007162853,0.000782079,0.015368168,0.21193932,0.0013711072,0.01214004,0.17584698],"study_design_scores_gemma":[0.31165838,0.63426685,0.020161632,0.00004695121,0.0005645335,0.0009781194,0.00013602286,0.0064375075,0.018420042,0.00041548553,0.006810571,0.000103845436],"about_ca_topic_score_codex":0.0040838704,"about_ca_topic_score_gemma":0.009543863,"teacher_disagreement_score":0.0040838704,"about_ca_system_score_codex":0.0018018632,"about_ca_system_score_gemma":0.0023372064,"threshold_uncertainty_score":0.013073504},"labels":[],"label_agreement":null},{"id":"W2024080866","doi":"10.1007/s10637-007-9045-8","title":"Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of California, Davis","keywords":"Vinorelbine; Erlotinib; Medicine; Internal medicine; Vinca alkaloid; Neutropenia; Febrile neutropenia; Oncology; Lung cancer; Mucositis; Epidermal growth factor receptor; Combination therapy; Pharmacology; Chemotherapy; Gastroenterology; Cancer; Vincristine; Cisplatin","score_opus":0.01803718802920216,"score_gpt":0.3682471109087651,"score_spread":0.35020992287956293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024080866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901938,0.005355063,0.0003285878,0.00046001116,0.00012946028,0.00090162666,0.0011317887,0.00006409115,0.001435502],"genre_scores_gemma":[0.9859272,0.0063129785,0.0011196618,0.00056879374,0.0002284024,0.0011192636,0.0021669804,0.000046396875,0.002510313],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992167,0.0003611873,0.000034449502,0.00011400413,0.000070235044,0.00020335862],"domain_scores_gemma":[0.99910116,0.00025184362,0.00016128572,0.000105729174,0.000042984277,0.00033697317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023314517,0.0016492341,0.004475247,0.00064184784,0.0005034483,0.0012771507,0.0012643762,0.0016780467,0.0031853588],"category_scores_gemma":[0.0011560891,0.0009286737,0.002201886,0.0007972304,0.0012198763,0.0014572894,0.00038102284,0.0038995077,0.0006135777],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77947617,0.06459075,0.0049972297,0.0009859088,0.0032014598,0.00029077003,0.0002555394,0.004548773,0.023990408,0.00041062006,0.0035513795,0.113700956],"study_design_scores_gemma":[0.618855,0.35865027,0.010744193,0.000046480403,0.001488606,0.0004324634,0.000088942914,0.0013408255,0.004288805,0.00019089434,0.0038220163,0.00005147601],"about_ca_topic_score_codex":0.0018261794,"about_ca_topic_score_gemma":0.0044906265,"teacher_disagreement_score":0.004475247,"about_ca_system_score_codex":0.0013996289,"about_ca_system_score_gemma":0.0016645137,"threshold_uncertainty_score":0.012330055},"labels":[],"label_agreement":null},{"id":"W2024677994","doi":"10.1007/s10637-009-9222-z","title":"N-4-iodophenyl-N′-2-chloroethylurea, a novel potential anticancer agent with colon-specific accumulation: radioiodination and comparative in vivo biodistribution profiles","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise","funders":"","keywords":"In vivo; Biodistribution; Pharmacology; Potency; Chemistry; Colorectal cancer; Pharmacokinetics; Medicine; In vitro; Cancer; Biochemistry; Internal medicine; Biology","score_opus":0.08898249194808416,"score_gpt":0.3413369859002879,"score_spread":0.2523544939522037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024677994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718921,0.009233065,0.010933592,0.00009241676,0.000028630662,0.000083246625,0.0001182855,0.00010558332,0.0075130253],"genre_scores_gemma":[0.98243815,0.003593679,0.010094825,0.00005320324,0.000019299318,0.00004870048,0.0002384472,0.000031134616,0.003482547],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998938,0.000031409654,0.0000059734593,0.000020971143,0.000017684584,0.000030249666],"domain_scores_gemma":[0.9999237,0.000025809893,0.000019075122,0.000007586785,0.000008094612,0.000015712645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037335046,0.000303411,0.00039398737,0.0002764738,0.00017326041,0.00019954982,0.00031059093,0.0003261897,0.00060814345],"category_scores_gemma":[0.00017729185,0.0002208966,0.00014981769,0.00022313664,0.0002750763,0.00035499045,0.00015074252,0.00028340283,0.0002461833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024986095,0.000020741036,0.00010859051,0.000054294713,0.0000054964457,0.0000952722,0.000015925349,0.000069386675,0.99758196,0.00012400917,0.000030222009,0.0016442928],"study_design_scores_gemma":[0.00003977302,0.0009618084,0.0018926274,0.0000057683405,0.000029556912,0.0007988952,0.000013148524,0.000557885,0.9926984,0.00002148337,0.0029740615,0.0000066587295],"about_ca_topic_score_codex":0.0011265911,"about_ca_topic_score_gemma":0.0015387448,"teacher_disagreement_score":0.0011265911,"about_ca_system_score_codex":0.00035743922,"about_ca_system_score_gemma":0.00033285582,"threshold_uncertainty_score":0.002593398},"labels":[],"label_agreement":null},{"id":"W2025486703","doi":"10.1007/s10637-005-1157-4","title":"Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hôpital Notre-Dame; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Nausea; Toxicity; Gastroenterology; Internal medicine; Chemotherapy; Surgery; Progressive disease","score_opus":0.011628574128180441,"score_gpt":0.265100812633515,"score_spread":0.2534722385053345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025486703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365366,0.0017236334,0.00048835605,0.0005433352,0.00017593999,0.0012066369,0.00065917784,0.000050084825,0.0014991526],"genre_scores_gemma":[0.9909402,0.001916337,0.00085977156,0.00058488525,0.00018125294,0.0017343299,0.001207181,0.000026099513,0.0025500064],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960524,0.00018041501,0.000011776445,0.000056602188,0.000024368872,0.00012159827],"domain_scores_gemma":[0.9993587,0.0001224164,0.000081616614,0.0000648499,0.00003210382,0.00034042422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014296494,0.0014940952,0.0023980343,0.00054218626,0.0005718779,0.0008374354,0.000867401,0.0011361988,0.0029936158],"category_scores_gemma":[0.00081108575,0.000518405,0.0013585886,0.0004438461,0.0011844542,0.00097299664,0.00035422624,0.0030267555,0.0006944405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6836698,0.101517886,0.010388424,0.00086183735,0.0016023432,0.0007046371,0.0005418528,0.005654168,0.06709456,0.0007212395,0.004940076,0.12230316],"study_design_scores_gemma":[0.30356437,0.67484456,0.012262839,0.000031679552,0.0003746998,0.0003479682,0.00011076048,0.0012138614,0.004365328,0.00028388557,0.0025766056,0.0000235506],"about_ca_topic_score_codex":0.0018350946,"about_ca_topic_score_gemma":0.004368552,"teacher_disagreement_score":0.0029936158,"about_ca_system_score_codex":0.0008984122,"about_ca_system_score_gemma":0.0014623104,"threshold_uncertainty_score":0.010014653},"labels":[],"label_agreement":null},{"id":"W2025697283","doi":"10.1007/s10637-015-0216-8","title":"The oncolytic virus, pelareorep, as a novel anticancer agent: a review","year":2015,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Oncolytic virus; Virus; Virology; Medicine","score_opus":0.0784854877160039,"score_gpt":0.3969353303191214,"score_spread":0.31844984260311754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025697283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001499578,0.9988488,0.00016786567,0.00013380904,0.00012615783,0.000004242728,0.000017814951,0.000006323806,0.0005449886],"genre_scores_gemma":[0.0006985605,0.99847084,0.0002155654,0.00011939137,0.00008141714,0.0000048719126,0.00002668571,0.0000011086868,0.0003815599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998946,0.000011825937,0.00001552946,0.000022463139,0.000042188898,0.000013376678],"domain_scores_gemma":[0.99981266,0.00008290887,0.000034226014,0.00000503377,0.000042902553,0.000022249933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041570415,0.00073880196,0.001145898,0.0019567441,0.0002638396,0.0008787622,0.0007843812,0.00087395543,0.0021961734],"category_scores_gemma":[0.00047785818,0.00030400057,0.00035383474,0.0019019914,0.00037975184,0.0013112263,0.000542853,0.0015080522,0.001151636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012428146,0.000101343816,0.00018498187,0.018947197,0.00008954681,0.00026586707,0.00006309545,0.00043494877,0.007846693,0.003925741,0.026674746,0.9413415],"study_design_scores_gemma":[0.000021109086,0.00012884905,0.0003907638,0.0014625944,0.00014190072,0.0010500735,0.000041547966,0.00012305689,0.0020521416,0.0011431184,0.99342346,0.000021338245],"about_ca_topic_score_codex":0.0009125203,"about_ca_topic_score_gemma":0.0018504973,"teacher_disagreement_score":0.0021961734,"about_ca_system_score_codex":0.00056970125,"about_ca_system_score_gemma":0.0010001437,"threshold_uncertainty_score":0.0073468685},"labels":[],"label_agreement":null},{"id":"W2026940417","doi":"10.1007/s10637-014-0139-9","title":"A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Afatinib; Pemetrexed; Medicine; Oncology; Maximum tolerated dose; Internal medicine; Pharmacology; Chemotherapy; Cisplatin; Cancer; Gefitinib","score_opus":0.008347684921314954,"score_gpt":0.287026971593901,"score_spread":0.27867928667258607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026940417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143314,0.001985318,0.0005508211,0.0010891901,0.00034896642,0.001373042,0.0012407771,0.00010978077,0.0018689473],"genre_scores_gemma":[0.98988986,0.0012926568,0.001587617,0.0011512659,0.00017623213,0.0013955324,0.0022219014,0.000049138285,0.0022358007],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99939406,0.00020718825,0.000031267147,0.00017963306,0.000043433738,0.00014445763],"domain_scores_gemma":[0.99889237,0.00021420255,0.00016536748,0.00013370428,0.000060648537,0.0005337654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017410243,0.0018361177,0.0032607752,0.0005069212,0.00054849935,0.0017101989,0.0013373907,0.0018682835,0.005621273],"category_scores_gemma":[0.001585411,0.0007779199,0.0024904215,0.0006411869,0.0016349715,0.0023926378,0.0005105613,0.006598702,0.0012027278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8839504,0.030022467,0.0026390848,0.0005757696,0.0021409027,0.00013927526,0.00029489832,0.0034591735,0.013588007,0.0004495558,0.0039960076,0.058744445],"study_design_scores_gemma":[0.84961593,0.14200929,0.0038495385,0.000021744967,0.0003888137,0.00015844266,0.00006916555,0.001217204,0.0010076902,0.00039107565,0.0012390837,0.0000320788],"about_ca_topic_score_codex":0.0011369041,"about_ca_topic_score_gemma":0.0026928422,"teacher_disagreement_score":0.005621273,"about_ca_system_score_codex":0.0016440558,"about_ca_system_score_gemma":0.0014951903,"threshold_uncertainty_score":0.018805087},"labels":[],"label_agreement":null},{"id":"W2027376895","doi":"10.1007/s10637-005-2904-2","title":"A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Hôpital Notre-Dame; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Cmax; Cardiotoxicity; Toxicity; Refractory (planetary science); Cancer; Internal medicine; Lethargy; Neutropenia; Gastroenterology","score_opus":0.07668926564023175,"score_gpt":0.42262326365263103,"score_spread":0.34593399801239927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027376895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97829676,0.0038340928,0.0011209548,0.0016190142,0.00054130715,0.004945455,0.0039475355,0.00033993454,0.005354905],"genre_scores_gemma":[0.9683704,0.0067118895,0.0037613716,0.0020818734,0.0004986038,0.0043311464,0.0054099686,0.000117782496,0.008716983],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994777,0.00021430395,0.000017428778,0.0000901367,0.00005524231,0.00014527216],"domain_scores_gemma":[0.9990877,0.0001275252,0.00012624724,0.000064384796,0.000060112616,0.00053395634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013976916,0.0023465913,0.0031862205,0.0008711419,0.00070199947,0.001214549,0.0017200003,0.0022404823,0.005952872],"category_scores_gemma":[0.0011260669,0.0009444808,0.0022066652,0.00083521765,0.0016952012,0.0010691116,0.0004378162,0.0061615966,0.0017052256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73564464,0.10290951,0.0029262255,0.001188379,0.0017275739,0.00037782063,0.00041019768,0.0039112954,0.039388996,0.0008381989,0.015192669,0.09548437],"study_design_scores_gemma":[0.67417544,0.31618613,0.004021188,0.000027123426,0.00031075804,0.0001803275,0.000050322302,0.0010028987,0.001630484,0.00016305842,0.0022184108,0.00003380078],"about_ca_topic_score_codex":0.0075749466,"about_ca_topic_score_gemma":0.01668555,"teacher_disagreement_score":0.0075749466,"about_ca_system_score_codex":0.001447972,"about_ca_system_score_gemma":0.003714027,"threshold_uncertainty_score":0.019914329},"labels":[],"label_agreement":null},{"id":"W2028540870","doi":"10.1007/s10637-009-9332-7","title":"Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BioPhage Pharma (Canada)","funders":"Louisiana Board of Regents; Ohio Board of Regents","keywords":"Resveratrol; Cardiotoxicity; Medicine; Pharmacology; Hepatocellular carcinoma; Carcinogen; Liver cancer; Carcinogenesis; Cancer; Internal medicine; Toxicity; Chemistry; Biochemistry","score_opus":0.0273199683245389,"score_gpt":0.2657664345778118,"score_spread":0.2384464662532729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028540870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395305,0.0013942143,0.0016794852,0.0003915843,0.00014639505,0.000044764958,0.00036426695,0.00017929189,0.0018469238],"genre_scores_gemma":[0.990585,0.0017550426,0.001347485,0.00015876761,0.000042684067,0.00005861682,0.0008615712,0.000050975865,0.0051398147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997466,0.00006197097,0.00002769162,0.000037379497,0.000054745546,0.00007170634],"domain_scores_gemma":[0.99930775,0.00009861754,0.00016259267,0.00018367426,0.00006385573,0.0001835013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003403328,0.00081247074,0.0008412464,0.0012962377,0.0003597639,0.00034658797,0.00054035167,0.00082492025,0.0029307408],"category_scores_gemma":[0.00037577376,0.0005890948,0.0006227678,0.0004490384,0.0008341264,0.00066624815,0.00022493691,0.0017083327,0.0006644039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005299376,0.0012438108,0.00072569354,0.00010187457,0.00006959543,0.00023556587,0.00006436672,0.0001831264,0.9862664,0.00040772604,0.00027341812,0.0051291813],"study_design_scores_gemma":[0.00029877227,0.007545927,0.004153768,0.000025466603,0.00014082415,0.00038643656,0.0001595053,0.0007020416,0.98451865,0.0002896916,0.0017581328,0.00002070766],"about_ca_topic_score_codex":0.0011961135,"about_ca_topic_score_gemma":0.002677552,"teacher_disagreement_score":0.0029307408,"about_ca_system_score_codex":0.00032688546,"about_ca_system_score_gemma":0.0005248067,"threshold_uncertainty_score":0.009804249},"labels":[],"label_agreement":null},{"id":"W2028577286","doi":"10.1007/s10637-009-9279-8","title":"Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":150,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Cancer Institute","keywords":"Viral shedding; Medicine; Viral load; Neutralizing antibody; Virology; Antibody; Virus; Viral replication; Chemotherapy; Oncolytic virus; Immunology; Internal medicine","score_opus":0.01033617842663142,"score_gpt":0.2731821496401648,"score_spread":0.26284597121353337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028577286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750523,0.010405755,0.009510296,0.00072653504,0.00006983098,0.00007056504,0.00018800644,0.0003425369,0.0036340682],"genre_scores_gemma":[0.9972562,0.00092317874,0.00084486627,0.0001137542,0.00004053703,0.000014985262,0.0001068418,0.000027009948,0.00067268836],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999889,0.000051311268,0.0000036339275,0.000014766403,0.000020990492,0.00002039173],"domain_scores_gemma":[0.99967337,0.00013875804,0.00010383859,0.000036240202,0.000010114777,0.000037732647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024396354,0.00019589273,0.0004968314,0.00009281645,0.00014496961,0.00032176185,0.00012867677,0.00027627245,0.0007628291],"category_scores_gemma":[0.00075588765,0.00008418328,0.00016431592,0.00013993584,0.00025166647,0.0001882465,0.00012274772,0.00069194,0.00021603281],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031463582,0.0012820547,0.05245645,0.0005053075,0.0002095535,0.0027735913,0.0003886346,0.0015752272,0.35754016,0.0023721138,0.0047342633,0.544699],"study_design_scores_gemma":[0.008574681,0.1053466,0.3502263,0.00031807864,0.00072744413,0.027210252,0.0004784601,0.01421134,0.41271147,0.0034543462,0.07665294,0.00008803695],"about_ca_topic_score_codex":0.00025848433,"about_ca_topic_score_gemma":0.000285254,"teacher_disagreement_score":0.0007628291,"about_ca_system_score_codex":0.00016232308,"about_ca_system_score_gemma":0.00030144118,"threshold_uncertainty_score":0.0025519133},"labels":[],"label_agreement":null},{"id":"W2031256158","doi":"10.1007/s10637-014-0187-1","title":"In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Centre Hospitalier Universitaire de Québec","keywords":"Selective estrogen receptor modulator; Steroid sulfatase; Estrogen receptor; Chemistry; Estrogen; Pharmacology; Raloxifene; Cell growth; Antiestrogen; Alkaline phosphatase; Estrogen receptor alpha; Steroid; Endocrinology; Internal medicine; Biochemistry; Hormone; Biology; Medicine; Cancer; Breast cancer; Enzyme","score_opus":0.007794038978604045,"score_gpt":0.2511937937726388,"score_spread":0.24339975479403475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031256158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792671,0.013365184,0.0035497763,0.00014643338,0.00011512819,0.000109037785,0.00035816577,0.00007443009,0.0030147568],"genre_scores_gemma":[0.98610944,0.0067152376,0.0028207744,0.000056051886,0.00006122471,0.0000551722,0.00061077834,0.000014188865,0.0035571202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998294,0.000070348375,0.000013255181,0.000019779756,0.00003737236,0.000029823506],"domain_scores_gemma":[0.99988365,0.00005305785,0.0000142453955,0.000009384122,0.000023398603,0.000016254051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004572322,0.0002800593,0.00038139062,0.00020529405,0.00022376556,0.00016524924,0.00043046108,0.00023584443,0.0014366878],"category_scores_gemma":[0.00021191829,0.00015617463,0.00026754785,0.00018671632,0.00017927104,0.00015223553,0.00010257893,0.00027735875,0.00026244269],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012808692,0.00031626914,0.0001943656,0.0001346751,0.000028122033,0.000157754,0.000053006726,0.0005900329,0.9925332,0.00016326224,0.0001408825,0.004407507],"study_design_scores_gemma":[0.00023282036,0.008282329,0.0013825528,0.000010163435,0.00011316078,0.00029104485,0.00004899705,0.0014320868,0.98244953,0.000036490044,0.005710184,0.000010689216],"about_ca_topic_score_codex":0.0019004588,"about_ca_topic_score_gemma":0.0035658216,"teacher_disagreement_score":0.0019004588,"about_ca_system_score_codex":0.00021125074,"about_ca_system_score_gemma":0.0002925408,"threshold_uncertainty_score":0.004806161},"labels":[],"label_agreement":null},{"id":"W2033997665","doi":"10.1007/s10637-011-9650-4","title":"A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre; University of Alberta; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Cancer; Gastroenterology; Clinical endpoint; Adenocarcinoma; Oncology; Phases of clinical research; Chemotherapy; Surgery; Clinical trial","score_opus":0.03554854809381155,"score_gpt":0.2814283974656747,"score_spread":0.24587984937186316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033997665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859757,0.0033607064,0.00048651482,0.002975326,0.00045254893,0.0016189972,0.0020480636,0.000106846426,0.0029753528],"genre_scores_gemma":[0.9791712,0.003298122,0.0022728369,0.0029270977,0.00048885256,0.0019842363,0.0048229434,0.00004228228,0.0049924054],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99965143,0.00018892414,0.000011432255,0.000058282676,0.0000254006,0.00006458082],"domain_scores_gemma":[0.99939394,0.00012178412,0.00008500953,0.000044523014,0.000026867707,0.00032775642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001648198,0.0016345754,0.0018303824,0.00035691314,0.0003755741,0.00091999356,0.0007783018,0.0012873196,0.0044962834],"category_scores_gemma":[0.0012081088,0.00044566125,0.0013857723,0.00033218978,0.0009300949,0.00096906297,0.00046970596,0.0041981693,0.00083411887],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7773586,0.030532205,0.007993081,0.0010708539,0.0020201148,0.0003337041,0.00026660517,0.0041994974,0.018355964,0.0009880101,0.019052101,0.13782932],"study_design_scores_gemma":[0.88979214,0.09707935,0.006806516,0.000027047956,0.00038568818,0.00021452362,0.000053487274,0.0014275201,0.0010877631,0.00046043354,0.0026426783,0.000022808375],"about_ca_topic_score_codex":0.00094880385,"about_ca_topic_score_gemma":0.003292269,"teacher_disagreement_score":0.0044962834,"about_ca_system_score_codex":0.000827162,"about_ca_system_score_gemma":0.0012169171,"threshold_uncertainty_score":0.01504153},"labels":[],"label_agreement":null},{"id":"W2035105453","doi":"10.1007/s10637-009-9230-z","title":"A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint-Vincent Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Gemcitabine; Medicine; Internal medicine; Regimen; Lung cancer; Overall survival; Oncology; Gastroenterology; Surgery; Chemotherapy","score_opus":0.022813625574936238,"score_gpt":0.3220910436634508,"score_spread":0.2992774180885146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035105453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904268,0.0014963028,0.00044868817,0.00069390476,0.0002891293,0.0023798852,0.0020022064,0.00012247759,0.0021406163],"genre_scores_gemma":[0.9802106,0.0024329915,0.0018130583,0.0015873549,0.00030036198,0.003443876,0.0051324028,0.000077456105,0.00500202],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99940383,0.00028311263,0.000027249393,0.00009997954,0.000035261884,0.0001505461],"domain_scores_gemma":[0.9987105,0.00019972006,0.00014157817,0.00009971248,0.000048912058,0.00079951435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019764146,0.0020758081,0.0039270795,0.0008069659,0.0006408808,0.0012802655,0.0015515795,0.002200023,0.00685222],"category_scores_gemma":[0.0010800266,0.0009088992,0.0026496537,0.0008507752,0.0013558123,0.0012559862,0.00053872506,0.0053989184,0.001762623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88350415,0.050124917,0.0035453804,0.00042455437,0.0015355882,0.00026892888,0.00021122243,0.0017698025,0.0153667005,0.0002545012,0.0045874026,0.03840683],"study_design_scores_gemma":[0.7254609,0.26516458,0.0052900137,0.000019723519,0.00046022498,0.0002010529,0.000060093385,0.0007850743,0.0010563704,0.00014818677,0.001321675,0.000032054144],"about_ca_topic_score_codex":0.0037700243,"about_ca_topic_score_gemma":0.011023704,"teacher_disagreement_score":0.00685222,"about_ca_system_score_codex":0.0014583707,"about_ca_system_score_gemma":0.0031289225,"threshold_uncertainty_score":0.022922933},"labels":[],"label_agreement":null},{"id":"W2036144482","doi":"10.1007/s10637-014-0070-0","title":"Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Cancer Institute; National Institutes of Health","keywords":"Irinotecan; Bortezomib; Medicine; Adenocarcinoma; Internal medicine; Gastroenterology; Oncology; Stomach; Population; Cancer; Multiple myeloma; Colorectal cancer","score_opus":0.01462400329320097,"score_gpt":0.24959230195326385,"score_spread":0.23496829866006289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036144482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98705626,0.004283581,0.00049926725,0.0016415023,0.0006060676,0.0015815557,0.0012194875,0.0000862269,0.0030260654],"genre_scores_gemma":[0.9829736,0.0039335983,0.0014392841,0.0017015167,0.00050010235,0.0019632517,0.002766107,0.00004500775,0.004677533],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958557,0.00019461139,0.00001759671,0.000087894,0.000021088745,0.00009317391],"domain_scores_gemma":[0.9992204,0.00014007256,0.000111984424,0.000058223883,0.000033202283,0.00043610047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014543183,0.0018642773,0.0031732996,0.0005195675,0.00050778297,0.0016421833,0.0010851295,0.0014485036,0.0054782038],"category_scores_gemma":[0.0011601809,0.00084185257,0.0020953394,0.0005632591,0.0015411613,0.0016969249,0.0005455524,0.0052694487,0.001124788],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93065655,0.023563083,0.0027834564,0.0005117075,0.0012063676,0.00011271537,0.00014917998,0.0016886953,0.0064057577,0.00022591121,0.0024006397,0.030295977],"study_design_scores_gemma":[0.83633333,0.15670866,0.0036530213,0.000029062132,0.00039737872,0.00008663187,0.00007209491,0.00062485575,0.0006046383,0.00016018846,0.0013121936,0.00001795358],"about_ca_topic_score_codex":0.0014256991,"about_ca_topic_score_gemma":0.0038812454,"teacher_disagreement_score":0.0054782038,"about_ca_system_score_codex":0.0012078638,"about_ca_system_score_gemma":0.0016085407,"threshold_uncertainty_score":0.018326402},"labels":[],"label_agreement":null},{"id":"W2036546477","doi":"10.1007/s10637-009-9341-6","title":"A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Cancer Care Ontario; Regional Municipality of Durham; Lakeridge Health","funders":"","keywords":"Cetuximab; Medicine; Immunostaining; Colorectal cancer; Epidermal growth factor receptor; Immunohistochemistry; Internal medicine; Oncology; Cancer; Pathology","score_opus":0.01860524585751648,"score_gpt":0.28023986716293553,"score_spread":0.26163462130541904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036546477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99675226,0.00083411235,0.0002668976,0.00027192145,0.000076088014,0.0007822799,0.00037857544,0.000029290963,0.00060878193],"genre_scores_gemma":[0.9934563,0.00093961577,0.001108968,0.0006197364,0.0001901862,0.0008945208,0.0014459383,0.00002866102,0.0013161576],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992632,0.00036066887,0.000037832517,0.00014092123,0.000054882345,0.00014234298],"domain_scores_gemma":[0.99877816,0.00024308398,0.00018699729,0.00011549897,0.00008161597,0.0005946447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024404074,0.0019313094,0.0031679645,0.0004961331,0.0007248572,0.0009901631,0.0008606309,0.0014042633,0.002475828],"category_scores_gemma":[0.0014216785,0.0008382989,0.0013668324,0.0006592149,0.0013416467,0.0013276923,0.0004026347,0.0027338865,0.00069804175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8638516,0.04333299,0.012994731,0.00037850754,0.0015317558,0.0003383081,0.00036440397,0.0018202988,0.037062284,0.00016286029,0.0017571795,0.0364051],"study_design_scores_gemma":[0.65700734,0.31596255,0.021586977,0.000016741951,0.0007276216,0.00027442034,0.00010467074,0.0008932605,0.0021339243,0.00010524168,0.0011512106,0.000036029876],"about_ca_topic_score_codex":0.0022808122,"about_ca_topic_score_gemma":0.004600224,"teacher_disagreement_score":0.0031679645,"about_ca_system_score_codex":0.001229917,"about_ca_system_score_gemma":0.002002019,"threshold_uncertainty_score":0.012906253},"labels":[],"label_agreement":null},{"id":"W2037125902","doi":"10.1023/b:drug.0000047105.38511.2a","title":"Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; CancerCare Manitoba; Ontario Institute for Cancer Research; AstraZeneca (Canada); Hôpital Notre-Dame; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Doxorubicin; Bolus (digestion); Toxicity; Cancer; Internal medicine; Chemotherapy; Gastroenterology; Surgery","score_opus":0.023312347774086896,"score_gpt":0.33420681025171406,"score_spread":0.31089446247762714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037125902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022627,0.0018026221,0.0004649152,0.00048323112,0.00013520593,0.0016293086,0.0011068942,0.00012239911,0.0040291464],"genre_scores_gemma":[0.9789507,0.003414767,0.0022461556,0.0008729531,0.00022751774,0.0025138448,0.0032771619,0.000043447624,0.008453346],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998197,0.00009056587,0.0000058989604,0.000023702993,0.000013514823,0.00004671455],"domain_scores_gemma":[0.99960595,0.00008449736,0.00006143668,0.0000306242,0.000019954057,0.0001975011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066403806,0.0010485452,0.0014544375,0.00043499316,0.0003291367,0.000748668,0.0008562947,0.0010679684,0.00627682],"category_scores_gemma":[0.0007166031,0.00047374706,0.0008400829,0.0003568228,0.0006100225,0.00060500484,0.00029997592,0.0026254298,0.0011350963],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73638815,0.06756465,0.006270091,0.00074025145,0.001011485,0.0003327441,0.00034192405,0.0020347224,0.041582245,0.00070428115,0.007038015,0.13599153],"study_design_scores_gemma":[0.5334767,0.44677615,0.009388728,0.00004710528,0.0003558789,0.00037895524,0.00009154556,0.00095100084,0.0033130967,0.00019507465,0.004999112,0.000026666443],"about_ca_topic_score_codex":0.0009052037,"about_ca_topic_score_gemma":0.0022382748,"teacher_disagreement_score":0.00627682,"about_ca_system_score_codex":0.00043185332,"about_ca_system_score_gemma":0.0009977886,"threshold_uncertainty_score":0.02099806},"labels":[],"label_agreement":null},{"id":"W2037598471","doi":"10.1007/s10637-014-0166-6","title":"A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; National Center for Research Resources; Institute of Clinical and Translational Sciences","keywords":"Capecitabine; Refractory (planetary science); Medicine; Internal medicine; Solid tumor; Oncology; Pharmacology; Cancer; Materials science; Colorectal cancer; Metallurgy","score_opus":0.00805643969638922,"score_gpt":0.25682505050062404,"score_spread":0.24876861080423482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037598471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874862,0.00350642,0.0009775179,0.0011352423,0.0002979226,0.0028370207,0.001839897,0.00016666313,0.0017530103],"genre_scores_gemma":[0.97811866,0.00461825,0.002877796,0.0014902378,0.00033408942,0.004064145,0.004529169,0.00013328505,0.003834411],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99936384,0.00025263496,0.00002966306,0.00013749549,0.00004462199,0.0001716533],"domain_scores_gemma":[0.9992095,0.00010506574,0.00012355675,0.000085226144,0.000044688513,0.00043192547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019462792,0.002306795,0.0041903006,0.0007822545,0.00072647474,0.001425222,0.0013189173,0.0015759569,0.0046064397],"category_scores_gemma":[0.000945384,0.00094859104,0.0024508808,0.00085525704,0.0014258947,0.0014387374,0.00053219433,0.004540651,0.0011634274],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76222295,0.065298036,0.004099757,0.0011182564,0.0030076457,0.0003666663,0.00036721272,0.0056638084,0.0541289,0.0005162157,0.007815687,0.09539482],"study_design_scores_gemma":[0.6710311,0.31534657,0.006106618,0.000037493246,0.00077075337,0.00022146905,0.00006826435,0.0010093201,0.0025851682,0.00020559647,0.002578968,0.00003876976],"about_ca_topic_score_codex":0.0030236694,"about_ca_topic_score_gemma":0.007260966,"teacher_disagreement_score":0.0046064397,"about_ca_system_score_codex":0.0018344554,"about_ca_system_score_gemma":0.0026771086,"threshold_uncertainty_score":0.015410006},"labels":[],"label_agreement":null},{"id":"W2037647430","doi":"10.1007/s10637-005-2907-z","title":"A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Cancer; Nausea; Toxicity; Population; Phases of clinical research; Internal medicine; Gastroenterology; Vomiting; Pharmacology","score_opus":0.0318275384668315,"score_gpt":0.3383269827617641,"score_spread":0.3064994442949326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037647430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695444,0.0005640632,0.0003153555,0.00020141104,0.000042457843,0.0006607189,0.00043713662,0.000038605584,0.0007858628],"genre_scores_gemma":[0.9941094,0.00085007923,0.0011164494,0.00043263254,0.00012952034,0.00076778483,0.0012527877,0.000033976266,0.0013074835],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991924,0.00041238975,0.000026408981,0.0001347564,0.00006763142,0.00016630358],"domain_scores_gemma":[0.99896455,0.0001802844,0.0001614714,0.00011679666,0.000045683475,0.0005311365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014058134,0.0017857247,0.0032035366,0.0005078541,0.00056657835,0.001013614,0.0010273071,0.0012567898,0.0027575083],"category_scores_gemma":[0.0013288049,0.0009950512,0.0012113255,0.0005818767,0.001658943,0.0014132721,0.00044237069,0.003961256,0.0008594098],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7261634,0.104480766,0.022003898,0.00034574463,0.0012210837,0.00054218934,0.0004677987,0.004043724,0.05326904,0.00039785207,0.00285217,0.08421238],"study_design_scores_gemma":[0.40404546,0.5490877,0.03661223,0.00001706717,0.00048611613,0.0005182576,0.00014116813,0.0022860253,0.004311758,0.00018183656,0.002251684,0.00006063638],"about_ca_topic_score_codex":0.0023459676,"about_ca_topic_score_gemma":0.00429555,"teacher_disagreement_score":0.0032035366,"about_ca_system_score_codex":0.0013108018,"about_ca_system_score_gemma":0.0020868788,"threshold_uncertainty_score":0.009510517},"labels":[],"label_agreement":null},{"id":"W2040084015","doi":"10.1007/s10637-011-9775-5","title":"A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Regional Cancer Foundation; BC Cancer Agency; Princess Margaret Cancer Centre; McGill University; University Health Network","funders":"","keywords":"Medicine; Everolimus; Temozolomide; Regimen; Pharmacokinetics; Pharmacology; Internal medicine; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy","score_opus":0.03297897731114133,"score_gpt":0.2907754117416299,"score_spread":0.2577964344304886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040084015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950452,0.0014170746,0.00026409767,0.0003693645,0.0000978216,0.00096853555,0.00090051163,0.000048405163,0.0008888798],"genre_scores_gemma":[0.99009645,0.0023017584,0.0011138716,0.0008366052,0.0002158053,0.0012949941,0.002533432,0.000037414386,0.0015696172],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99934477,0.00033518462,0.000028244289,0.000109054556,0.00004859819,0.00013417559],"domain_scores_gemma":[0.998831,0.00023337807,0.00017006928,0.00009901348,0.000050097977,0.00061649515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018339272,0.0021833945,0.003330587,0.0006423833,0.0005307288,0.0011023853,0.0012125254,0.0015409419,0.0025883731],"category_scores_gemma":[0.0015089982,0.0009475937,0.002260557,0.00084425416,0.0015184054,0.0013355814,0.00042861913,0.0037459151,0.0007294988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9060195,0.03339282,0.009550102,0.00035307644,0.0018686899,0.00028644296,0.0002618358,0.0013528892,0.015743513,0.00016617826,0.0018957386,0.029109245],"study_design_scores_gemma":[0.71849823,0.26056933,0.016429894,0.000016952294,0.0010268348,0.00024898982,0.00007230209,0.0005209151,0.0011855586,0.00012286118,0.0012696319,0.000038405284],"about_ca_topic_score_codex":0.0038952888,"about_ca_topic_score_gemma":0.009831792,"teacher_disagreement_score":0.0038952888,"about_ca_system_score_codex":0.0013701309,"about_ca_system_score_gemma":0.0024396623,"threshold_uncertainty_score":0.0099410415},"labels":[],"label_agreement":null},{"id":"W2042791872","doi":"10.1007/s10637-015-0228-4","title":"Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Concomitant; Glioma; Radiation therapy; Medicine; Chemotherapy; Pharmacology; Cancer research; Internal medicine","score_opus":0.0162601562638525,"score_gpt":0.2394931991475106,"score_spread":0.2232330428836581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042791872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393445,0.0012706511,0.0035094842,0.000089503104,0.000059025395,0.00005253193,0.00023332266,0.00011588772,0.0007350837],"genre_scores_gemma":[0.99138415,0.0011683046,0.004063823,0.000037332302,0.0000142482,0.000080930906,0.00024476968,0.000024706698,0.002981759],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989784,0.0000063553207,0.0000069553284,0.000030835734,0.000023335957,0.000034712826],"domain_scores_gemma":[0.99996376,0.000003529199,0.00001262042,0.000004468113,0.0000053948897,0.000010196875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014144197,0.00041473698,0.00034389438,0.00026134402,0.00013568564,0.0001352702,0.00031945447,0.00031811933,0.00078390515],"category_scores_gemma":[0.00006468547,0.00013659109,0.0003655229,0.00022693796,0.0002032271,0.00030037598,0.00012123491,0.00050295575,0.00015405136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040085296,0.00013841243,0.00007513642,0.000050005467,0.000005412444,0.000026629754,0.000017676217,0.00017649813,0.9964665,0.000077423916,0.00007814867,0.0024871496],"study_design_scores_gemma":[0.000022006634,0.0006975902,0.00051073986,0.000001499621,0.000020999456,0.000046473506,0.0000062913114,0.00072319456,0.9972185,0.00001746044,0.0007309612,0.000004308889],"about_ca_topic_score_codex":0.0017519264,"about_ca_topic_score_gemma":0.0018725165,"teacher_disagreement_score":0.0017519264,"about_ca_system_score_codex":0.0002653373,"about_ca_system_score_gemma":0.0003414459,"threshold_uncertainty_score":0.0034834146},"labels":[],"label_agreement":null},{"id":"W2043276988","doi":"10.1007/s10637-011-9649-x","title":"Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Phytochemicals and Medicinal Plants","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Tubulin; Cell cycle checkpoint; Chemistry; Cell cycle; Pharmacology; Microtubule; Cell; Biology; Biochemistry; Cell biology","score_opus":0.019239528468736885,"score_gpt":0.2366865553387708,"score_spread":0.21744702687003392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043276988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079835,0.002939033,0.0007312083,0.00010022183,0.000039706545,0.000031941978,0.00033752655,0.00011368617,0.0049083605],"genre_scores_gemma":[0.99633116,0.001291559,0.00048409682,0.000026589343,0.000013485505,0.000011821104,0.00026975386,0.000009053396,0.0015624422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99997675,0.0000024860624,0.0000020847283,0.0000047552135,0.0000054338566,0.000008500975],"domain_scores_gemma":[0.99997807,0.0000024421463,0.0000068465174,0.0000022212787,0.00000307006,0.0000073886945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003417473,0.00027349315,0.00014546256,0.00031979207,0.00018915097,0.000112684276,0.00012567572,0.00012450879,0.0009288644],"category_scores_gemma":[0.00003313381,0.000059639842,0.000168832,0.00012910902,0.00012890813,0.00013999724,0.00008414829,0.00025819908,0.00014747886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014102359,0.000029355966,0.00017539992,0.000047091427,0.000004528231,0.00006014659,0.000008245125,0.000050243238,0.99626046,0.00005565845,0.00006265329,0.0031052674],"study_design_scores_gemma":[0.000058809146,0.0006109442,0.00828553,0.0000055537116,0.000022479944,0.00023364068,0.000015568894,0.0004758002,0.9869761,0.00006602903,0.0032445749,0.0000050241024],"about_ca_topic_score_codex":0.0012593102,"about_ca_topic_score_gemma":0.001871358,"teacher_disagreement_score":0.0012593102,"about_ca_system_score_codex":0.00015214339,"about_ca_system_score_gemma":0.00016093021,"threshold_uncertainty_score":0.0031074286},"labels":[],"label_agreement":null},{"id":"W2044055451","doi":"10.1023/b:drug.0000036679.12112.4c","title":"Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-François d'Assise; Centre hospitalier universitaire de Québec","funders":"University of Texas MD Anderson Cancer Center","keywords":"Potency; In vivo; Medicine; Pharmacology; Life span; Bioisostere; Cytotoxicity; In vitro; Colorectal cancer; Cancer; Internal medicine; Chemistry; Chemical synthesis; Biology; Biochemistry","score_opus":0.010332806309681109,"score_gpt":0.24072094335159686,"score_spread":0.23038813704191574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044055451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402916,0.003587953,0.0005449173,0.00004835763,0.000026603155,0.000021379537,0.00033187206,0.00003515855,0.001374584],"genre_scores_gemma":[0.9935455,0.003169098,0.0007713694,0.000026150468,0.000023710796,0.000025253012,0.00036128864,0.000010018167,0.0020675936],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997961,0.00005938397,0.000020615218,0.000017709724,0.000051333467,0.000054824435],"domain_scores_gemma":[0.9996407,0.0001364254,0.00007203512,0.0000440234,0.000047829988,0.00005904559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036392594,0.0003202375,0.00032109412,0.0006876539,0.0002189526,0.00016612557,0.0002771621,0.00032863347,0.0010852917],"category_scores_gemma":[0.00023460822,0.0002105385,0.0002611191,0.00034454576,0.00025539086,0.00021464509,0.000117162876,0.0003838013,0.00017058024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077827694,0.00012182661,0.00042485775,0.000057529694,0.000014527444,0.00009159659,0.000035534667,0.00029139302,0.9956618,0.00007527829,0.000038229555,0.0024092565],"study_design_scores_gemma":[0.0000331465,0.0023111089,0.0030381281,0.0000070589604,0.000027108475,0.00010666242,0.000026304695,0.00036290305,0.99330294,0.000020481642,0.0007596092,0.0000045566553],"about_ca_topic_score_codex":0.0017061578,"about_ca_topic_score_gemma":0.0035220191,"teacher_disagreement_score":0.0017061578,"about_ca_system_score_codex":0.0002484195,"about_ca_system_score_gemma":0.00022349092,"threshold_uncertainty_score":0.0036306381},"labels":[],"label_agreement":null},{"id":"W2046295314","doi":"10.1007/s10637-010-9495-2","title":"Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acid","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Eicosanoids and Hypertension Pharmacology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FuelCell Energy (Canada); Quest University Canada; University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Sonodynamic therapy; Ascorbic acid; Chemistry; Reactive oxygen species; Mitochondrion; Photodynamic therapy; Fragmentation (computing); Programmed cell death; Apoptosis; Epoxyeicosatrienoic acid; Arachidonic acid; Antioxidant; Biochemistry; Pharmacology; Biology","score_opus":0.011147436213922881,"score_gpt":0.23489736729297583,"score_spread":0.22374993107905294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046295314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948376,0.0016079597,0.0020392037,0.00018430295,0.000030287632,0.00002252538,0.000045286408,0.00006551593,0.00116737],"genre_scores_gemma":[0.9971649,0.0007526029,0.0007867412,0.000067136105,0.00001676363,0.00001683791,0.00009300741,0.000010075589,0.0010919523],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992883,0.000013795704,0.000004971501,0.000008823073,0.000014416084,0.000029101551],"domain_scores_gemma":[0.9999343,0.000015097611,0.000020438523,0.0000069817397,0.000007983,0.000015256723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021924757,0.00026430763,0.00021965535,0.00013342663,0.00010357423,0.0001669709,0.0002927802,0.00032578816,0.0016993111],"category_scores_gemma":[0.00014851085,0.00013321622,0.0001994277,0.00006521092,0.0003407404,0.00034048353,0.00014204328,0.0005802106,0.00016084676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010081185,0.000049741153,0.00008855336,0.000034902045,0.0000064280484,0.000064194996,0.000014460115,0.000037476082,0.9957074,0.00022317666,0.000060583403,0.002705049],"study_design_scores_gemma":[0.00013023365,0.0011994825,0.0020341936,0.0000062270924,0.000023773287,0.00026470696,0.000031632415,0.000687915,0.9946338,0.00008586306,0.0008976725,0.0000044746835],"about_ca_topic_score_codex":0.0003357337,"about_ca_topic_score_gemma":0.00047804383,"teacher_disagreement_score":0.0016993111,"about_ca_system_score_codex":0.00023407354,"about_ca_system_score_gemma":0.00024963944,"threshold_uncertainty_score":0.0056847334},"labels":[],"label_agreement":null},{"id":"W2047528221","doi":"10.1007/s10637-010-9611-3","title":"A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Essar Steel Algoma (Canada); BC Cancer Agency; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Pancreatic cancer; Clinical endpoint; Oncology; Progressive disease; Phases of clinical research; Stage (stratigraphy); Deoxycytidine; Cancer; Chemotherapy; Clinical trial; Gastroenterology","score_opus":0.024561046939553282,"score_gpt":0.3483358976497588,"score_spread":0.3237748507102055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047528221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908059,0.0030055528,0.00051098096,0.00072490383,0.00023161342,0.0018606023,0.0009398477,0.000102197264,0.0018183821],"genre_scores_gemma":[0.98493356,0.005020354,0.0019129639,0.0008830995,0.00022801537,0.0017780935,0.0022118383,0.00004609449,0.0029859575],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957687,0.00019212098,0.000022476783,0.00007110728,0.000036369758,0.00010102874],"domain_scores_gemma":[0.999433,0.000090907015,0.00007666667,0.00005839945,0.000028581735,0.00031251268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015981041,0.0016372591,0.002858205,0.0007894281,0.0005484599,0.0013222836,0.0009625683,0.0013669508,0.0032666372],"category_scores_gemma":[0.0007803772,0.000907433,0.0018999387,0.00073288806,0.0014441018,0.0014009146,0.00043154552,0.0042586955,0.0009305577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6804173,0.12915723,0.005633905,0.0012748026,0.0021295142,0.0005293061,0.00041873875,0.0055312146,0.051310502,0.00062065135,0.0060531525,0.11692369],"study_design_scores_gemma":[0.54314804,0.43897006,0.007720801,0.000037643,0.0006627146,0.0003504401,0.00011036072,0.0016122289,0.0039956076,0.0002532857,0.0030944862,0.000044383614],"about_ca_topic_score_codex":0.0014795377,"about_ca_topic_score_gemma":0.004960762,"teacher_disagreement_score":0.0032666372,"about_ca_system_score_codex":0.0010922826,"about_ca_system_score_gemma":0.001799132,"threshold_uncertainty_score":0.010927975},"labels":[],"label_agreement":null},{"id":"W2050197847","doi":"10.1007/s10637-014-0159-5","title":"A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Doxorubicin; Pharmacokinetics; Pantoprazole; Medicine; Pharmacology; Chemotherapy; Internal medicine","score_opus":0.01229624724605933,"score_gpt":0.29589252283165135,"score_spread":0.28359627558559203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050197847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99387866,0.0016705883,0.00048332996,0.00073185697,0.00016056906,0.0010553414,0.0006724395,0.00009100019,0.0012562807],"genre_scores_gemma":[0.99053323,0.0021961196,0.0014231494,0.00059709104,0.00020267202,0.0013605023,0.0015853131,0.00005229289,0.002049667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99942315,0.0002529875,0.000023390503,0.000114161194,0.0000429753,0.00014334173],"domain_scores_gemma":[0.99898094,0.00020912683,0.00014447217,0.0000942773,0.000054400574,0.00051671104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011661424,0.0020664816,0.003308749,0.0006988036,0.00059839035,0.0012028693,0.0011986718,0.002050477,0.0031348013],"category_scores_gemma":[0.0012710824,0.0009026509,0.001738866,0.00096664566,0.0016539815,0.0014953747,0.00047049444,0.0047445674,0.0009014884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8280819,0.04330454,0.004879894,0.0006530506,0.0013507657,0.00035989014,0.00041991362,0.0035800573,0.038166568,0.00041233544,0.003139229,0.07565183],"study_design_scores_gemma":[0.56371635,0.42171267,0.007366919,0.00002404579,0.0004672202,0.0002614856,0.00009459901,0.001332752,0.0032722803,0.00012870226,0.001583903,0.000039118375],"about_ca_topic_score_codex":0.0020581225,"about_ca_topic_score_gemma":0.00558375,"teacher_disagreement_score":0.003308749,"about_ca_system_score_codex":0.0014843026,"about_ca_system_score_gemma":0.0020462896,"threshold_uncertainty_score":0.010769427},"labels":[],"label_agreement":null},{"id":"W2052076354","doi":"10.1007/s10637-013-9931-1","title":"A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Tolerability; Internal medicine; Sunitinib; Clinical endpoint; Renal cell carcinoma; Progressive disease; Phases of clinical research; Pazopanib; Oncology; Adverse effect; Gastroenterology; Clinical trial; Surgery; Disease","score_opus":0.03995789522017983,"score_gpt":0.3047918596194014,"score_spread":0.2648339643992216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052076354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901016,0.0031096549,0.00041011212,0.00071889046,0.00019078443,0.0011644325,0.0011259262,0.00008265241,0.003096077],"genre_scores_gemma":[0.98619825,0.002974094,0.0014857973,0.0013044291,0.00023008605,0.0010979122,0.0033390534,0.000034814344,0.0033356368],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995951,0.00024659108,0.000013164305,0.000046298464,0.00003657292,0.00006228731],"domain_scores_gemma":[0.99934155,0.00015382304,0.00010217666,0.00005774738,0.000030714124,0.0003138876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014716261,0.0011779033,0.0014882018,0.00038307792,0.00035139755,0.0007726428,0.0009050196,0.0009521985,0.0031095138],"category_scores_gemma":[0.0011163694,0.0004291782,0.0009509325,0.0003547734,0.0006904957,0.0005878556,0.00029700182,0.0028596707,0.0006563137],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7318078,0.05498347,0.009069496,0.00086773135,0.0024718104,0.0005305759,0.00028315146,0.003723381,0.03571662,0.0005813842,0.011371347,0.1485932],"study_design_scores_gemma":[0.7994143,0.17742042,0.014018847,0.00002733214,0.00059136795,0.00037736972,0.000046827543,0.0015541546,0.002681268,0.00027137328,0.0035637172,0.00003311396],"about_ca_topic_score_codex":0.0013893275,"about_ca_topic_score_gemma":0.0039070086,"teacher_disagreement_score":0.0031095138,"about_ca_system_score_codex":0.00072657753,"about_ca_system_score_gemma":0.0012038402,"threshold_uncertainty_score":0.010402381},"labels":[],"label_agreement":null},{"id":"W2052229320","doi":"10.1007/s10637-013-0040-y","title":"Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Androgen receptor; Antiandrogens; Prostate cancer; NF-κB; Androgen Receptor Antagonists; Chemistry; Androgen; Mutant; Cancer research; In vitro; Hedgehog signaling pathway; Signal transduction; Pharmacology; Biology; Medicine; Cancer; Internal medicine; Biochemistry; Gene; Hormone","score_opus":0.015647080231729855,"score_gpt":0.24870473195222512,"score_spread":0.23305765172049525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052229320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9403318,0.01993309,0.01834484,0.0002436045,0.00024813786,0.0005835131,0.0045322343,0.00017785405,0.015604926],"genre_scores_gemma":[0.9761945,0.006843957,0.0065443125,0.00009807873,0.000029328061,0.00014628802,0.0022587471,0.000025070694,0.007859671],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991655,0.000011011291,0.000011280934,0.000013833742,0.000022334332,0.00002494378],"domain_scores_gemma":[0.999936,0.000011187151,0.000017075197,0.000008365248,0.000012343078,0.000015064844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000171252,0.0004103352,0.0002068652,0.00027704504,0.00017954886,0.00016005532,0.00028619927,0.00015847263,0.0024572238],"category_scores_gemma":[0.00012540852,0.00009816172,0.00026173127,0.00026064055,0.00011825137,0.00020040022,0.00015387578,0.00030235792,0.0005557514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043109502,0.00012431583,0.00012178539,0.00022657774,0.000017472883,0.00015767867,0.00003815868,0.0006717897,0.99185115,0.0002813249,0.00023404112,0.0058445507],"study_design_scores_gemma":[0.00006906879,0.0012774176,0.0008012544,0.000019561989,0.00004170972,0.00013323252,0.000023108576,0.000344142,0.9863907,0.000058638332,0.010828835,0.000012301066],"about_ca_topic_score_codex":0.0006883266,"about_ca_topic_score_gemma":0.0017395804,"teacher_disagreement_score":0.0024572238,"about_ca_system_score_codex":0.00020130337,"about_ca_system_score_gemma":0.00033261854,"threshold_uncertainty_score":0.008220255},"labels":[],"label_agreement":null},{"id":"W2052372910","doi":"10.1023/b:drug.0000047107.35764.d9","title":"An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Fluorouracil; Angiogenesis; Pharmacokinetics; Matrix metalloproteinase; Angiogenesis inhibitor; Medicine; Matrix metalloproteinase inhibitor; Pharmacology; Internal medicine; Chemotherapy","score_opus":0.01035810629076799,"score_gpt":0.2652112211502177,"score_spread":0.2548531148594497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052372910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910851,0.00241448,0.0010725298,0.0006014546,0.00014131298,0.0013196225,0.0010950456,0.0001642118,0.0021063618],"genre_scores_gemma":[0.98946136,0.0020938385,0.0018903477,0.00048225222,0.00013824838,0.0010313647,0.001888771,0.00007410496,0.0029396992],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99933535,0.00033653775,0.000017879524,0.000079194724,0.0000752273,0.00015591146],"domain_scores_gemma":[0.998919,0.00018009283,0.00019234476,0.00008668483,0.000042492527,0.00057937973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014675166,0.001978432,0.0024852504,0.0009929929,0.00064443814,0.0011300467,0.0014372721,0.0015783514,0.0029230537],"category_scores_gemma":[0.0015066793,0.0010657426,0.0012784932,0.0010932591,0.0013024476,0.0009531403,0.00036686382,0.0048531457,0.0007807178],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5759237,0.118557915,0.007646422,0.0006227055,0.0017364348,0.0010444903,0.00062582863,0.011448664,0.16973543,0.0010466415,0.009421715,0.10219005],"study_design_scores_gemma":[0.33358237,0.6179906,0.018435622,0.00004513474,0.0008563309,0.0011969456,0.00012577463,0.00431993,0.016955297,0.00031123465,0.006097847,0.00008288734],"about_ca_topic_score_codex":0.00765771,"about_ca_topic_score_gemma":0.01425782,"teacher_disagreement_score":0.00765771,"about_ca_system_score_codex":0.00197321,"about_ca_system_score_gemma":0.0028201402,"threshold_uncertainty_score":0.015226245},"labels":[],"label_agreement":null},{"id":"W2056723407","doi":"10.1007/s10637-008-9143-2","title":"O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","year":2008,"lang":"fr","type":"article","venue":"Investigational New Drugs","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Mashhad University of Medical Sciences","keywords":"Medicine; Imatinib mesylate; Adverse effect; Phases of clinical research; Clinical trial; Melanoma; Internal medicine; Imatinib; Surgery; Oncology; Gastroenterology","score_opus":0.04069337693991506,"score_gpt":0.3313887372190749,"score_spread":0.2906953602791599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056723407","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987298,0.0047911895,0.00028829565,0.0015584686,0.00026968642,0.00063973636,0.0011915532,0.00008219858,0.0038808878],"genre_scores_gemma":[0.9814633,0.004392017,0.0017850469,0.0013446,0.00024711376,0.00079118606,0.003418049,0.00004966021,0.006509081],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996898,0.00013856146,0.0000098701585,0.00003783366,0.000025263918,0.00009863106],"domain_scores_gemma":[0.99949527,0.000075657386,0.00006217403,0.000022461963,0.000022292754,0.00032211552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015322792,0.0009052611,0.0013184771,0.00039106642,0.00043586153,0.0012823617,0.0006215755,0.0009294535,0.0029760806],"category_scores_gemma":[0.00075649953,0.00031811598,0.00086896954,0.00034954422,0.00067248166,0.0007971259,0.0004015243,0.002342496,0.000530728],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67696416,0.039989125,0.012912855,0.0012404476,0.001763452,0.0006550428,0.0004979821,0.0057960018,0.055354636,0.0014587721,0.024114061,0.17925347],"study_design_scores_gemma":[0.80658555,0.14399576,0.02507978,0.00014466073,0.0009699442,0.0007329703,0.00026493616,0.0031356346,0.004469988,0.0008859457,0.013666662,0.0000680907],"about_ca_topic_score_codex":0.0024072232,"about_ca_topic_score_gemma":0.011404433,"teacher_disagreement_score":0.0029760806,"about_ca_system_score_codex":0.001071376,"about_ca_system_score_gemma":0.0013398705,"threshold_uncertainty_score":0.009956002},"labels":[],"label_agreement":null},{"id":"W2058272907","doi":"10.1023/b:drug.0000006179.20974.af","title":"Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Cancer Institute","keywords":"Gemcitabine; Medicine; Cisplatin; Internal medicine; Regimen; Neutropenia; Chemotherapy; Oncology; Esophageal cancer; Toxicity; Phases of clinical research; Cancer","score_opus":0.03715668079495866,"score_gpt":0.3237959246812277,"score_spread":0.28663924388626905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058272907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781203,0.0013420676,0.000042792093,0.00012538253,0.000021472222,0.000096944685,0.00020059588,0.0000035398887,0.00035508486],"genre_scores_gemma":[0.9972422,0.0012617441,0.00011572711,0.0003152282,0.00009790724,0.00009365157,0.00049547304,0.000005038442,0.00037304425],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99869955,0.00071176974,0.0000991107,0.00018557328,0.00013820153,0.00016580784],"domain_scores_gemma":[0.99817884,0.00046724456,0.0004001257,0.00020055311,0.000100826845,0.00065244484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023634296,0.00092360424,0.002327264,0.00050221966,0.0008205176,0.0012031897,0.0008303575,0.0015796993,0.001804358],"category_scores_gemma":[0.0024576765,0.000732703,0.002412664,0.0012607619,0.0009360624,0.0015692523,0.0005911032,0.0021097562,0.00030302917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44877732,0.015243715,0.4903893,0.00053548533,0.0063265474,0.00071521016,0.0005323165,0.0014390575,0.0058108536,0.00020944542,0.0012153471,0.028805334],"study_design_scores_gemma":[0.105977625,0.15042533,0.7286722,0.00009791487,0.007761891,0.0009009259,0.0005100932,0.0012523682,0.0012301854,0.000260609,0.002836908,0.00007393159],"about_ca_topic_score_codex":0.0033364282,"about_ca_topic_score_gemma":0.0052388217,"teacher_disagreement_score":0.0033364282,"about_ca_system_score_codex":0.0015524981,"about_ca_system_score_gemma":0.0019068815,"threshold_uncertainty_score":0.012499154},"labels":[],"label_agreement":null},{"id":"W2058783279","doi":"10.1007/s10637-012-9837-3","title":"Investigational agents in development for the treatment of ovarian cancer","year":2012,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ovarian cancer; PI3K/AKT/mTOR pathway; Cancer research; Epidermal growth factor receptor; Cancer; Protein kinase B; Receptor tyrosine kinase; Biology; Tyrosine kinase; Medicine; Signal transduction; Pharmacology; Internal medicine; Receptor; Cell biology","score_opus":0.21656059714362874,"score_gpt":0.398267042823047,"score_spread":0.18170644567941824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058783279","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002000077,0.9984011,0.00013173513,0.00011542454,0.000102827384,0.000011534008,0.000030265379,0.000008007727,0.000999133],"genre_scores_gemma":[0.0009367598,0.9980149,0.00026336775,0.0001493571,0.00007796771,0.0000075470693,0.000043859847,0.0000011462905,0.0005051325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998,0.00003108741,0.00003643461,0.000031001848,0.000080114754,0.000021290702],"domain_scores_gemma":[0.99956864,0.00020632385,0.000097026474,0.000011040597,0.00008239196,0.000034691602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006056412,0.0008723143,0.0016214094,0.002675588,0.00028611088,0.0008469735,0.0008704931,0.0007627451,0.0042292755],"category_scores_gemma":[0.00079925265,0.00034337805,0.0007058595,0.0024832864,0.0004770074,0.0010334192,0.0006707841,0.0019750276,0.001368093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014933133,0.00014113431,0.0002236668,0.017178198,0.00014003104,0.0002404705,0.00004567223,0.00026602106,0.0018363551,0.0015644352,0.013716771,0.9644979],"study_design_scores_gemma":[0.000111008696,0.00032489095,0.0014220241,0.005121475,0.00047524445,0.0017574414,0.00007150648,0.00014313449,0.0011353834,0.0011161852,0.9882919,0.000029809591],"about_ca_topic_score_codex":0.0013374131,"about_ca_topic_score_gemma":0.0034306669,"teacher_disagreement_score":0.0042292755,"about_ca_system_score_codex":0.00047177076,"about_ca_system_score_gemma":0.0010440004,"threshold_uncertainty_score":0.0141483545},"labels":[],"label_agreement":null},{"id":"W2059255702","doi":"10.1007/s10637-014-0106-5","title":"A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Docetaxel; Dasatinib; Medicine; Prostate cancer; Oncology; Cancer; Internal medicine; Prostate; Pharmacology; Tyrosine kinase; Receptor","score_opus":0.03335540329604145,"score_gpt":0.3297910892392198,"score_spread":0.2964356859431784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059255702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873482,0.0031311626,0.00076731713,0.0009911752,0.0008231161,0.003780653,0.0010463694,0.000110778805,0.002001276],"genre_scores_gemma":[0.98614776,0.0020693026,0.0019084045,0.0014012301,0.000601854,0.0033801238,0.0014624377,0.000048474165,0.0029803484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989484,0.000531325,0.00006035225,0.00021648411,0.000063185675,0.00018026722],"domain_scores_gemma":[0.9981501,0.00042921645,0.00031273696,0.00018189911,0.00009061965,0.0008354742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023388881,0.0022161966,0.005246327,0.0006613592,0.0007244442,0.0018417441,0.0016069012,0.00204151,0.007915541],"category_scores_gemma":[0.0024137672,0.0013977368,0.002639798,0.00071392325,0.0023723373,0.0023725757,0.00069118146,0.0057364195,0.0015070983],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98159206,0.008564121,0.00040753558,0.00016848232,0.00055509654,0.000023320967,0.000038650207,0.00032377322,0.0016058712,0.00007788199,0.00038381136,0.0062593105],"study_design_scores_gemma":[0.93363583,0.06441218,0.000805063,0.00000764369,0.00027382938,0.000020666817,0.000018735072,0.00021937687,0.00016490597,0.000099233745,0.00032900224,0.00001349295],"about_ca_topic_score_codex":0.0014808994,"about_ca_topic_score_gemma":0.0035551551,"teacher_disagreement_score":0.007915541,"about_ca_system_score_codex":0.0015415532,"about_ca_system_score_gemma":0.002070746,"threshold_uncertainty_score":0.026480079},"labels":[],"label_agreement":null},{"id":"W2061189534","doi":"10.1007/s10637-009-9236-6","title":"Cyclin-dependent kinase inhibitors as potential targeted anticancer agents","year":2009,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cyclin-dependent kinase; Kinase; Cell cycle; Cyclin; CDK inhibitor; Biology; Cancer research; Drug development; Cell biology; Cell; Drug; Pharmacology; Biochemistry","score_opus":0.03175408200627041,"score_gpt":0.32445668209352097,"score_spread":0.2927026000872506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061189534","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005542269,0.99451905,0.00055965723,0.00031112862,0.00034435614,0.00001990347,0.00004964172,0.000024052535,0.0036179705],"genre_scores_gemma":[0.0025106147,0.9940216,0.0006108359,0.00028224505,0.00017831588,0.00001851507,0.00008424259,0.0000032728258,0.0022902854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998989,0.0000151111635,0.000014070547,0.000020393798,0.000036901325,0.000014508362],"domain_scores_gemma":[0.9998797,0.000049118382,0.000023480234,0.000005330166,0.00002913814,0.00001322181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004586164,0.0010004888,0.0013094036,0.0015306371,0.00020004953,0.0006722574,0.0007513544,0.0006065941,0.003516344],"category_scores_gemma":[0.00039856153,0.00030067368,0.00033535334,0.0015322026,0.0004046026,0.0010340953,0.0004682843,0.0015018199,0.0018321824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019247025,0.00014919031,0.00013415194,0.0065442477,0.000076418444,0.00029175467,0.00003511782,0.00064266485,0.006288972,0.0032676565,0.028564043,0.95381343],"study_design_scores_gemma":[0.00007630078,0.00017448142,0.000569889,0.00083086727,0.00016433712,0.0011473034,0.000023734325,0.00023771306,0.00244991,0.0011361331,0.99317414,0.000015349951],"about_ca_topic_score_codex":0.0006228924,"about_ca_topic_score_gemma":0.0022313315,"teacher_disagreement_score":0.003516344,"about_ca_system_score_codex":0.0006019687,"about_ca_system_score_gemma":0.000629427,"threshold_uncertainty_score":0.011763334},"labels":[],"label_agreement":null},{"id":"W2063038645","doi":"10.1007/s10637-009-9246-4","title":"Esophageal ulcer in a patient who received bevacizumab","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Bevacizumab; Irinotecan; Perforation; Esophagus; Esophageal Ulcer; Surgery; Esophageal cancer; Regimen; Endoscopy; Dysphagia; Gastroenterology; Endoscopic mucosal resection; Ileostomy; Internal medicine; Colorectal cancer; Chemotherapy; Cancer","score_opus":0.015227393686470305,"score_gpt":0.2713807269272034,"score_spread":0.2561533332407331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063038645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96611965,0.004331348,0.00063055585,0.0063123666,0.0005477105,0.00012507546,0.0002826482,0.0000933613,0.021557236],"genre_scores_gemma":[0.99381423,0.0012499611,0.00046081684,0.0018347474,0.00074660126,0.000008757812,0.00013188593,0.000009553,0.001743438],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99968374,0.000040154508,0.00003853837,0.000049483533,0.000046636582,0.00014151867],"domain_scores_gemma":[0.9990108,0.00035594826,0.00016534561,0.000050485498,0.000057348716,0.000360086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002630128,0.0006633034,0.0008768887,0.0017852121,0.0017004019,0.0012397498,0.0006109128,0.0045420243,0.00397157],"category_scores_gemma":[0.0023931626,0.00058031484,0.0011207536,0.0010023358,0.0006279979,0.0011618419,0.00068496336,0.0023014797,0.0006645135],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033315693,0.00009426756,0.019331371,0.000022484019,0.000019817793,0.97794205,0.000057440036,0.000027553197,0.0004976269,0.00009058122,0.00028068986,0.0013028734],"study_design_scores_gemma":[0.00011564493,0.0006686712,0.042668197,0.000036225407,0.00011994395,0.9531383,0.00034308914,0.00048752635,0.0007561164,0.00015483607,0.0014915135,0.000019943433],"about_ca_topic_score_codex":0.0028558522,"about_ca_topic_score_gemma":0.0046599843,"teacher_disagreement_score":0.0045420243,"about_ca_system_score_codex":0.0011618985,"about_ca_system_score_gemma":0.0006698157,"threshold_uncertainty_score":0.013286233},"labels":[],"label_agreement":null},{"id":"W2063432158","doi":"10.1007/s10637-011-9719-0","title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Internal medicine; Gallbladder; Gastroenterology; Oncology; Carcinoma; Hepatocellular carcinoma; Stage (stratigraphy); Chemotherapy; Gallbladder cancer","score_opus":0.04928934074195547,"score_gpt":0.27559561059896975,"score_spread":0.2263062698570143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063432158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949981,0.002284264,0.00020656492,0.0003763201,0.000105970925,0.0007266558,0.00059570605,0.000035906214,0.0006704669],"genre_scores_gemma":[0.9885698,0.0032533866,0.0013992854,0.0007985196,0.00020779399,0.0015246657,0.0025458066,0.00003114834,0.0016695951],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99910116,0.000579303,0.000051220257,0.00008212253,0.000052279225,0.0001338971],"domain_scores_gemma":[0.9989128,0.0002218646,0.00018966699,0.00009387192,0.00007645165,0.0005053153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033432485,0.0018060353,0.0032131565,0.0006994082,0.0005668968,0.0010649398,0.0009434691,0.0009602834,0.0030856114],"category_scores_gemma":[0.0015559582,0.0009009663,0.0025675576,0.0008004168,0.0012783465,0.0014626135,0.0006103276,0.0028407304,0.0005935458],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8113683,0.040982604,0.034775134,0.0016512201,0.0060611903,0.00027636386,0.00041791055,0.002223189,0.014480198,0.00036140473,0.004466065,0.082936436],"study_design_scores_gemma":[0.6564785,0.2995722,0.034400456,0.000049341477,0.0022195664,0.00032783407,0.00020151309,0.00092489604,0.0019444656,0.00016647002,0.0036568404,0.00005791236],"about_ca_topic_score_codex":0.0019153574,"about_ca_topic_score_gemma":0.006044092,"teacher_disagreement_score":0.0033432485,"about_ca_system_score_codex":0.00116014,"about_ca_system_score_gemma":0.0030638229,"threshold_uncertainty_score":0.017681003},"labels":[],"label_agreement":null},{"id":"W2064256411","doi":"10.1007/s10637-015-0222-x","title":"3,4′,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sirtuins and Resveratrol in Medicine","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Resveratrol; Phytoalexin; In vivo; Pharmacology; Polyphenol; Potency; Apoptosis; Angiogenesis; In vitro; Cell growth; Cell cycle; Cancer; Chemistry; Cancer research; Biology; Biochemistry; Biotechnology; Antioxidant; Genetics","score_opus":0.023703673029608102,"score_gpt":0.28568552796131413,"score_spread":0.261981854931706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064256411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94899756,0.016247544,0.011186397,0.0007639322,0.00034287074,0.00010909858,0.0009744367,0.0004063308,0.02097184],"genre_scores_gemma":[0.9846036,0.004085287,0.004029397,0.00017783915,0.000047274596,0.000017312748,0.0006489542,0.000023544662,0.0063667246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999182,0.00002701029,0.0000066743037,0.000016884853,0.000017390359,0.000013745759],"domain_scores_gemma":[0.99994123,0.000010755209,0.000012718474,0.000009030883,0.000008945817,0.000017327817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018059846,0.00025367198,0.0002529308,0.00035317955,0.00015134296,0.0002065735,0.00027627088,0.00030220518,0.002275078],"category_scores_gemma":[0.00012112675,0.000100743775,0.000288492,0.00019391857,0.00021463975,0.00020528877,0.0001308132,0.0005065169,0.00067830423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043224866,0.00008017249,0.00009537694,0.00010494857,0.0000145526055,0.00015622325,0.000025687204,0.00018494736,0.9908021,0.0005818803,0.0002659209,0.007255979],"study_design_scores_gemma":[0.00004921257,0.0015242974,0.00097426993,0.000012133592,0.00004573836,0.0005578145,0.00003439026,0.00048140666,0.9810714,0.00013250747,0.015105866,0.000010848086],"about_ca_topic_score_codex":0.0003185008,"about_ca_topic_score_gemma":0.00090948876,"teacher_disagreement_score":0.002275078,"about_ca_system_score_codex":0.00019131033,"about_ca_system_score_gemma":0.00015030031,"threshold_uncertainty_score":0.007610917},"labels":[],"label_agreement":null},{"id":"W2066557153","doi":"10.1007/s10637-011-9673-x","title":"A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Gemcitabine; Eribulin; Medicine; Internal medicine; Pancreatic cancer; Neutropenia; Gastroenterology; Phases of clinical research; Oncology; Progressive disease; Clinical endpoint; Refractory (planetary science); Adverse effect; Cancer; Metastatic breast cancer; Chemotherapy; Breast cancer; Clinical trial","score_opus":0.04866918016163396,"score_gpt":0.34107250550963053,"score_spread":0.29240332534799657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066557153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474996,0.0015593676,0.0003659733,0.00034556098,0.000088270834,0.0009529833,0.00047339557,0.000043225147,0.0014213852],"genre_scores_gemma":[0.99097097,0.00263449,0.00096736895,0.0005635799,0.00012096899,0.001028304,0.0012184145,0.000031004565,0.002464819],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962187,0.0002094315,0.000016115038,0.00005206713,0.000023228062,0.000077285746],"domain_scores_gemma":[0.9994436,0.00010264693,0.000075196214,0.00006531311,0.00002547753,0.00028775804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011905126,0.0011593583,0.0022779126,0.00046833637,0.00043367737,0.0008930809,0.0008365808,0.0011068122,0.0031446638],"category_scores_gemma":[0.0006931683,0.0005426839,0.0010028105,0.0004700531,0.0009917959,0.0010351883,0.00034933735,0.0026882295,0.0007296066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73749495,0.08203226,0.0056531997,0.00086208433,0.0014897599,0.0005624188,0.0003835496,0.0049992804,0.06086393,0.00044563497,0.0032732922,0.10193968],"study_design_scores_gemma":[0.4963288,0.48335332,0.008862546,0.00003409113,0.00051339925,0.00040138935,0.0001427749,0.0014713849,0.0053763418,0.00026277232,0.0032126342,0.000040576055],"about_ca_topic_score_codex":0.0012822364,"about_ca_topic_score_gemma":0.003241423,"teacher_disagreement_score":0.0031446638,"about_ca_system_score_codex":0.00079063897,"about_ca_system_score_gemma":0.0010978088,"threshold_uncertainty_score":0.010519922},"labels":[],"label_agreement":null},{"id":"W2067193622","doi":"10.1023/b:drug.0000026252.86842.e2","title":"A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hamilton Regional Laboratory Medicine Program; BC Cancer Agency","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Toxicity; Limiting; Maximum tolerated dose; Chemotherapy; Gastroenterology; Internal medicine; Surgery; Pharmacology","score_opus":0.012139141604533549,"score_gpt":0.2486694885995397,"score_spread":0.23653034699500614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067193622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953244,0.0011427647,0.00037881624,0.00034364514,0.00014424238,0.0010890662,0.00039263026,0.000047311292,0.0011370867],"genre_scores_gemma":[0.99072707,0.002064853,0.0013775136,0.000524477,0.0001734616,0.001528955,0.0009567969,0.00003621252,0.0026105624],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967086,0.00013143143,0.000009930112,0.000060288115,0.000024367195,0.00010326614],"domain_scores_gemma":[0.99951506,0.00012189009,0.00006190322,0.000048753827,0.000029624263,0.00022265436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010386731,0.0014188908,0.002696197,0.00047271993,0.0005876242,0.00094859645,0.0007627273,0.0012327477,0.0021290155],"category_scores_gemma":[0.0007762061,0.00075787737,0.0015383654,0.00051994005,0.0013287675,0.0007441179,0.00026075813,0.0039367476,0.00060184795],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7201899,0.10966451,0.006403272,0.0008940361,0.00096249196,0.00051345996,0.0006624283,0.0043976586,0.059400003,0.0006204675,0.0039730123,0.09231872],"study_design_scores_gemma":[0.30748618,0.6774377,0.0067006485,0.000025780913,0.00037333995,0.00026543858,0.00010245022,0.0011820982,0.0038901893,0.0001818347,0.0023158025,0.00003852509],"about_ca_topic_score_codex":0.0018059794,"about_ca_topic_score_gemma":0.0039835316,"teacher_disagreement_score":0.002696197,"about_ca_system_score_codex":0.0009106979,"about_ca_system_score_gemma":0.0019750493,"threshold_uncertainty_score":0.007122278},"labels":[],"label_agreement":null},{"id":"W2068833931","doi":"10.1007/s10637-008-9184-6","title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Docetaxel; Calcitriol; Medicine; Pancreatic cancer; Internal medicine; Oncology; Cancer; Cancer research; Calcium","score_opus":0.04046030513904524,"score_gpt":0.3491620148261989,"score_spread":0.30870170968715366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068833931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928738,0.0018760039,0.00047447011,0.00046427577,0.00018020639,0.0016787667,0.0007140452,0.00007099639,0.0016673099],"genre_scores_gemma":[0.9904143,0.0023692674,0.0009621883,0.0005086562,0.00016099574,0.001263526,0.0012269766,0.00003732143,0.00305679],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995857,0.00016008009,0.000015353717,0.000081563565,0.000030850933,0.00012649206],"domain_scores_gemma":[0.9992737,0.0001311725,0.000093222865,0.00006589644,0.00003416101,0.00040180763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012592498,0.0015772968,0.0030181159,0.0005828384,0.00067674194,0.0014760415,0.0011111536,0.0012562345,0.003459282],"category_scores_gemma":[0.00090767205,0.0008038251,0.0015080472,0.00070736086,0.0015946164,0.0010040394,0.00039597985,0.004287837,0.0009371874],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7230403,0.119841315,0.007950253,0.0008972535,0.0016289589,0.0006086057,0.0007391652,0.005828693,0.038754914,0.0006060656,0.004508068,0.09559638],"study_design_scores_gemma":[0.49014103,0.4937225,0.008158169,0.000031994005,0.0005056339,0.00027431338,0.00013027914,0.0012018114,0.0029989704,0.00017028266,0.0026298484,0.000035120516],"about_ca_topic_score_codex":0.004259155,"about_ca_topic_score_gemma":0.009895863,"teacher_disagreement_score":0.004259155,"about_ca_system_score_codex":0.0014519092,"about_ca_system_score_gemma":0.0024739325,"threshold_uncertainty_score":0.011572421},"labels":[],"label_agreement":null},{"id":"W2070030853","doi":"10.1007/s10637-012-9856-0","title":"A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Neutropenia; Paclitaxel; Lung cancer; Adverse effect; Internal medicine; Toxicity; Population; Oncology; Pharmacology; Chemotherapy; Gastroenterology","score_opus":0.011286878644105476,"score_gpt":0.31518292024716726,"score_spread":0.3038960416030618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070030853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961235,0.00093486323,0.0005007082,0.00032200702,0.000085158346,0.00061858754,0.0003673142,0.0000851633,0.0009627335],"genre_scores_gemma":[0.9953479,0.0009492563,0.00086713996,0.00029130006,0.00014368973,0.000589469,0.0006593522,0.000050653536,0.001101216],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994324,0.0002582595,0.000019580913,0.000115620816,0.000048449365,0.00012569518],"domain_scores_gemma":[0.9991359,0.00017597462,0.00016103372,0.000094848925,0.000039178092,0.00039308314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011023339,0.0016154335,0.0028680912,0.0006565217,0.00065068627,0.0014344634,0.0009857124,0.0012872539,0.00239973],"category_scores_gemma":[0.0014345817,0.000976937,0.0016061094,0.0007865521,0.0011420127,0.0014934628,0.00035792566,0.004557115,0.0007841032],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72682804,0.089410484,0.011558042,0.00038527325,0.0015251146,0.0005714374,0.000569791,0.005521827,0.060379107,0.00045451557,0.0031290366,0.09966727],"study_design_scores_gemma":[0.42586803,0.53787786,0.020321952,0.000024258943,0.00075923523,0.0006041259,0.00013244359,0.004063998,0.007103363,0.0002497412,0.0029195226,0.000075462645],"about_ca_topic_score_codex":0.0014368937,"about_ca_topic_score_gemma":0.0026593541,"teacher_disagreement_score":0.0028680912,"about_ca_system_score_codex":0.0014046222,"about_ca_system_score_gemma":0.0017118296,"threshold_uncertainty_score":0.010191321},"labels":[],"label_agreement":null},{"id":"W2070830789","doi":"10.1023/b:drug.0000011792.13160.b0","title":"Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days","year":2004,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Pharmacokinetics; Medicine; Pharmacology; Dosing; Bolus (digestion); Tolerability; Bilirubin; Toxicity; Nausea; Internal medicine; Adverse effect","score_opus":0.020678511874418576,"score_gpt":0.3127480514658571,"score_spread":0.29206953959143855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070830789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956234,0.0006217081,0.00083252555,0.00024573857,0.000111953515,0.0008694264,0.0006645145,0.00007896334,0.00095193216],"genre_scores_gemma":[0.99457586,0.0005780992,0.00097168697,0.00030120753,0.00010525419,0.00073073927,0.0009424067,0.000036813868,0.001757911],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993862,0.00020316958,0.00001970394,0.00014061514,0.000059557802,0.00019074442],"domain_scores_gemma":[0.9990305,0.00017735487,0.00016283551,0.00014204798,0.00006337796,0.00042402238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009951006,0.001464216,0.0024722375,0.00058492133,0.0005499916,0.0010158201,0.0012206045,0.0013738112,0.0018919313],"category_scores_gemma":[0.0013133404,0.00080766715,0.0010096744,0.0006616029,0.0017688256,0.0012381291,0.00028583227,0.0036546078,0.000651497],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7408345,0.0881433,0.0031473376,0.0002772811,0.0006560503,0.00039099864,0.00038763747,0.004623393,0.10013251,0.0006934435,0.0038937866,0.05681976],"study_design_scores_gemma":[0.18851343,0.7765649,0.010724988,0.00002205666,0.00031529737,0.00044534012,0.000115480274,0.002817221,0.016589932,0.00034551974,0.0034857825,0.000060002887],"about_ca_topic_score_codex":0.0028804454,"about_ca_topic_score_gemma":0.0033234085,"teacher_disagreement_score":0.0028804454,"about_ca_system_score_codex":0.0013599162,"about_ca_system_score_gemma":0.0022555282,"threshold_uncertainty_score":0.009866893},"labels":[],"label_agreement":null},{"id":"W2072016597","doi":"10.1007/s10637-011-9700-y","title":"Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Apoptosis; Jurkat cells; Cell culture; Cell growth; Chemistry; Growth inhibition; Cell biology; Kinase; Flow cytometry; Cancer research; Molecular biology; Biology; Biochemistry; Immunology; T cell; Genetics","score_opus":0.023515593660788064,"score_gpt":0.2322449968493194,"score_spread":0.20872940318853134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072016597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746824,0.018803634,0.0024721152,0.00022675788,0.00008518941,0.00005463062,0.00020112909,0.00014855497,0.0033256034],"genre_scores_gemma":[0.9889338,0.0070095574,0.001868873,0.00008191638,0.000040306335,0.000032896634,0.00033617424,0.000011291106,0.0016852595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999162,0.000026367967,0.000007662188,0.000010614992,0.000020432522,0.000018796001],"domain_scores_gemma":[0.9999467,0.000013164792,0.000015612659,0.000005725807,0.0000053306653,0.000013442686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019951841,0.00021843775,0.00033129187,0.00017606727,0.00012549908,0.00016732248,0.00016191391,0.00015520434,0.00047939137],"category_scores_gemma":[0.00010203962,0.0001088774,0.00012326804,0.00012670731,0.0001318701,0.00009238174,0.00012648688,0.00034518476,0.00019022259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015144604,0.00010531614,0.000577275,0.00013203696,0.000016745684,0.00025243414,0.00001870867,0.00026603736,0.9679537,0.00026105501,0.0003437353,0.028558517],"study_design_scores_gemma":[0.00040025316,0.0042072153,0.0049298415,0.0000093234385,0.000046545934,0.0015697296,0.000013537993,0.00061531493,0.9765371,0.000057011,0.0116050495,0.000009077181],"about_ca_topic_score_codex":0.00021994207,"about_ca_topic_score_gemma":0.0007055387,"teacher_disagreement_score":0.00047939137,"about_ca_system_score_codex":0.0002083067,"about_ca_system_score_gemma":0.00013247506,"threshold_uncertainty_score":0.0016037822},"labels":[],"label_agreement":null},{"id":"W2073021016","doi":"10.1007/s10637-005-0793-z","title":"Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Medicine; Carcinoma; Internal medicine; Oncology; Phases of clinical research; Chemotherapy","score_opus":0.019725545834419628,"score_gpt":0.2647082686783908,"score_spread":0.24498272284397118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073021016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563295,0.001087751,0.00035475826,0.0003076402,0.000091338785,0.00091233366,0.00044138252,0.00005548823,0.0011162448],"genre_scores_gemma":[0.9941426,0.0011007503,0.0007545383,0.00042211317,0.00010420569,0.00079975877,0.00085496553,0.00002192037,0.0017992317],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996674,0.00017485891,0.000011632202,0.00004824164,0.00002633678,0.00007147427],"domain_scores_gemma":[0.99952006,0.00010668211,0.00006455367,0.000044537723,0.000022693472,0.0002414633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008105429,0.0010028478,0.0027305475,0.00035331867,0.00041079492,0.0007346649,0.0008075501,0.00088333496,0.002507199],"category_scores_gemma":[0.0007149241,0.00044620136,0.0008783035,0.00041037414,0.001229098,0.0005452852,0.00029308768,0.0034019721,0.00054836815],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7448692,0.08123733,0.0075309216,0.00071936456,0.0013560625,0.00051053095,0.00030409513,0.0031322183,0.059796743,0.00046927185,0.004151102,0.095923215],"study_design_scores_gemma":[0.5466919,0.43304417,0.009839546,0.000022023329,0.0004412385,0.00028838858,0.0000863653,0.0014745308,0.0056767934,0.00019064156,0.0022112909,0.00003322076],"about_ca_topic_score_codex":0.0027649861,"about_ca_topic_score_gemma":0.004830645,"teacher_disagreement_score":0.0027649861,"about_ca_system_score_codex":0.0010972813,"about_ca_system_score_gemma":0.0019278032,"threshold_uncertainty_score":0.008387446},"labels":[],"label_agreement":null},{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","score_opus":0.026954450114541846,"score_gpt":0.30517916414720736,"score_spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073369621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890661,0.0035949266,0.0005000499,0.0012059434,0.0003945815,0.0013438775,0.0013454978,0.00011281976,0.002436002],"genre_scores_gemma":[0.9835707,0.0042345487,0.001581452,0.0012328335,0.00033834318,0.0010321545,0.003187013,0.000030068863,0.0047929045],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978894,0.000091353926,0.000010340119,0.00003497463,0.000019141084,0.000055189623],"domain_scores_gemma":[0.99951017,0.00009343346,0.000059137456,0.000029245499,0.000023178047,0.00028485936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009606758,0.0013891264,0.0022263413,0.0005156381,0.00043039705,0.00071928,0.0006501324,0.0009898527,0.003649394],"category_scores_gemma":[0.00086111034,0.00050002337,0.0010004115,0.00049861457,0.00090851524,0.00079372956,0.0002519464,0.0029986624,0.00080660614],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8685768,0.020580279,0.0040417137,0.00068265013,0.0009908834,0.0002754401,0.00018978081,0.0019399964,0.02064134,0.0003728233,0.005736889,0.075971335],"study_design_scores_gemma":[0.82863265,0.15853651,0.0073812394,0.000023090859,0.00034799206,0.00021776224,0.000050363025,0.00078115036,0.0012873589,0.00017650404,0.0025419623,0.000023486158],"about_ca_topic_score_codex":0.0017013241,"about_ca_topic_score_gemma":0.0050756745,"teacher_disagreement_score":0.003649394,"about_ca_system_score_codex":0.0008193612,"about_ca_system_score_gemma":0.0012697738,"threshold_uncertainty_score":0.012208402},"labels":[],"label_agreement":null},{"id":"W2074077730","doi":"10.1007/s10637-008-9190-8","title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Colorectal cancer; Internal medicine; Chemotherapy; Oncology; Regimen; Performance status; Mucositis; Induction chemotherapy; Cancer; Surgery; Histone deacetylase; Biology; Histone","score_opus":0.0150066062739379,"score_gpt":0.30320357760859734,"score_spread":0.28819697133465944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074077730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932995,0.0015753282,0.00032622123,0.0007166256,0.00018386275,0.0010300197,0.001445881,0.00010453709,0.0013179525],"genre_scores_gemma":[0.98306966,0.0027773527,0.0015580785,0.00122796,0.0002900943,0.0016140628,0.005082017,0.000049963037,0.004330957],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996308,0.00017866406,0.00001473609,0.000059822654,0.000024710898,0.0000911963],"domain_scores_gemma":[0.9991272,0.000096890995,0.00012742885,0.00006103086,0.00003367264,0.0005537823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013689805,0.00208435,0.0028751462,0.00048697248,0.0004713646,0.0009210409,0.0010616381,0.0013711244,0.0041123307],"category_scores_gemma":[0.0007252908,0.0006339309,0.0018944488,0.0005856714,0.001222596,0.0008032229,0.00043967395,0.0036592642,0.0012248678],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85513365,0.03381192,0.008348008,0.00047752907,0.001727502,0.00031927516,0.00023357979,0.0027813227,0.025941733,0.00023533503,0.005691161,0.06529902],"study_design_scores_gemma":[0.6952971,0.2839941,0.014782594,0.000023770719,0.00052883325,0.00029726172,0.00007084549,0.0010881925,0.0018003047,0.00016431918,0.0019248308,0.000027909615],"about_ca_topic_score_codex":0.0036829116,"about_ca_topic_score_gemma":0.011560454,"teacher_disagreement_score":0.0041123307,"about_ca_system_score_codex":0.0011873873,"about_ca_system_score_gemma":0.0024472938,"threshold_uncertainty_score":0.01375711},"labels":[],"label_agreement":null},{"id":"W2075532113","doi":"10.1007/s10637-014-0138-x","title":"Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Irinotecan; Diarrhea; Medicine; Camptothecin; Toxicity; Pharmacology; Pharmacokinetics; Gastroenterology; Colorectal cancer; Internal medicine; Cancer; Biology; Biochemistry","score_opus":0.0234114526948035,"score_gpt":0.2835922386419162,"score_spread":0.2601807859471127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075532113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926165,0.0011876634,0.0034662716,0.00020337738,0.000115395036,0.00014508689,0.00034985656,0.00019812881,0.001717829],"genre_scores_gemma":[0.98577833,0.00212141,0.004396568,0.00009808006,0.000032925724,0.00016922846,0.00065252994,0.00003292604,0.0067179813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997631,0.000031240026,0.000022546199,0.000043483895,0.000060331808,0.000079390324],"domain_scores_gemma":[0.9997676,0.000023233973,0.000071799266,0.00002208914,0.000046585683,0.00006877476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002545415,0.00088034023,0.0006726259,0.0005699508,0.00022001065,0.00024586054,0.0003252764,0.00060885854,0.0013593024],"category_scores_gemma":[0.00015264573,0.00027377598,0.00046251543,0.0002138337,0.00038976473,0.00051347807,0.00017111342,0.0015043182,0.0003145477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005878497,0.00045307545,0.000060518607,0.00007869612,0.000008484797,0.00005965859,0.00002598934,0.00016387638,0.99662316,0.00006992118,0.000064014646,0.0018048498],"study_design_scores_gemma":[0.000053224692,0.005555298,0.00084526936,0.000007505165,0.000024229397,0.00009039374,0.000024628775,0.0005535218,0.9919314,0.00002199016,0.00088579115,0.0000067410024],"about_ca_topic_score_codex":0.0015825988,"about_ca_topic_score_gemma":0.0024015459,"teacher_disagreement_score":0.0015825988,"about_ca_system_score_codex":0.00041823057,"about_ca_system_score_gemma":0.00062052195,"threshold_uncertainty_score":0.0045473576},"labels":[],"label_agreement":null},{"id":"W2076465532","doi":"10.1007/s10637-007-9104-1","title":"A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Doxorubicin; Hepatocellular carcinoma; Medicine; Sodium; Chemistry; Internal medicine; Chemotherapy","score_opus":0.013069935389937452,"score_gpt":0.25746976716384384,"score_spread":0.2443998317739064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076465532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939056,0.001124618,0.00058988575,0.00043466437,0.00013965942,0.0018539481,0.00069209427,0.00009013935,0.0011692923],"genre_scores_gemma":[0.9872443,0.002379349,0.0017326112,0.0005379514,0.00020044317,0.0024418163,0.0017272633,0.00005932892,0.0036769127],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993772,0.00029778067,0.000021343447,0.000103520826,0.000039283874,0.0001608933],"domain_scores_gemma":[0.9990896,0.00014635889,0.000112446825,0.000121301644,0.00004179574,0.00048856414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016794308,0.0021795977,0.0031329677,0.0009778617,0.00072441285,0.001038211,0.0013134005,0.0016829666,0.0034255157],"category_scores_gemma":[0.00090980117,0.0011435671,0.0014781569,0.00093118113,0.0022609388,0.0014897954,0.0004580624,0.0037081107,0.0009325485],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7071076,0.12948747,0.0046544243,0.0007580164,0.0013350998,0.00049180497,0.00063973985,0.0041536805,0.08192389,0.0006296682,0.0039016588,0.06491685],"study_design_scores_gemma":[0.41422167,0.5676158,0.006024907,0.000022042323,0.00040075762,0.00024509564,0.00012029782,0.0009540699,0.007867347,0.00023210314,0.0022520635,0.000043845546],"about_ca_topic_score_codex":0.003904621,"about_ca_topic_score_gemma":0.008547385,"teacher_disagreement_score":0.003904621,"about_ca_system_score_codex":0.0012442003,"about_ca_system_score_gemma":0.002448831,"threshold_uncertainty_score":0.01145947},"labels":[],"label_agreement":null},{"id":"W2078057935","doi":"10.1007/s10637-011-9722-5","title":"A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"Bayer Canada","keywords":"Bicalutamide; Medicine; Sorafenib; Prostate cancer; Internal medicine; Oncology; Adverse effect; Clinical endpoint; Rash; Clinical trial; Cancer; Androgen receptor; Hepatocellular carcinoma","score_opus":0.031659175896759706,"score_gpt":0.30201894918646277,"score_spread":0.27035977328970306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078057935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928126,0.002044889,0.0004710047,0.0005937749,0.00025446166,0.0017262376,0.00062993926,0.0000814872,0.0013856502],"genre_scores_gemma":[0.9916421,0.0019998571,0.0009771188,0.0005089765,0.0002450969,0.0014698972,0.0012068442,0.000034700457,0.0019153988],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993754,0.00029990135,0.000029427845,0.00010683383,0.00004414358,0.00014429977],"domain_scores_gemma":[0.9989711,0.00015856298,0.00012057557,0.00008860965,0.000056641096,0.0006043734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014110941,0.0018597912,0.003869176,0.00072714937,0.0006362434,0.0012413107,0.0010456607,0.0012138122,0.004030726],"category_scores_gemma":[0.0012383802,0.0010130632,0.002183112,0.0006947122,0.0014728627,0.0014756733,0.00045938735,0.0046015778,0.0010825513],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8629736,0.05618214,0.0034047663,0.00071247946,0.0016084602,0.00024532486,0.0003452315,0.0021534387,0.016337508,0.00023257436,0.0022066727,0.053597897],"study_design_scores_gemma":[0.6729148,0.31792048,0.0051543578,0.000018592522,0.00044432745,0.00016675412,0.000089345696,0.000732431,0.0010740426,0.00011988292,0.0013289739,0.000035988654],"about_ca_topic_score_codex":0.002008704,"about_ca_topic_score_gemma":0.0050944914,"teacher_disagreement_score":0.004030726,"about_ca_system_score_codex":0.0010337929,"about_ca_system_score_gemma":0.0019498476,"threshold_uncertainty_score":0.01348412},"labels":[],"label_agreement":null},{"id":"W2079006697","doi":"10.1007/s10637-013-0018-9","title":"NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; BC Cancer Agency; University Health Network; Queen's University","funders":"","keywords":"Medicine; Pharmacokinetics; Neutropenia; Tolerability; Pharmacodynamics; Internal medicine; Febrile neutropenia; Cmax; Gastroenterology; Anemia; Response Evaluation Criteria in Solid Tumors; Toxicity; Pharmacology; Phases of clinical research; Adverse effect","score_opus":0.010791651067732083,"score_gpt":0.25858450297743635,"score_spread":0.24779285190970426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079006697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97911304,0.0056288443,0.0010366945,0.0011661217,0.0002535896,0.0020047594,0.0033555024,0.00044637942,0.0069950125],"genre_scores_gemma":[0.9781382,0.005568022,0.0017916455,0.00082697626,0.00018760012,0.0021155595,0.0035010919,0.00015521955,0.0077155954],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960095,0.00016218469,0.00001412953,0.00005680311,0.000035550274,0.00013034354],"domain_scores_gemma":[0.9995228,0.00007122029,0.00008567407,0.000055273893,0.000019604997,0.00024533176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009802076,0.0016936517,0.0028837852,0.0009627683,0.00070272473,0.0013143447,0.001996785,0.0015124413,0.0059596677],"category_scores_gemma":[0.00063226465,0.0006744945,0.0011439802,0.0011618111,0.0012494029,0.0008784152,0.0004774541,0.0045594256,0.0019635689],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37309027,0.10582341,0.007896211,0.0023262466,0.0021801398,0.0013571011,0.00104205,0.017583603,0.17045933,0.0029180953,0.034024242,0.2812993],"study_design_scores_gemma":[0.30946955,0.6268463,0.019829452,0.00016773288,0.0009983656,0.0014174678,0.00024078423,0.0042743203,0.019702503,0.0006073499,0.016308239,0.00013781327],"about_ca_topic_score_codex":0.0064271833,"about_ca_topic_score_gemma":0.011909167,"teacher_disagreement_score":0.0064271833,"about_ca_system_score_codex":0.0013664569,"about_ca_system_score_gemma":0.0025596907,"threshold_uncertainty_score":0.019937038},"labels":[],"label_agreement":null},{"id":"W2081181781","doi":"10.1007/s10637-007-9103-2","title":"A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)","year":2008,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University Health Network; University of Toronto; Cancer Care Ontario; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Leukocytopenia; Internal medicine; Hepatocellular carcinoma; Gastroenterology; Phases of clinical research; Cancer; Liver function; Pharmacokinetics; Neutropenia; Toxicity; Oncology; Surgery","score_opus":0.06080585527464875,"score_gpt":0.3347445557224106,"score_spread":0.2739387004477618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081181781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901816,0.0028452112,0.00063721073,0.00093264104,0.00016221739,0.0014023824,0.0017999779,0.00011994869,0.001918834],"genre_scores_gemma":[0.9853909,0.0034461496,0.0019055946,0.0011243758,0.00021994117,0.0016347173,0.0029651483,0.00007633486,0.003236838],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996351,0.0001685087,0.000012879728,0.00005468142,0.00004046377,0.00008833466],"domain_scores_gemma":[0.99918324,0.0001196331,0.000114819944,0.0000686718,0.000046748126,0.00046688202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012626173,0.0020290213,0.0029665611,0.00065938523,0.000577265,0.0009939304,0.00091492,0.001608033,0.0031548159],"category_scores_gemma":[0.001203059,0.00083473226,0.0014076761,0.0007868287,0.0011644452,0.0010756258,0.00032767237,0.004375518,0.0011468225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7036815,0.06838562,0.012389034,0.0008093162,0.00185561,0.0006014858,0.00043246368,0.0052077174,0.06376314,0.0004856749,0.009530139,0.13285822],"study_design_scores_gemma":[0.5946732,0.3752063,0.019483833,0.000029861088,0.0005391782,0.0004830904,0.00010417785,0.0018086984,0.0039823996,0.00026800297,0.0033499782,0.00007114794],"about_ca_topic_score_codex":0.0057822363,"about_ca_topic_score_gemma":0.009931062,"teacher_disagreement_score":0.99421775,"about_ca_system_score_codex":0.001380149,"about_ca_system_score_gemma":0.0022287597,"threshold_uncertainty_score":0.0114972},"labels":[],"label_agreement":null},{"id":"W2081183120","doi":"10.1007/s10637-014-0182-6","title":"Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"China Scholarship Council","keywords":"Homeobox protein NANOG; SOX2; Stem cell; Downregulation and upregulation; Cell biology; Apoptosis; Cancer stem cell; Embryonic stem cell; Cancer cell; Biology; Cancer research; Reactive oxygen species; Chemistry; Induced pluripotent stem cell; Cancer; Biochemistry; Genetics","score_opus":0.020079328103634525,"score_gpt":0.26918912615858676,"score_spread":0.24910979805495223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081183120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744844,0.0007666966,0.0005591985,0.00003713971,0.000008548188,0.000013452601,0.000102627426,0.000028023404,0.0010359567],"genre_scores_gemma":[0.99808145,0.0004928119,0.00037637158,0.000013622969,0.0000033272609,0.000009836261,0.00012956843,0.0000058528167,0.00088722305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99996233,0.000009857617,0.0000030498036,0.0000067935775,0.0000068183654,0.00001116894],"domain_scores_gemma":[0.999961,0.000012635595,0.000007652089,0.000006584182,0.000004474334,0.0000075604016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006989009,0.00017133335,0.000116157906,0.00015225586,0.0000828453,0.00008908424,0.00011224801,0.0001311852,0.0015912198],"category_scores_gemma":[0.000061395804,0.00007237695,0.00011184799,0.0000914353,0.00012678743,0.00013444797,0.00008223035,0.00026143523,0.00015978496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021189437,0.000032093023,0.00010676658,0.000025537984,0.0000032511746,0.000060829414,0.000024370582,0.00006476887,0.99766195,0.00012165435,0.00003386716,0.0016531206],"study_design_scores_gemma":[0.0000133428075,0.00024141528,0.0008380649,0.000002112891,0.00000667217,0.000051702533,0.000011565863,0.00021283502,0.9980736,0.000018487626,0.000528984,0.0000012490202],"about_ca_topic_score_codex":0.00036928957,"about_ca_topic_score_gemma":0.00062382634,"teacher_disagreement_score":0.0015912198,"about_ca_system_score_codex":0.00007066608,"about_ca_system_score_gemma":0.00013003703,"threshold_uncertainty_score":0.005323112},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","score_opus":0.14092656980953736,"score_gpt":0.45770799104479143,"score_spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081649373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852186,0.0023980455,0.0006780874,0.0011164579,0.0002923056,0.0024957638,0.003641396,0.0002765887,0.0038827984],"genre_scores_gemma":[0.9722748,0.004432375,0.00255535,0.0016519015,0.00044048458,0.0027429145,0.0071385326,0.000116897034,0.008646777],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99953485,0.0002394167,0.000018061564,0.00006392996,0.00004398676,0.00009976823],"domain_scores_gemma":[0.9989473,0.00020599159,0.00014339227,0.000087296896,0.000059321843,0.0005567085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017077114,0.0029067488,0.0043728948,0.00084533246,0.0006848984,0.0013093817,0.0011480472,0.0017421029,0.005540175],"category_scores_gemma":[0.0014942167,0.0010239795,0.0020904588,0.0007576622,0.0013407794,0.0010724242,0.00037415285,0.0048358794,0.001690491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8218663,0.06527223,0.0035283528,0.00088697317,0.0011980884,0.00028952994,0.0002526314,0.0024122298,0.025569694,0.00037963112,0.009664354,0.06867995],"study_design_scores_gemma":[0.77003026,0.22024819,0.0052389945,0.000018069391,0.00031909771,0.00017677575,0.000043692813,0.00088149065,0.0012191689,0.00012660575,0.0016622833,0.00003538436],"about_ca_topic_score_codex":0.0020146852,"about_ca_topic_score_gemma":0.004770187,"teacher_disagreement_score":0.005540175,"about_ca_system_score_codex":0.0009713415,"about_ca_system_score_gemma":0.002042409,"threshold_uncertainty_score":0.018533707},"labels":[],"label_agreement":null},{"id":"W2082800072","doi":"10.1007/s10637-013-9936-9","title":"Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Bevacizumab; Medicine; Colorectal cancer; Chemotherapy; Oncology; Multicenter study; Retrospective cohort study; Internal medicine; First line; Surgery; Cancer; Randomized controlled trial","score_opus":0.022730997414071086,"score_gpt":0.2621809158162232,"score_spread":0.23944991840215213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082800072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982058,0.0014071069,0.00005837165,0.000018169627,0.000008185889,0.00001687205,0.00012749808,0.0000013450231,0.000156641],"genre_scores_gemma":[0.99890554,0.00043921563,0.00006756586,0.00004700287,0.000031584957,0.000020869655,0.000400215,0.000002340162,0.000085709726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989581,0.0003080078,0.00014666979,0.00030596487,0.00012774355,0.00015337518],"domain_scores_gemma":[0.99764013,0.0005072109,0.0012015733,0.00017577485,0.00016826933,0.00030705688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075511,0.00044223366,0.0011035695,0.00051065785,0.0004874269,0.0008978902,0.00052858394,0.0006506735,0.0011720842],"category_scores_gemma":[0.0027674893,0.00042163194,0.001078114,0.0014504243,0.00048273167,0.00080734584,0.0004177582,0.00070616836,0.00016132659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010777456,0.00021619047,0.9844913,0.00007938722,0.00052866247,0.00022216252,0.000098505734,0.00006587354,0.00061619334,0.000031310985,0.00010992295,0.0027630557],"study_design_scores_gemma":[0.00084171165,0.0046526706,0.99049336,0.000037034446,0.0012047939,0.0010510073,0.00034565377,0.0003075185,0.00025243172,0.00005061212,0.0007413744,0.000021871421],"about_ca_topic_score_codex":0.002883752,"about_ca_topic_score_gemma":0.0028481216,"teacher_disagreement_score":0.002883752,"about_ca_system_score_codex":0.00078545936,"about_ca_system_score_gemma":0.0007856472,"threshold_uncertainty_score":0.005733907},"labels":[],"label_agreement":null},{"id":"W2083983329","doi":"10.1007/s10637-006-6406-7","title":"A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Vomiting; Sarcoma; Soft tissue sarcoma; Internal medicine; Adverse effect; Toxicity; Progressive disease; Surgery; Population; Dosing; Gastroenterology; Phases of clinical research; Chemotherapy; Soft tissue; Pathology","score_opus":0.04329356748062302,"score_gpt":0.3666796670381587,"score_spread":0.32338609955753567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083983329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899739,0.0025741935,0.00043607014,0.0010942054,0.00018301963,0.0016652076,0.0016287838,0.00009376816,0.0023508905],"genre_scores_gemma":[0.9843886,0.0030756216,0.0013351503,0.001245221,0.0001749498,0.0021767602,0.0030508297,0.00003355271,0.004519347],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99969983,0.00013949002,0.000008549999,0.00004430479,0.000022130107,0.00008567593],"domain_scores_gemma":[0.99939656,0.00007283942,0.000094544004,0.00004075484,0.000030745185,0.0003645535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012149441,0.0018861003,0.0021403357,0.00043158935,0.00046758892,0.0009194906,0.00089296995,0.0012646803,0.0037748285],"category_scores_gemma":[0.00075104006,0.00051429856,0.0012465358,0.000525538,0.0011402202,0.0006962748,0.0003399265,0.002515405,0.0010046522],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8385738,0.028049298,0.005982309,0.00074943027,0.0012916705,0.00048445613,0.0002508329,0.0038794742,0.029054426,0.0006115599,0.008988122,0.082084574],"study_design_scores_gemma":[0.77947116,0.20483868,0.0091983685,0.000033665474,0.00037474404,0.0003256727,0.00006344916,0.0009440257,0.0015199912,0.00027260155,0.0029265184,0.000031112646],"about_ca_topic_score_codex":0.004451155,"about_ca_topic_score_gemma":0.013754379,"teacher_disagreement_score":0.004451155,"about_ca_system_score_codex":0.0013052312,"about_ca_system_score_gemma":0.0024337405,"threshold_uncertainty_score":0.012628019},"labels":[],"label_agreement":null},{"id":"W2086020450","doi":"10.1007/s10637-011-9697-2","title":"Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Gemcitabine; Axitinib; Medicine; Pharmacokinetics; Pancreatic cancer; Adverse effect; Internal medicine; Oncology; Pharmacology; Cancer; Gastroenterology","score_opus":0.03711149899049349,"score_gpt":0.3264996208753025,"score_spread":0.289388121884809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086020450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893846,0.0040688296,0.0004146305,0.0006850772,0.00026448554,0.0014752402,0.0011785394,0.00014355933,0.0023850282],"genre_scores_gemma":[0.985838,0.004937307,0.0015292672,0.000670605,0.0002618891,0.0015480686,0.0023697063,0.00006011725,0.0027849588],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994431,0.00026131707,0.000026481743,0.00009653401,0.000036588357,0.00013604705],"domain_scores_gemma":[0.99942964,0.000095220006,0.000080782345,0.000053768676,0.00002482553,0.00031577202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015534719,0.0019562347,0.00418059,0.0009296834,0.00053438003,0.0014647089,0.0011527494,0.0012400356,0.0038417955],"category_scores_gemma":[0.0009603176,0.0011217576,0.0023091962,0.0010936648,0.001492359,0.0013733492,0.0005687136,0.0049055265,0.0010045307],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7664427,0.07160089,0.0059725856,0.001291998,0.0024695632,0.00037404548,0.00041338254,0.0056396592,0.028035019,0.0005267537,0.0059055313,0.111327924],"study_design_scores_gemma":[0.5793227,0.4032018,0.008074897,0.0000503389,0.00090772746,0.00029193427,0.00010329196,0.0017092951,0.0031115073,0.00024069939,0.0029421384,0.000043532247],"about_ca_topic_score_codex":0.0026359616,"about_ca_topic_score_gemma":0.007683186,"teacher_disagreement_score":0.00418059,"about_ca_system_score_codex":0.0016644939,"about_ca_system_score_gemma":0.0024755523,"threshold_uncertainty_score":0.012852073},"labels":[],"label_agreement":null},{"id":"W2087779901","doi":"10.1007/s10637-014-0091-8","title":"A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Bicalutamide; Medicine; Vandetanib; Prostate cancer; Tolerability; Internal medicine; Urology; Oncology; Adverse effect; Pharmacology; Cancer; Tyrosine kinase; Androgen receptor","score_opus":0.017686455145267975,"score_gpt":0.3041144943748178,"score_spread":0.28642803922954985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087779901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898733,0.0020360718,0.0007695987,0.0006919733,0.0005218748,0.0031218368,0.001130125,0.000118538745,0.0017366941],"genre_scores_gemma":[0.9876623,0.0017595852,0.0018068663,0.0009922925,0.00059594645,0.0027871737,0.0014833339,0.00005291068,0.002859468],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987552,0.0007115036,0.00006156461,0.00019563477,0.00009271721,0.00018337587],"domain_scores_gemma":[0.9982204,0.00044210543,0.00037647958,0.000196215,0.00009963883,0.0006651562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022889574,0.0020497493,0.00434904,0.0007631377,0.00070132874,0.0015690343,0.0015713479,0.0018350037,0.0072171944],"category_scores_gemma":[0.0024567565,0.0014759451,0.0019788407,0.00087572966,0.0023987233,0.0018034333,0.0006252108,0.0049051167,0.0012404067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.973944,0.011994923,0.00073887454,0.00014788655,0.0006646342,0.0000317941,0.000039006656,0.00035108198,0.0029463628,0.00008891248,0.0005567762,0.0084957],"study_design_scores_gemma":[0.9234344,0.07387622,0.0013108042,0.000006063967,0.0002971765,0.000026066933,0.000016486652,0.00025156856,0.00030105884,0.00008949335,0.00037777444,0.000012875083],"about_ca_topic_score_codex":0.001953933,"about_ca_topic_score_gemma":0.004088109,"teacher_disagreement_score":0.0072171944,"about_ca_system_score_codex":0.0016541407,"about_ca_system_score_gemma":0.0019959612,"threshold_uncertainty_score":0.024143934},"labels":[],"label_agreement":null},{"id":"W2088460013","doi":"10.1007/s10637-014-0082-9","title":"Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","year":2014,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nausea; Rash; Internal medicine; Cancer; Adverse effect; Pharmacodynamics; Breast cancer; Oncology; Tolerability; Phases of clinical research; Colorectal cancer; Clinical trial; Gastroenterology; Pharmacokinetics","score_opus":0.009291892874384198,"score_gpt":0.27114006667339163,"score_spread":0.26184817379900743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088460013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990767,0.002080883,0.0007062385,0.0007555885,0.00016048654,0.0018160136,0.0011890075,0.00020355287,0.0023212254],"genre_scores_gemma":[0.9886308,0.0015543653,0.0017152583,0.0009352974,0.0000977053,0.0020765038,0.002379034,0.000056034387,0.002555085],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995914,0.00014651648,0.0000158356,0.00007012729,0.000044652286,0.00013145606],"domain_scores_gemma":[0.9995086,0.00005851236,0.00007880715,0.00005478745,0.000025248428,0.00027411498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011628789,0.0016044939,0.0023263863,0.0006332422,0.000450822,0.0011019266,0.0010565188,0.0011440864,0.002907024],"category_scores_gemma":[0.00073307246,0.0006917366,0.001275788,0.00067294424,0.0009802679,0.0010898836,0.00048570024,0.005112633,0.00085458497],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52997696,0.1492973,0.0066580423,0.00089874316,0.0018503189,0.00029092742,0.0005784447,0.010514555,0.07651227,0.0008630699,0.013312173,0.20924723],"study_design_scores_gemma":[0.5606875,0.40683615,0.015507075,0.00003700909,0.00050847605,0.0003848098,0.000120618715,0.0041111885,0.0069959215,0.0005951358,0.004155405,0.00006081284],"about_ca_topic_score_codex":0.0013216704,"about_ca_topic_score_gemma":0.0033345972,"teacher_disagreement_score":0.002907024,"about_ca_system_score_codex":0.0013051851,"about_ca_system_score_gemma":0.0015040546,"threshold_uncertainty_score":0.009725034},"labels":[],"label_agreement":null},{"id":"W2089379119","doi":"10.1007/s10637-010-9626-9","title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôtel-Dieu de Québec; McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"RAD51; Molecular biology; DNA-PKcs; DNA damage; Irinotecan; Comet assay; Cancer research; DNA repair; DNA; Chemistry; Homologous recombination; DNA ligase; Biology; Colorectal cancer; Cancer; Biochemistry; Genetics","score_opus":0.0160094944983551,"score_gpt":0.2261960770657665,"score_spread":0.2101865825674114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089379119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769299,0.01332853,0.00076512777,0.0003926206,0.00014216414,0.00008457686,0.0003845136,0.0001561022,0.007816429],"genre_scores_gemma":[0.9871574,0.0059145046,0.00082938944,0.000070895614,0.00005566178,0.000040630937,0.00037416306,0.00001378467,0.0055435793],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996996,0.000080403974,0.000021008582,0.000023643528,0.00008732798,0.00008800887],"domain_scores_gemma":[0.9998534,0.000046439083,0.000024630632,0.000024179748,0.000013101294,0.00003825797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003034741,0.00047139922,0.0006438546,0.0007931057,0.00027585553,0.00038868684,0.00027265146,0.00030066393,0.0022689935],"category_scores_gemma":[0.00024848463,0.0002659005,0.00033205713,0.0006065738,0.00026792742,0.00034258072,0.00025824292,0.000663555,0.00041912758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00449536,0.00049949775,0.00092767033,0.00024700875,0.00007868896,0.00030784536,0.00006591327,0.0010130677,0.9593537,0.00048015482,0.0007438273,0.031787254],"study_design_scores_gemma":[0.00036878313,0.005173629,0.011867133,0.000017019345,0.00010369727,0.00097618933,0.00007584389,0.0012122161,0.9695007,0.00015271305,0.010535382,0.000016666556],"about_ca_topic_score_codex":0.0010807408,"about_ca_topic_score_gemma":0.0043128505,"teacher_disagreement_score":0.0022689935,"about_ca_system_score_codex":0.0005530158,"about_ca_system_score_gemma":0.0006080707,"threshold_uncertainty_score":0.0075905323},"labels":[],"label_agreement":null},{"id":"W2091394897","doi":"10.1007/s10637-006-9009-4","title":"A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Tolerability; Internal medicine; Phases of clinical research; Adverse effect; Metastatic Urothelial Carcinoma; Population; Cancer; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Gastroenterology; Multiple myeloma; Urothelial carcinoma; Bladder cancer","score_opus":0.016727054797264086,"score_gpt":0.2777420946554259,"score_spread":0.26101503985816177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091394897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97685313,0.006265402,0.0010910596,0.0028424817,0.0006029355,0.005264013,0.0023576485,0.00018381211,0.004539566],"genre_scores_gemma":[0.9679248,0.005331824,0.003642209,0.0036650107,0.00058276346,0.005054173,0.0054789586,0.00007741941,0.008242881],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993082,0.00041568998,0.000018806764,0.00008087496,0.00006223987,0.000114238566],"domain_scores_gemma":[0.9987174,0.00024163393,0.0001311724,0.00006871216,0.000059394453,0.0007816167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002692248,0.0016743508,0.0016773279,0.00067652174,0.00059976993,0.0010619148,0.0009356166,0.001736879,0.005108596],"category_scores_gemma":[0.0013205437,0.00072886195,0.0013867214,0.0005506806,0.0009829642,0.00071348867,0.00046147127,0.0036581133,0.0009123938],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8036508,0.033211287,0.004852248,0.0006933801,0.00093656185,0.00035039906,0.00025664092,0.0021865072,0.026547804,0.0006594706,0.012902509,0.11375254],"study_design_scores_gemma":[0.8648313,0.12397932,0.0054109613,0.000029757446,0.000251846,0.00015447261,0.000027543221,0.00067427126,0.0015258373,0.00027775177,0.0028127907,0.000024126324],"about_ca_topic_score_codex":0.0015596873,"about_ca_topic_score_gemma":0.0031531067,"teacher_disagreement_score":0.005108596,"about_ca_system_score_codex":0.0009011307,"about_ca_system_score_gemma":0.0019872228,"threshold_uncertainty_score":0.017089963},"labels":[],"label_agreement":null},{"id":"W2092271538","doi":"10.1007/s10637-015-0221-y","title":"A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Vomiting; Pharmacokinetics; Internal medicine; Tolerability; Toxicity; Gastroenterology; Adverse effect; Surgery; Urology","score_opus":0.025287211490589104,"score_gpt":0.28693944945764266,"score_spread":0.26165223796705356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092271538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907816,0.0011310024,0.00092147756,0.0007776677,0.00022980293,0.0027412542,0.001269799,0.00010160488,0.0020456647],"genre_scores_gemma":[0.9847112,0.0018134172,0.0026851338,0.0014757277,0.0002529952,0.0030763887,0.0023738488,0.00007052166,0.0035406959],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993899,0.00023603126,0.00001919584,0.00012243412,0.00004937599,0.00018309875],"domain_scores_gemma":[0.99878067,0.0002215437,0.00012227563,0.00013406355,0.00006169243,0.00067981484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358876,0.0021718608,0.0032214734,0.00089049904,0.00071814784,0.0015200699,0.0012664541,0.0015949172,0.0033929779],"category_scores_gemma":[0.0011378326,0.00093356724,0.0015832447,0.0009471731,0.001967385,0.0012558952,0.00045640313,0.005427384,0.0008902348],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7359959,0.14252202,0.004689347,0.0005155255,0.0009497921,0.00021154238,0.0004505963,0.0053137923,0.040296853,0.00054634846,0.0040484923,0.06445984],"study_design_scores_gemma":[0.62432307,0.36455774,0.0040416853,0.000017607168,0.00025856623,0.00014552897,0.00008269523,0.0014280541,0.0029188115,0.00028743106,0.0019030038,0.00003578169],"about_ca_topic_score_codex":0.0030714632,"about_ca_topic_score_gemma":0.005709439,"teacher_disagreement_score":0.0033929779,"about_ca_system_score_codex":0.0015848511,"about_ca_system_score_gemma":0.003053067,"threshold_uncertainty_score":0.011498988},"labels":[],"label_agreement":null},{"id":"W2092652143","doi":"10.1007/s10637-013-0010-4","title":"Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hôpital Notre-Dame","funders":"Pfizer","keywords":"Medicine; Carboplatin; Pemetrexed; Neutropenia; Sunitinib; Rash; Leukopenia; Internal medicine; Adverse effect; Pharmacokinetics; Dosing; Oncology; Gastroenterology; Pharmacology; Toxicity; Chemotherapy; Cancer; Cisplatin","score_opus":0.010599644717435757,"score_gpt":0.2852261942459808,"score_spread":0.27462654952854504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092652143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708194,0.0020206452,0.00014074656,0.000082051505,0.000020027588,0.00025882636,0.00010386298,0.000034767618,0.0002572267],"genre_scores_gemma":[0.99664956,0.0013301191,0.00063446385,0.00016491344,0.00006216047,0.00027045375,0.00054886995,0.000011857348,0.00032757412],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99942696,0.00026133104,0.000046498233,0.0001132905,0.000076607,0.00007540897],"domain_scores_gemma":[0.99942386,0.00011641469,0.00015236209,0.000056516034,0.000035771816,0.00021514732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016991453,0.0010362081,0.0026042117,0.00040899587,0.00032643235,0.0006680682,0.0006898735,0.00077285594,0.001023156],"category_scores_gemma":[0.0008274422,0.000407598,0.0011170077,0.0004928572,0.00045706145,0.00062333606,0.00021242163,0.0017173904,0.0002717325],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41236314,0.08516973,0.033441108,0.0018561322,0.0057826727,0.0006310316,0.0007236814,0.008206732,0.13227639,0.00017024316,0.0032961026,0.31608295],"study_design_scores_gemma":[0.23463187,0.66345173,0.07812666,0.00006136158,0.0014677453,0.00112438,0.000073296695,0.0031198633,0.014213001,0.00011402161,0.0035670483,0.00004900675],"about_ca_topic_score_codex":0.00055048463,"about_ca_topic_score_gemma":0.0011797891,"teacher_disagreement_score":0.0026042117,"about_ca_system_score_codex":0.00090961397,"about_ca_system_score_gemma":0.00080271444,"threshold_uncertainty_score":0.008986056},"labels":[],"label_agreement":null},{"id":"W2093988174","doi":"10.1007/s10637-012-9886-7","title":"The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines","year":2012,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Abbott Laboratories","keywords":"PARP inhibitor; Irinotecan; Cancer research; Veliparib; Poly ADP ribose polymerase; Olaparib; Oxaliplatin; DNA damage; PARP1; Cancer; Synthetic lethality; DNA repair; Base excision repair; Colorectal cancer; Biology; Medicine; Polymerase; Internal medicine; DNA; Biochemistry","score_opus":0.03616634036575846,"score_gpt":0.31929290745368355,"score_spread":0.2831265670879251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093988174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98105615,0.005144343,0.0015698333,0.00058984256,0.0002650453,0.00013961647,0.001173616,0.00048582585,0.009575675],"genre_scores_gemma":[0.9872859,0.0039011487,0.0014060029,0.0001384843,0.000057917998,0.0000809189,0.0018724281,0.0000417042,0.0052155117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996867,0.000073151736,0.000027411477,0.00003411697,0.000106075626,0.00007259853],"domain_scores_gemma":[0.99986434,0.000031354826,0.000024154588,0.000029894058,0.000017726987,0.000032428965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026100883,0.0006067051,0.0008596088,0.0008628988,0.0003239188,0.0004633026,0.00034311155,0.0003596437,0.0032371632],"category_scores_gemma":[0.0002598166,0.00031560747,0.00051066495,0.00080529286,0.00024842162,0.0004547687,0.00034110915,0.0012391596,0.0009210509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031055673,0.0016526482,0.0017789582,0.0004581717,0.00016388766,0.0004472996,0.00012668097,0.0017463287,0.9250078,0.00051306485,0.004140048,0.06085971],"study_design_scores_gemma":[0.0005749463,0.009193888,0.023956805,0.0000325587,0.0001674019,0.0015612259,0.00015165242,0.0035822105,0.93693674,0.00027343788,0.023534514,0.000034605448],"about_ca_topic_score_codex":0.0010313296,"about_ca_topic_score_gemma":0.003436544,"teacher_disagreement_score":0.0032371632,"about_ca_system_score_codex":0.00046579813,"about_ca_system_score_gemma":0.00052572286,"threshold_uncertainty_score":0.010829389},"labels":[],"label_agreement":null},{"id":"W2149472508","doi":"10.1007/s10637-007-9090-3","title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","year":2007,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada)","funders":"","keywords":"Pharmacokinetics; Cmax; Medicine; Tolerability; Bioavailability; Nausea; Adverse effect; Pharmacology; Pharmacodynamics; Maximum tolerated dose; Cyclin-dependent kinase; Dysgeusia; Toxicity; Refractory (planetary science); Oral administration; Internal medicine; Cancer; Cell cycle","score_opus":0.02381757120153434,"score_gpt":0.3125895757310258,"score_spread":0.2887720045294915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149472508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879522,0.0019951211,0.0009989797,0.0009566107,0.00027322202,0.0025504925,0.0018918138,0.0001507936,0.0032308593],"genre_scores_gemma":[0.9752666,0.003319918,0.0033513468,0.0016112388,0.00039441432,0.0039830976,0.005334057,0.00010270918,0.0066367304],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995448,0.00022332428,0.000012800333,0.00007223982,0.000040372044,0.00010643628],"domain_scores_gemma":[0.9992385,0.00015878338,0.000088574394,0.000060298313,0.000038583777,0.00041521012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016351887,0.002271293,0.0025801617,0.0007906793,0.00059500796,0.00095439877,0.0011915386,0.0016010284,0.0042486438],"category_scores_gemma":[0.0010338313,0.0009039931,0.0015708676,0.0005615705,0.0015577956,0.0010365349,0.00033934656,0.004431476,0.00105777],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6619341,0.13655508,0.0053512007,0.00090380304,0.0014484442,0.00050408527,0.0005770196,0.0059209038,0.07856636,0.0009788224,0.010971912,0.09628828],"study_design_scores_gemma":[0.5571852,0.42290333,0.00623882,0.00002724442,0.0004611403,0.00042242903,0.00009726492,0.0019062589,0.006479457,0.00036063557,0.0038783774,0.00003989723],"about_ca_topic_score_codex":0.0024118666,"about_ca_topic_score_gemma":0.0070416224,"teacher_disagreement_score":0.0042486438,"about_ca_system_score_codex":0.0010843244,"about_ca_system_score_gemma":0.0026961877,"threshold_uncertainty_score":0.014213145},"labels":[],"label_agreement":null},{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","score_opus":0.027555083651461375,"score_gpt":0.35338870311606624,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150308444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097276,0.0014926362,0.0006268179,0.0012241155,0.00022129317,0.0014236288,0.0009527787,0.000114090486,0.002971947],"genre_scores_gemma":[0.9863121,0.001360706,0.0025107877,0.0015367821,0.00016667768,0.0015148551,0.002764375,0.000051971463,0.003781755],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999632,0.00016883103,0.000014564176,0.000064079504,0.000031470197,0.00008902134],"domain_scores_gemma":[0.9993998,0.00011094579,0.0000682813,0.000056933535,0.000025351377,0.00033871699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013175557,0.0014062125,0.0018798306,0.00048401213,0.00042943933,0.0009396631,0.0008354723,0.0010957317,0.0030765408],"category_scores_gemma":[0.0011089029,0.0003973426,0.001071376,0.0004602381,0.00093725475,0.0010992509,0.00048696206,0.0036106962,0.00074527756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67665875,0.06611189,0.008279435,0.00065661257,0.0015167171,0.00046496553,0.00069317396,0.0073652198,0.033413697,0.0011600577,0.012271351,0.19140805],"study_design_scores_gemma":[0.76467335,0.20656553,0.014955079,0.00003254411,0.0003624628,0.00043980367,0.00009342579,0.003267334,0.0029820027,0.0008807951,0.0057088397,0.00003890587],"about_ca_topic_score_codex":0.0010244513,"about_ca_topic_score_gemma":0.003189988,"teacher_disagreement_score":0.0030765408,"about_ca_system_score_codex":0.0010681571,"about_ca_system_score_gemma":0.0011465023,"threshold_uncertainty_score":0.010292113},"labels":[],"label_agreement":null},{"id":"W2154086425","doi":"10.1007/s10637-009-9251-7","title":"Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants","year":2009,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Canadian Institutes of Health Research","keywords":"Antiandrogens; LNCaP; Chalcone; Antiandrogen; Prostate cancer; Androgen receptor; Pharmacology; Antagonist; Cancer research; Chemistry; Biology; Internal medicine; Endocrinology; Medicine; Cancer; Receptor; Stereochemistry","score_opus":0.022414702491515264,"score_gpt":0.2939460139984815,"score_spread":0.27153131150696624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154086425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754151,0.0059894836,0.009299512,0.00014533848,0.00008194335,0.0003026859,0.002017876,0.0001623929,0.0065856874],"genre_scores_gemma":[0.98733634,0.002101631,0.0036535484,0.000052664454,0.000015352794,0.000050368642,0.0021723716,0.000032536478,0.0045851925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999075,0.000021691103,0.000010655002,0.000012106698,0.000023042081,0.000025067033],"domain_scores_gemma":[0.99990094,0.000019163648,0.000018915853,0.000012696246,0.000022198614,0.000026112542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018129256,0.00037410273,0.00026192347,0.00036985273,0.0002024751,0.00022997394,0.00031618722,0.0001801817,0.001892034],"category_scores_gemma":[0.00017649926,0.00009433389,0.00024596066,0.0004012398,0.0001766183,0.00018179785,0.00012927779,0.00026137714,0.00042366964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004436875,0.00009283633,0.00012144315,0.00009072868,0.000008069219,0.00014036716,0.000030797986,0.00063830405,0.9941135,0.00018229365,0.00012433813,0.0040136254],"study_design_scores_gemma":[0.000049451814,0.0007322094,0.00077395013,0.0000058371616,0.00001912151,0.000086321605,0.000019532856,0.00031629018,0.994499,0.00003962469,0.0034510635,0.0000076206557],"about_ca_topic_score_codex":0.0016706533,"about_ca_topic_score_gemma":0.0027056437,"teacher_disagreement_score":0.001892034,"about_ca_system_score_codex":0.00037348465,"about_ca_system_score_gemma":0.00036951725,"threshold_uncertainty_score":0.006329477},"labels":[],"label_agreement":null},{"id":"W2166042057","doi":"10.1007/s10637-011-9660-2","title":"Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia","year":2011,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Tolerability; Medicine; Pharmacokinetics; Pharmacodynamics; Myeloid leukemia; Refractory (planetary science); Pharmacology; Internal medicine; Adverse effect; Gastroenterology","score_opus":0.038472222433530136,"score_gpt":0.32911549674982593,"score_spread":0.2906432743162958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166042057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947556,0.0011674368,0.00048874895,0.0003722591,0.00007783443,0.0013249404,0.0007627844,0.000060935254,0.0009894338],"genre_scores_gemma":[0.9902575,0.0010289719,0.0016472768,0.00091496314,0.00022952679,0.0021132904,0.002114278,0.00003611478,0.0016581506],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994072,0.00032790613,0.000023527942,0.00007517011,0.00004350657,0.00012277484],"domain_scores_gemma":[0.9991635,0.00013646879,0.00013445341,0.00009379953,0.000049464197,0.00042230467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015672147,0.0014722605,0.0027735916,0.0004115565,0.0005025467,0.0007748573,0.00077616546,0.00090829923,0.002689227],"category_scores_gemma":[0.0010334837,0.0004603509,0.0009516689,0.00042181188,0.0011615399,0.00084391556,0.00035378683,0.0026075742,0.0008124645],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78550464,0.056331478,0.018140912,0.0004022801,0.0014200594,0.00046222302,0.0002706865,0.00267138,0.050254,0.000439653,0.004583422,0.0795192],"study_design_scores_gemma":[0.6196616,0.35072893,0.02100437,0.000017390865,0.00042877102,0.00040789318,0.000064868844,0.0014806439,0.0034716758,0.00018424951,0.002517517,0.0000321528],"about_ca_topic_score_codex":0.0008959177,"about_ca_topic_score_gemma":0.001268524,"teacher_disagreement_score":0.0027735916,"about_ca_system_score_codex":0.00074164406,"about_ca_system_score_gemma":0.0013119396,"threshold_uncertainty_score":0.008996308},"labels":[],"label_agreement":null},{"id":"W2167646022","doi":"10.1023/a:1015694802521","title":"Targeting Anti-Apoptotic Genes Upregulated by Androgen Withdrawal Using Antisense Oligonucleotides to Enhance Androgen- and Chemo-Sensitivity in Prostate Cancer","year":2002,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"Ministry of Education, India; Ministry of Earth Sciences","keywords":"Androgen; Clusterin; Prostate cancer; Cancer research; Tumor progression; Biology; Cancer; Prostate; Medicine; Apoptosis; Oncology; Internal medicine; Hormone; Endocrinology; Genetics","score_opus":0.02925980522481499,"score_gpt":0.33273400604123765,"score_spread":0.3034742008164227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167646022","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027394637,0.99292266,0.0012782381,0.00023051995,0.00029013338,0.00003037359,0.000045380464,0.000042644544,0.0024205155],"genre_scores_gemma":[0.008141014,0.9869285,0.0013551306,0.00023710428,0.0001352511,0.000036459805,0.00012266039,0.000005648138,0.0030383158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991417,0.000010095547,0.000011137301,0.000017510743,0.000035986504,0.00001113898],"domain_scores_gemma":[0.99990726,0.000033746142,0.000016085087,0.0000041088947,0.000029228813,0.000009569625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040408317,0.00076775934,0.00110941,0.0009854147,0.00021341901,0.0005017089,0.0007007822,0.00052166113,0.0014528407],"category_scores_gemma":[0.00022033477,0.00020492384,0.00027854464,0.0011042099,0.00030287405,0.00050340086,0.0002227453,0.00090536114,0.000832357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038906393,0.00022383756,0.0002954825,0.008210763,0.00010760019,0.00044390056,0.00006523456,0.00068722176,0.05499592,0.0023597078,0.014355376,0.9178658],"study_design_scores_gemma":[0.00021711834,0.00061796105,0.002536494,0.00074633514,0.00032832575,0.0028233817,0.00006266571,0.0004328291,0.041677948,0.00093570916,0.94957715,0.00004399633],"about_ca_topic_score_codex":0.0009222575,"about_ca_topic_score_gemma":0.002015774,"teacher_disagreement_score":0.0014528407,"about_ca_system_score_codex":0.00057131733,"about_ca_system_score_gemma":0.00052274525,"threshold_uncertainty_score":0.0048602223},"labels":[],"label_agreement":null},{"id":"W2205041904","doi":"10.1007/s10637-015-0316-5","title":"Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Vandetanib; Capecitabine; Gemcitabine; Medicine; Internal medicine; Pancreatic cancer; Gastroenterology; Tyrosine-kinase inhibitor; Oncology; Neutropenia; Cancer; Chemotherapy; Sorafenib; Hepatocellular carcinoma","score_opus":0.02157323949200639,"score_gpt":0.31281611314657065,"score_spread":0.29124287365456425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2205041904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916535,0.0025857242,0.00036527292,0.0007466349,0.00023432274,0.000979123,0.0012278933,0.00009188505,0.0021156583],"genre_scores_gemma":[0.9857599,0.0031719503,0.0015619983,0.000773811,0.00021963735,0.0012400526,0.0041040354,0.00006151302,0.003107043],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995888,0.00017351362,0.000019246976,0.000086595006,0.000031497995,0.000100392965],"domain_scores_gemma":[0.999421,0.00009313202,0.000082461695,0.000054061755,0.00003213474,0.00031727378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013627906,0.0015674625,0.0026740183,0.00045586115,0.00048633027,0.001492126,0.0008585855,0.00081823417,0.0031940814],"category_scores_gemma":[0.000952975,0.00074439734,0.0017806422,0.0006299768,0.00086536485,0.0010854221,0.00051438215,0.003723325,0.0007304449],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80874926,0.033038896,0.01160853,0.0007346591,0.0031788012,0.00033048514,0.0003357566,0.0058473176,0.023800362,0.00044328478,0.008325858,0.10360683],"study_design_scores_gemma":[0.75121015,0.20935002,0.02536912,0.00005314891,0.0014704438,0.00044089882,0.00017840836,0.002820808,0.002524744,0.0003831655,0.0061429827,0.000056218993],"about_ca_topic_score_codex":0.001967358,"about_ca_topic_score_gemma":0.006888956,"teacher_disagreement_score":0.0031940814,"about_ca_system_score_codex":0.001293386,"about_ca_system_score_gemma":0.0017838589,"threshold_uncertainty_score":0.010685325},"labels":[],"label_agreement":null},{"id":"W222191070","doi":"10.1023/a:1020694425356","title":"A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Cancer Centre; Université de Montréal; Cancer Care Ontario; Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute","keywords":"Medicine; Nausea; myalgia; Adverse effect; Toxicity; Internal medicine; Lethargy; Phases of clinical research; Chemotherapy; Surgery; Clinical endpoint; Randomized controlled trial; Bryostatin 1; Gastroenterology","score_opus":0.05453415470042501,"score_gpt":0.34755567791445957,"score_spread":0.2930215232140346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W222191070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99125403,0.0011111351,0.00050875056,0.00074210303,0.00038066762,0.0032236683,0.0012126884,0.00008901207,0.0014780277],"genre_scores_gemma":[0.98283654,0.001557415,0.0018592131,0.001252119,0.0005111734,0.005580193,0.0023236463,0.000050544335,0.0040291483],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992161,0.00037728666,0.000032098076,0.0001299495,0.000046124354,0.0001985227],"domain_scores_gemma":[0.9986659,0.00023103619,0.00021393455,0.00017235447,0.000055329783,0.0006614007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002136332,0.0025145162,0.0042958884,0.00059181324,0.0006333128,0.001009724,0.0016167792,0.0019135108,0.0072456077],"category_scores_gemma":[0.0013807748,0.0010510444,0.0020019095,0.00070066773,0.002018472,0.0014339419,0.0005134837,0.004997739,0.0013034013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9628806,0.018223712,0.00067654264,0.00014804158,0.0005112707,0.00003337586,0.000052777297,0.0007200553,0.004001828,0.00014275359,0.0010626415,0.011546425],"study_design_scores_gemma":[0.9031536,0.094057955,0.0014187022,0.0000055971072,0.00019792732,0.000019710258,0.000018954264,0.00027142253,0.00031978494,0.00011205709,0.0004113347,0.000013041744],"about_ca_topic_score_codex":0.003735674,"about_ca_topic_score_gemma":0.008606678,"teacher_disagreement_score":0.0072456077,"about_ca_system_score_codex":0.0016569392,"about_ca_system_score_gemma":0.002620343,"threshold_uncertainty_score":0.024238944},"labels":[],"label_agreement":null},{"id":"W2265121903","doi":"10.1007/s10637-016-0324-0","title":"A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Health Sciences Centre; Ontario Clinical Oncology Group; Juravinski Cancer Centre; Princess Margaret Cancer Centre; Hamilton Health Sciences","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Nausea; Internal medicine; Progressive disease; Melanoma; Adverse effect; Gastroenterology; Phases of clinical research; Response Evaluation Criteria in Solid Tumors; Oncology; Toxicity; Chemotherapy; Surgery; Cancer research","score_opus":0.024027290171344008,"score_gpt":0.27115774109121094,"score_spread":0.24713045091986693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2265121903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923091,0.003380069,0.00050409127,0.00039718993,0.0001650932,0.0010794307,0.000537573,0.000054197295,0.0015731821],"genre_scores_gemma":[0.98962003,0.0032415076,0.001261879,0.0007225273,0.00020534969,0.0010751656,0.0014467009,0.000030416097,0.0023963642],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99958473,0.00019470423,0.000016888658,0.000065248605,0.000036079506,0.00010232246],"domain_scores_gemma":[0.99936134,0.00011972906,0.00008449175,0.000063851054,0.00003322528,0.0003373407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014292315,0.0012875176,0.002851775,0.00044517027,0.0005216651,0.0009441022,0.00081037416,0.001127123,0.0021378319],"category_scores_gemma":[0.0009223146,0.0006351198,0.0015447926,0.00038387722,0.0009131925,0.00067085953,0.0002573188,0.0029772795,0.0005734261],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71797967,0.06643746,0.01356006,0.00104321,0.0030393656,0.0007653118,0.00050157646,0.00346812,0.07973911,0.00046302142,0.003733934,0.109269165],"study_design_scores_gemma":[0.53514725,0.43499735,0.019320846,0.00003569509,0.0009793811,0.00055245194,0.00010223699,0.0013335694,0.0036481305,0.00017107699,0.0036686365,0.000043354816],"about_ca_topic_score_codex":0.0021370435,"about_ca_topic_score_gemma":0.005294906,"teacher_disagreement_score":0.002851775,"about_ca_system_score_codex":0.0008550208,"about_ca_system_score_gemma":0.001233049,"threshold_uncertainty_score":0.007558584},"labels":[],"label_agreement":null},{"id":"W2283246712","doi":"10.1007/s10637-015-0313-8","title":"A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Adverse effect; Pharmacology; Tolerability; Internal medicine; Nausea; Rash; Toxicity; Gastroenterology; Urology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Chemistry","score_opus":0.026928520588647132,"score_gpt":0.31284350585575443,"score_spread":0.2859149852671073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283246712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933964,0.00086512335,0.00030239127,0.00043418072,0.000106868356,0.0020731194,0.0009048284,0.00007744195,0.0018396656],"genre_scores_gemma":[0.9896628,0.0009914618,0.0013476848,0.00064018316,0.00014462069,0.0022497384,0.0022242293,0.000020314412,0.002718934],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997367,0.000101857404,0.000015447902,0.00005342444,0.000029331966,0.00006317134],"domain_scores_gemma":[0.99951625,0.00006515217,0.00006744411,0.000035616693,0.0000250963,0.0002904446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010515257,0.0015428961,0.0017044385,0.00037334388,0.00041025403,0.0007615515,0.0007944571,0.0010891617,0.0040484737],"category_scores_gemma":[0.0006158621,0.00050264015,0.0008588617,0.0003494901,0.0007856809,0.0008686876,0.00032412854,0.0029942566,0.0009109309],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7694704,0.073947944,0.004738585,0.0008839727,0.0009862358,0.00049699005,0.00036830807,0.0032310223,0.058313828,0.00046680815,0.0054585524,0.08163734],"study_design_scores_gemma":[0.6114421,0.37338173,0.0071574957,0.000028817183,0.00025326325,0.00044892947,0.00005715006,0.0015236798,0.0031343873,0.00023891641,0.002308295,0.000025186913],"about_ca_topic_score_codex":0.0009414353,"about_ca_topic_score_gemma":0.0028009603,"teacher_disagreement_score":0.0040484737,"about_ca_system_score_codex":0.000799851,"about_ca_system_score_gemma":0.0013969537,"threshold_uncertainty_score":0.013543487},"labels":[],"label_agreement":null},{"id":"W2302509459","doi":"10.1007/s10637-016-0340-0","title":"Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research","keywords":"Oxaliplatin; Medicine; Glioma; Toxicity; Radiation therapy; Chemotherapy; Liposome; Pharmacology; Drug delivery; Internal medicine; Colorectal cancer; Cancer; Cancer research; Chemistry","score_opus":0.024651485260664144,"score_gpt":0.23841443219605876,"score_spread":0.2137629469353946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2302509459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633443,0.00071671174,0.002193416,0.000046185876,0.000026844269,0.00001901744,0.00010512794,0.000057506226,0.0005008009],"genre_scores_gemma":[0.9952053,0.00042974413,0.0018040913,0.00002484442,0.0000067513106,0.00002596306,0.00025713167,0.000015973701,0.0022302358],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993193,0.00000659987,0.000005792127,0.000019529032,0.000012360946,0.000023660394],"domain_scores_gemma":[0.9999603,0.000005054594,0.0000144511705,0.0000046375244,0.000006044453,0.000009533423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012437874,0.00023654572,0.00022025264,0.00012991384,0.000105915366,0.000119688135,0.00015546576,0.00017593856,0.000627429],"category_scores_gemma":[0.00006609934,0.00007525158,0.00019350373,0.00011950361,0.00014483849,0.00025734995,0.00008518656,0.00030884586,0.00010430043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033736607,0.000070801805,0.00009816751,0.000029669802,0.0000038271623,0.000022186123,0.000017152694,0.000070031485,0.9974322,0.00006141303,0.000060211183,0.0017970983],"study_design_scores_gemma":[0.000012003249,0.00043932244,0.00074886676,0.000001089745,0.000008400558,0.000050079645,0.0000058272153,0.0003652652,0.99774396,0.0000075876656,0.0006147478,0.0000027215979],"about_ca_topic_score_codex":0.0012654117,"about_ca_topic_score_gemma":0.0012400628,"teacher_disagreement_score":0.0012654117,"about_ca_system_score_codex":0.00020954796,"about_ca_system_score_gemma":0.00024569934,"threshold_uncertainty_score":0.0025160909},"labels":[],"label_agreement":null},{"id":"W2308312264","doi":"10.1007/s10637-015-0315-6","title":"Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Isotype; Tubulin; Colchicine; In vivo; Microtubule; Protein subunit; Cancer research; Paclitaxel; Biology; Breast cancer; Cancer; Chemistry; Pharmacology; Antibody; Immunology; Biochemistry; Cell biology; Genetics; Gene","score_opus":0.011244367174109949,"score_gpt":0.25703212659933466,"score_spread":0.2457877594252247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308312264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922897,0.0026870614,0.00016647002,0.00016172278,0.0000912204,0.000032221375,0.00069657835,0.00007987327,0.003795046],"genre_scores_gemma":[0.99660873,0.0010920928,0.00022716963,0.00006320214,0.0000116626,0.000010337982,0.00043632856,0.0000063531697,0.0015441474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991035,0.000015856735,0.0000071819823,0.000014289699,0.000015470634,0.0000368131],"domain_scores_gemma":[0.99988997,0.00004185153,0.00000983073,0.0000099276685,0.000011633925,0.000036728994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086771855,0.00029121537,0.0003396178,0.00024864913,0.00022313026,0.00023316342,0.00022307558,0.00040884656,0.0022030878],"category_scores_gemma":[0.000099953664,0.00012916086,0.0002618895,0.0002892786,0.0002709068,0.00016703921,0.00010052105,0.00047238884,0.0002965022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042831358,0.0002875679,0.00027982806,0.00019348181,0.000035272944,0.0002518802,0.0001048362,0.0003218667,0.98909587,0.00017902763,0.00048122133,0.0044859597],"study_design_scores_gemma":[0.00025359058,0.0039566457,0.0060320827,0.000013247744,0.000059490158,0.00018951767,0.00009175827,0.0008376314,0.98525304,0.000034168024,0.0032612036,0.000017584973],"about_ca_topic_score_codex":0.00902323,"about_ca_topic_score_gemma":0.010838169,"teacher_disagreement_score":0.00902323,"about_ca_system_score_codex":0.00034608034,"about_ca_system_score_gemma":0.00041676953,"threshold_uncertainty_score":0.017941415},"labels":[],"label_agreement":null},{"id":"W2309983655","doi":"10.1007/s10637-016-0335-x","title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health","keywords":"Veliparib; Cyclophosphamide; PARP inhibitor; Medicine; Triple-negative breast cancer; Nitrogen mustard; Internal medicine; Oncology; Breast cancer; Chemotherapy; Metastatic breast cancer; Pharmacology; Cancer; Poly ADP ribose polymerase; Biology; Polymerase","score_opus":0.01259685493353731,"score_gpt":0.2914200369288869,"score_spread":0.2788231819953496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2309983655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98040843,0.00454415,0.0011481022,0.0015205706,0.0011943408,0.004668663,0.0019523574,0.00017846041,0.004384933],"genre_scores_gemma":[0.9793968,0.0029978768,0.0018272558,0.0020672472,0.00063845556,0.004459908,0.0022291262,0.000056193923,0.006327215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99939406,0.00032265566,0.000027936185,0.00012265996,0.000030470463,0.00010226705],"domain_scores_gemma":[0.9989441,0.0003094677,0.0001857232,0.0001104339,0.00004870674,0.0004015133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001453006,0.0016244906,0.0031338807,0.00036298385,0.00043707935,0.0014671463,0.0010256047,0.001531784,0.008649279],"category_scores_gemma":[0.0018314857,0.00088380644,0.0016471047,0.00047716472,0.0014203686,0.0011607391,0.00054300186,0.004484181,0.0013481419],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97938424,0.005052014,0.00052593736,0.0002632641,0.00074619753,0.000034553163,0.000037986454,0.00049224665,0.001607927,0.0001432824,0.00088468246,0.010827703],"study_design_scores_gemma":[0.967272,0.030400569,0.0007364611,0.000012728129,0.00025702687,0.000027002816,0.00001958701,0.00034786153,0.00018074842,0.00016288323,0.0005745239,0.000008655544],"about_ca_topic_score_codex":0.0014891054,"about_ca_topic_score_gemma":0.003701757,"teacher_disagreement_score":0.008649279,"about_ca_system_score_codex":0.0011398813,"about_ca_system_score_gemma":0.0014596699,"threshold_uncertainty_score":0.028934777},"labels":[],"label_agreement":null},{"id":"W2312359773","doi":"10.1007/s10637-005-1761-3","title":"Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; Ottawa Hospital","funders":"Central China Normal University","keywords":"Medicine; Glioma; Anaplastic astrocytoma; Toxicity; Nitrosourea; Pulmonary toxicity; Internal medicine; Progressive disease; DLCO; Surgery; Gastroenterology; Phases of clinical research; Chemotherapy; Oncology; Astrocytoma; Lung; Cancer research; Diffusing capacity","score_opus":0.025338808346491087,"score_gpt":0.281879103434974,"score_spread":0.2565402950884829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312359773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248415,0.0024790622,0.0006591063,0.0008380711,0.00021491715,0.0010367372,0.0005363524,0.00006907279,0.00168259],"genre_scores_gemma":[0.9896381,0.0027267549,0.00107301,0.0008187788,0.00021540506,0.0014745668,0.001179074,0.000039245577,0.0028350519],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995215,0.00023672401,0.000024513296,0.00006663812,0.000037009704,0.00011359962],"domain_scores_gemma":[0.999368,0.0001297206,0.0000857782,0.00007550634,0.00003658289,0.0003043753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018811498,0.0016505003,0.0023937959,0.00048542206,0.0006011314,0.0009914874,0.0012022675,0.002264039,0.0020816806],"category_scores_gemma":[0.0007193215,0.0004923891,0.0016195517,0.0004268393,0.0012224383,0.000800688,0.0004417527,0.0031978867,0.00063285127],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72196597,0.06350087,0.007733259,0.0011748562,0.0026408853,0.0013935,0.0006556253,0.0069571096,0.06294228,0.001095276,0.0070904847,0.12284975],"study_design_scores_gemma":[0.4540405,0.52024615,0.00878647,0.00005515721,0.00067477924,0.00084875163,0.00015408076,0.0021623299,0.007956538,0.00042989288,0.0046065366,0.000038667153],"about_ca_topic_score_codex":0.0022212912,"about_ca_topic_score_gemma":0.00550726,"teacher_disagreement_score":0.0023937959,"about_ca_system_score_codex":0.001334211,"about_ca_system_score_gemma":0.0017645,"threshold_uncertainty_score":0.009948611},"labels":[],"label_agreement":null},{"id":"W2337001617","doi":"10.1007/s10637-016-0351-x","title":"A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Olaparib; Irinotecan; Medicine; Tolerability; Internal medicine; Regimen; Oncology; Neutropenia; PARP inhibitor; Colorectal cancer; Cancer; Chemotherapy; Adverse effect","score_opus":0.036393349825994216,"score_gpt":0.33026345964885223,"score_spread":0.293870109822858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337001617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502436,0.014717596,0.00070262846,0.004657306,0.00050508475,0.0074333376,0.010644348,0.00016910043,0.010926998],"genre_scores_gemma":[0.9418556,0.016572988,0.0045787403,0.005025383,0.00046707803,0.0051497133,0.0129884975,0.00010825317,0.013253783],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99925035,0.00030827543,0.000022953509,0.0000952862,0.000103401326,0.00021964527],"domain_scores_gemma":[0.9988944,0.00014608949,0.00012605234,0.00006740504,0.00011288963,0.0006531442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019716085,0.0015423569,0.002488875,0.0005447629,0.0010327505,0.0011956823,0.0012117969,0.0014815242,0.0055405167],"category_scores_gemma":[0.0012914495,0.0006816042,0.0022918994,0.0011993204,0.0013650021,0.0005792364,0.00044763257,0.004102436,0.00082467543],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8122028,0.02705969,0.008759258,0.001401943,0.0024911158,0.00033452772,0.00042680357,0.0026586272,0.011556946,0.0006437868,0.023382492,0.10908195],"study_design_scores_gemma":[0.8212768,0.1376027,0.024510631,0.00008378327,0.0012274205,0.00024211954,0.00013638176,0.0007854371,0.0009992409,0.00023581539,0.012834578,0.00006511639],"about_ca_topic_score_codex":0.10167877,"about_ca_topic_score_gemma":0.3116298,"teacher_disagreement_score":0.10167877,"about_ca_system_score_codex":0.004946951,"about_ca_system_score_gemma":0.0140303625,"threshold_uncertainty_score":0.20217383},"labels":[],"label_agreement":null},{"id":"W235826207","doi":"10.1007/s10637-015-0252-4","title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Adverse effect; Phases of clinical research; Oncology; Circulating tumor cell; Clinical trial; Cancer; Surgery; Metastasis","score_opus":0.08111566582937407,"score_gpt":0.40143433790230904,"score_spread":0.32031867207293496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W235826207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98078686,0.004727996,0.0009675038,0.0013834382,0.00032335526,0.003216951,0.0038823416,0.00025702603,0.0044546425],"genre_scores_gemma":[0.9766883,0.0044791247,0.002141405,0.0017040566,0.00028057554,0.0021762494,0.0067480365,0.00008611133,0.0056961784],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99956125,0.00021958104,0.00001625628,0.00005851176,0.00003744152,0.000107065156],"domain_scores_gemma":[0.9992118,0.0001131398,0.0001038971,0.00006350321,0.000032222062,0.00047544183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015791137,0.0021517721,0.0024053988,0.0008105827,0.0006653154,0.0011708846,0.0014331151,0.0014863202,0.0063958466],"category_scores_gemma":[0.00087407616,0.0006831647,0.0024510918,0.00077390904,0.0010776889,0.0008292502,0.00045290566,0.004352221,0.0014353443],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7299582,0.07592463,0.008237666,0.0011686449,0.0029614079,0.00043140637,0.00045689693,0.0046744924,0.044125337,0.00061358995,0.00973115,0.12171666],"study_design_scores_gemma":[0.61536443,0.3593542,0.015619735,0.000048204736,0.00085796416,0.00027791836,0.00014025295,0.0011242488,0.002800685,0.00022525777,0.004133662,0.000053408432],"about_ca_topic_score_codex":0.0050599165,"about_ca_topic_score_gemma":0.016273048,"teacher_disagreement_score":0.0063958466,"about_ca_system_score_codex":0.0012823829,"about_ca_system_score_gemma":0.0022266528,"threshold_uncertainty_score":0.02139622},"labels":[],"label_agreement":null},{"id":"W2405943329","doi":"10.1007/s10637-016-0364-5","title":"A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Dental and Craniofacial Research; National Institute on Deafness and Other Communication Disorders; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Docetaxel; Medicine; Oncology; Internal medicine; Clinical endpoint; Head and neck squamous-cell carcinoma; Head and neck cancer; Radiation therapy; Cancer; Clinical trial; Phases of clinical research; Chemotherapy; Surgery","score_opus":0.018481314063655246,"score_gpt":0.2890376702067251,"score_spread":0.27055635614306983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405943329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99006,0.002733163,0.00052968215,0.0006924759,0.00032618284,0.001454758,0.0007288164,0.00014164948,0.0033332994],"genre_scores_gemma":[0.98878026,0.0025466634,0.0010294253,0.00063291675,0.0001246237,0.0010819768,0.0013735755,0.000033599543,0.004396976],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997707,0.00008632133,0.0000090527965,0.00003897548,0.000022912543,0.00007206187],"domain_scores_gemma":[0.99970835,0.00005039857,0.00003327532,0.000028322578,0.000012821036,0.00016682672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074562564,0.0011282724,0.0020092959,0.00042405634,0.00040051524,0.0011738737,0.0010643019,0.0010561147,0.003510546],"category_scores_gemma":[0.0004923168,0.00048683627,0.0009277199,0.00048583632,0.0011006104,0.00091902545,0.00029546485,0.0036544774,0.0008234657],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58414584,0.0815233,0.005350489,0.0015820421,0.002263056,0.00083631894,0.0005648575,0.0075385626,0.09421403,0.0016487158,0.011182114,0.20915064],"study_design_scores_gemma":[0.48753494,0.48613462,0.007875226,0.000059916358,0.00065396127,0.0006619505,0.00014475893,0.0029306472,0.00725117,0.00046560646,0.0062221754,0.000064996246],"about_ca_topic_score_codex":0.002193025,"about_ca_topic_score_gemma":0.0077186543,"teacher_disagreement_score":0.003510546,"about_ca_system_score_codex":0.0012128605,"about_ca_system_score_gemma":0.0014654777,"threshold_uncertainty_score":0.011743903},"labels":[],"label_agreement":null},{"id":"W2415636816","doi":"10.1007/s10637-016-0367-2","title":"Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Cisplatin; Epidermal growth factor receptor; Oncology; Medicine; Head and neck; Radiation therapy; Head and neck squamous-cell carcinoma; Internal medicine; Basal cell; Cancer research; Chemotherapy; Carcinoma; Head and neck cancer; Receptor; Surgery","score_opus":0.01778624658383064,"score_gpt":0.2729515223007116,"score_spread":0.25516527571688097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415636816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862373,0.003196623,0.00039445795,0.0007712491,0.0003069216,0.0030360532,0.0021840755,0.00008976991,0.0037834882],"genre_scores_gemma":[0.98211044,0.0033316743,0.0015041018,0.0010023215,0.00017922514,0.0025881687,0.00444248,0.000040560255,0.0048011057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995017,0.00022389511,0.000021550979,0.00009766535,0.000033984023,0.00012124318],"domain_scores_gemma":[0.9990897,0.00012510864,0.000118344906,0.00007480202,0.000055974935,0.0005360284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019707829,0.0017210305,0.002463095,0.00054294517,0.0006581518,0.001448185,0.0012232384,0.001371603,0.0051196055],"category_scores_gemma":[0.0010939123,0.0008777003,0.0017308391,0.00073947146,0.0013022542,0.0013974673,0.00046053456,0.0041898508,0.0008921904],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8630871,0.04777519,0.005544371,0.0007614675,0.0016430209,0.00017761828,0.00034916692,0.0024895207,0.016075136,0.00046364177,0.0055624596,0.05607131],"study_design_scores_gemma":[0.6535842,0.33134305,0.008066077,0.000038858787,0.0005743562,0.00018738456,0.0001063689,0.0007123425,0.0020649657,0.00019224272,0.003101037,0.00002915781],"about_ca_topic_score_codex":0.0040296926,"about_ca_topic_score_gemma":0.01214499,"teacher_disagreement_score":0.0051196055,"about_ca_system_score_codex":0.0019378177,"about_ca_system_score_gemma":0.003044319,"threshold_uncertainty_score":0.017126739},"labels":[],"label_agreement":null},{"id":"W2464912596","doi":"10.1007/s10637-016-0375-2","title":"A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta; University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Myeloid leukemia; Gastroenterology; Refractory (planetary science); Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.02233236206226961,"score_gpt":0.29068264046947645,"score_spread":0.2683502784072068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2464912596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905171,0.002987124,0.0003556645,0.00080648577,0.00022197266,0.0010997748,0.00096142216,0.00010024031,0.0029501966],"genre_scores_gemma":[0.9867089,0.0029699807,0.0015284667,0.0011552698,0.00016185516,0.0011199956,0.0028424934,0.00002831128,0.003484771],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99978274,0.00010216398,0.0000105179515,0.00003413229,0.00001502277,0.000055470264],"domain_scores_gemma":[0.99966097,0.00006814605,0.000038002014,0.000025639842,0.000015303767,0.00019203546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008488646,0.0009801848,0.0018199449,0.00030564165,0.00031650538,0.0007623102,0.00064667215,0.00073458237,0.0029888065],"category_scores_gemma":[0.0006042764,0.00031166265,0.0009383963,0.00032034316,0.00075765606,0.00057662686,0.00028795094,0.0024807116,0.00067729753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73725355,0.029999122,0.007707756,0.0012514801,0.0014502091,0.00050829217,0.00028879396,0.0036542718,0.03838,0.0008024121,0.008619703,0.17008437],"study_design_scores_gemma":[0.69338936,0.28264755,0.010972378,0.00006064713,0.0005657106,0.0005403621,0.00010777795,0.0017544421,0.0037657975,0.00036803697,0.0057897256,0.000038112103],"about_ca_topic_score_codex":0.0009299031,"about_ca_topic_score_gemma":0.0040993295,"teacher_disagreement_score":0.0029888065,"about_ca_system_score_codex":0.00069124735,"about_ca_system_score_gemma":0.0012903265,"threshold_uncertainty_score":0.00999856},"labels":[],"label_agreement":null},{"id":"W2492626689","doi":"10.1007/s10637-016-0377-0","title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Dosing; Tolerability; Trametinib; Medicine; Adverse effect; Rash; MEK inhibitor; Pharmacokinetics; Cohort; Internal medicine; Pharmacology; Oncology; Gastroenterology; MAPK/ERK pathway; Biology","score_opus":0.007907842871237351,"score_gpt":0.24819467680905802,"score_spread":0.24028683393782066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492626689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918542,0.0017535009,0.00045205725,0.00070187513,0.00021572647,0.0018386944,0.0009872726,0.000121572935,0.0020750666],"genre_scores_gemma":[0.98964,0.0018945173,0.0014575891,0.000772963,0.0001414385,0.0015448993,0.0018551447,0.000041587642,0.0026519317],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959415,0.0001439996,0.000021609863,0.00008498311,0.000037058842,0.00011829393],"domain_scores_gemma":[0.9993716,0.00008363322,0.0000885579,0.00006931236,0.000037880272,0.00034902885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013573251,0.001606287,0.0026011372,0.0007665353,0.00052864815,0.0012955787,0.00094761414,0.0013204613,0.0039774254],"category_scores_gemma":[0.00097629504,0.000873111,0.00204882,0.0007324419,0.0010957776,0.0013718512,0.00044719648,0.00499915,0.0010849315],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7061063,0.0927025,0.006662945,0.00086481473,0.002071219,0.00031454075,0.00044159338,0.006387265,0.03393732,0.000530385,0.0056272047,0.14435399],"study_design_scores_gemma":[0.60282636,0.3774505,0.011243827,0.000037400572,0.00059571816,0.00030365522,0.00010157885,0.0018258082,0.0025358193,0.00034219952,0.0026892393,0.000047861202],"about_ca_topic_score_codex":0.0016805225,"about_ca_topic_score_gemma":0.0052551185,"teacher_disagreement_score":0.0039774254,"about_ca_system_score_codex":0.0013704958,"about_ca_system_score_gemma":0.0018106713,"threshold_uncertainty_score":0.013305783},"labels":[],"label_agreement":null},{"id":"W2514523591","doi":"10.1007/s10637-016-0383-2","title":"Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Nivolumab; Pembrolizumab; Medicine; Lung cancer; Tyrosine kinase; Erlotinib; EGFR inhibitors; Cancer research; Oncology; Anaplastic lymphoma kinase; Internal medicine; Immunotherapy; Cancer; Epidermal growth factor receptor; Receptor","score_opus":0.01607847236170796,"score_gpt":0.2932689510862317,"score_spread":0.27719047872452374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514523591","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2563019,0.56197023,0.025270274,0.0915922,0.007392613,0.0006499441,0.0010736365,0.00081448286,0.05493466],"genre_scores_gemma":[0.58082855,0.34228918,0.021587405,0.02111766,0.0060714865,0.00039633753,0.0008206768,0.00015839846,0.026730405],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9997874,0.00003541774,0.000021775293,0.000038884573,0.00006651329,0.000050031587],"domain_scores_gemma":[0.9998124,0.000055157354,0.000035923626,0.000015302787,0.000043951917,0.000037342725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062387093,0.00055056595,0.00092123746,0.0005123819,0.0003431845,0.0017734844,0.00083797064,0.00083791994,0.0058648493],"category_scores_gemma":[0.000517393,0.0002179551,0.00093222025,0.0005009312,0.0005069985,0.002447309,0.00065318716,0.0028798403,0.0011160111],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030959945,0.0014119087,0.002059807,0.001073162,0.00018363787,0.0008212978,0.0001677242,0.0016237181,0.06013858,0.016295856,0.023726944,0.8894015],"study_design_scores_gemma":[0.0062055816,0.018609807,0.013190994,0.0013385521,0.0015621867,0.007978737,0.00067771156,0.01061613,0.07538855,0.039230764,0.82494885,0.00025214197],"about_ca_topic_score_codex":0.0004956746,"about_ca_topic_score_gemma":0.0024995522,"teacher_disagreement_score":0.0058648493,"about_ca_system_score_codex":0.00077735784,"about_ca_system_score_gemma":0.00094742136,"threshold_uncertainty_score":0.019619882},"labels":[],"label_agreement":null},{"id":"W2514939920","doi":"10.1007/s10637-016-0386-z","title":"Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Medicine Hat College; BC Cancer Agency","funders":"Canadian Urological Oncology Group; Pfizer","keywords":"Docetaxel; Sunitinib; Medicine; Prostate cancer; Clinical endpoint; Internal medicine; Oncology; Adverse effect; Cancer; Surgery; Urology; Clinical trial","score_opus":0.04279131410167663,"score_gpt":0.3346133206473061,"score_spread":0.29182200654562945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514939920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97809464,0.017082706,0.00027192646,0.0007190243,0.000248445,0.000114443996,0.00039232822,0.000115702285,0.0029607867],"genre_scores_gemma":[0.996084,0.0019839997,0.00019146515,0.00017798005,0.00008815762,0.000031776475,0.00040950268,0.000009836339,0.0010233136],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998435,0.000029248558,0.00002053482,0.00002409599,0.000023651399,0.000059070357],"domain_scores_gemma":[0.9997296,0.00006359602,0.00006399598,0.00001866023,0.000016898419,0.00010720918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036308594,0.0002777088,0.0010228915,0.00040574276,0.00038383313,0.0004730251,0.00031434235,0.00044181145,0.0017346224],"category_scores_gemma":[0.0006394647,0.000116581235,0.0007275205,0.00037492515,0.00020567808,0.0004489881,0.000141336,0.0009145622,0.0003316433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13280341,0.0038937388,0.066660225,0.002155654,0.0017037304,0.0062752166,0.0005151731,0.0037336105,0.022219637,0.0006485945,0.012604469,0.74678665],"study_design_scores_gemma":[0.02665417,0.15642582,0.70661986,0.000614323,0.0031151713,0.025832297,0.0005548589,0.009292244,0.023831856,0.0015523707,0.04530119,0.00020584537],"about_ca_topic_score_codex":0.0010995897,"about_ca_topic_score_gemma":0.0065514846,"teacher_disagreement_score":0.0017346224,"about_ca_system_score_codex":0.00065231306,"about_ca_system_score_gemma":0.0005065731,"threshold_uncertainty_score":0.00580287},"labels":[],"label_agreement":null},{"id":"W2537645495","doi":"10.1007/s10637-016-0398-8","title":"Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)","year":2016,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Center, University of Colorado; Takeda Oncology","keywords":"Neddylation; NEDD8; Biology; Cancer research; Melanoma; Cell cycle; XIAP; Programmed cell death; Apoptosis; Gene; Ubiquitin; Biochemistry; Ubiquitin ligase; Caspase","score_opus":0.010605259637856208,"score_gpt":0.22690385579139907,"score_spread":0.21629859615354285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2537645495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854386,0.008686368,0.002027881,0.0005200168,0.00012172462,0.000040710165,0.00031184335,0.00017651153,0.002676382],"genre_scores_gemma":[0.99222916,0.0038422188,0.001310637,0.00007347268,0.0000126598015,0.000029276296,0.0002794338,0.000012550446,0.0022105686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993336,0.000010579762,0.000006068578,0.000009817881,0.000015785341,0.00002437213],"domain_scores_gemma":[0.9999832,0.0000021859119,0.0000044286103,0.0000021836784,0.0000019985596,0.000006018121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017297764,0.00023644941,0.00026222432,0.00018620232,0.00014185366,0.00033686962,0.000268964,0.0002921074,0.0012334184],"category_scores_gemma":[0.00007577487,0.0001404568,0.00021353971,0.00012159533,0.000142707,0.00027041032,0.00012914337,0.000578135,0.0003601865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014336333,0.0002337265,0.00036569536,0.000088092835,0.000025291087,0.00022050709,0.0000118837115,0.00056801527,0.97746664,0.00054698787,0.0006174506,0.018422145],"study_design_scores_gemma":[0.0004821522,0.0018105961,0.0030129484,0.0000103057855,0.000041210526,0.0009031349,0.000022498618,0.0030639628,0.98384905,0.00025622276,0.006536937,0.000011052078],"about_ca_topic_score_codex":0.00036978716,"about_ca_topic_score_gemma":0.001037865,"teacher_disagreement_score":0.0012334184,"about_ca_system_score_codex":0.00032770736,"about_ca_system_score_gemma":0.00025943093,"threshold_uncertainty_score":0.0041262507},"labels":[],"label_agreement":null},{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","score_opus":0.035873276828167516,"score_gpt":0.31157816259131627,"score_spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2585936581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98772776,0.0024332937,0.0016835527,0.00031771415,0.00012777463,0.004101073,0.0016531665,0.00020956287,0.0017462226],"genre_scores_gemma":[0.98497087,0.0017927337,0.003581054,0.00069729576,0.00013701031,0.003264811,0.0021916926,0.00006572793,0.0032988926],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959904,0.00014184948,0.000018658116,0.0000756739,0.000050536088,0.00011420187],"domain_scores_gemma":[0.9995498,0.000057463167,0.00007026663,0.000042744803,0.00004578642,0.00023386878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012989827,0.001077498,0.0022142932,0.00034886424,0.00050571945,0.00087337976,0.0006600513,0.00073511945,0.004284276],"category_scores_gemma":[0.00047871462,0.0004964491,0.0011025891,0.00036895313,0.00078832067,0.0005588244,0.00030083425,0.0024042581,0.00089905015],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3929257,0.122917615,0.010711178,0.0025707844,0.0015163115,0.00057062303,0.00059497694,0.0070593907,0.2367803,0.00073315535,0.011275339,0.21234463],"study_design_scores_gemma":[0.2677503,0.68944454,0.010440754,0.00005262839,0.00047773935,0.00050322706,0.000077644465,0.002266649,0.02102601,0.00026750448,0.0076449774,0.00004809271],"about_ca_topic_score_codex":0.00076869497,"about_ca_topic_score_gemma":0.00252323,"teacher_disagreement_score":0.004284276,"about_ca_system_score_codex":0.0007972232,"about_ca_system_score_gemma":0.0021493307,"threshold_uncertainty_score":0.014332294},"labels":[],"label_agreement":null},{"id":"W2597378792","doi":"10.1007/s10637-017-0450-3","title":"A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quebec Rehabilitation Research Network","funders":"University of Minnesota","keywords":"Carboplatin; Cetuximab; Medicine; Clinical endpoint; Paclitaxel; Internal medicine; Oncology; Adverse effect; Phases of clinical research; Chemotherapy; Lung cancer; Randomized controlled trial; Cancer; Colorectal cancer; Cisplatin","score_opus":0.023675209734914767,"score_gpt":0.34447456835469203,"score_spread":0.32079935861977726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597378792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892231,0.00090378284,0.00071876374,0.00036035466,0.0003130174,0.0063454127,0.0007025524,0.000085656815,0.0013473808],"genre_scores_gemma":[0.9816574,0.0010858616,0.0025757072,0.0011076542,0.0005177264,0.008561039,0.0013745545,0.00004023349,0.003079966],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992048,0.00046638545,0.00003515133,0.00012291271,0.000057523044,0.00011319686],"domain_scores_gemma":[0.99864596,0.00025796378,0.00026645465,0.00012016456,0.000086516135,0.0006229482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002239037,0.0018350764,0.0027061172,0.00036881003,0.00043497165,0.00089749374,0.00084681745,0.0012366187,0.0047956062],"category_scores_gemma":[0.0013451774,0.0008895662,0.001053207,0.0003537926,0.0015847462,0.0009275064,0.00040677894,0.003034534,0.0011244409],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9376539,0.035096258,0.001117301,0.00023682619,0.0004657255,0.00006084415,0.000071924704,0.00043800668,0.0091407215,0.0001336247,0.0011038493,0.014481009],"study_design_scores_gemma":[0.8456641,0.15097389,0.0013865812,0.000008403558,0.00015242911,0.00002975461,0.000015532652,0.0004256578,0.0007294418,0.000075761964,0.000528638,0.000009789326],"about_ca_topic_score_codex":0.0007904224,"about_ca_topic_score_gemma":0.0021883703,"teacher_disagreement_score":0.0047956062,"about_ca_system_score_codex":0.0009780732,"about_ca_system_score_gemma":0.0027387843,"threshold_uncertainty_score":0.016042888},"labels":[],"label_agreement":null},{"id":"W264127248","doi":"10.1023/a:1022976528441","title":"Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks","year":2003,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pyrogenesis (Canada); BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Pharmacokinetics; Pharmacology; Toxicity; Medicine; DNMT1; Hemoglobin; Chemistry; Methyltransferase; Internal medicine; DNA; Biochemistry","score_opus":0.017976582338079132,"score_gpt":0.30679116350208396,"score_spread":0.2888145811640048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W264127248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910255,0.0013877819,0.001156111,0.00044547534,0.00021833341,0.0024228713,0.0009352496,0.00013530295,0.0022733111],"genre_scores_gemma":[0.9833808,0.0018022585,0.0024275377,0.0006971334,0.00025420645,0.0041046473,0.0014989388,0.00005775337,0.0057767476],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996093,0.00013091209,0.000013143918,0.000076922704,0.000040015777,0.00012975428],"domain_scores_gemma":[0.9995171,0.00008435821,0.00010479233,0.000060115337,0.00003527624,0.00019850353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065216667,0.001772536,0.0021580195,0.0006839937,0.0005746607,0.0009306325,0.0013874202,0.0018429188,0.0021758066],"category_scores_gemma":[0.00058755366,0.00084880437,0.0009785271,0.00051510514,0.0012484584,0.0007252134,0.00022299968,0.002985452,0.00065989635],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6192992,0.11189866,0.003028776,0.00044439972,0.00073228293,0.00035430127,0.00027580725,0.004467477,0.17205535,0.0012766444,0.00469985,0.081467226],"study_design_scores_gemma":[0.2683624,0.6984095,0.0035824536,0.000026121306,0.00031464544,0.00025820543,0.000077709126,0.0012393139,0.022885477,0.00036503078,0.004440029,0.000039146253],"about_ca_topic_score_codex":0.0016993573,"about_ca_topic_score_gemma":0.0032968223,"teacher_disagreement_score":0.0021758066,"about_ca_system_score_codex":0.00094282796,"about_ca_system_score_gemma":0.0023026338,"threshold_uncertainty_score":0.0072788},"labels":[],"label_agreement":null},{"id":"W2724602822","doi":"10.1007/s10637-017-0486-4","title":"Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai","keywords":"Eribulin; Medicine; Observational study; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.03159839853472978,"score_gpt":0.33611036699038593,"score_spread":0.30451196845565615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2724602822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983047,0.0008971008,0.00007758361,0.000049972736,0.000005458904,0.00005567259,0.0002933475,0.0000028259583,0.00031320867],"genre_scores_gemma":[0.9985007,0.00040928173,0.00010085608,0.00015958032,0.00004222433,0.00006986131,0.00057125214,0.0000022934528,0.00014386416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841213,0.0006267521,0.00026716213,0.00027020695,0.0002834784,0.00014013982],"domain_scores_gemma":[0.99155384,0.0011910042,0.005422106,0.0004719542,0.00077010435,0.0005910369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002500732,0.000327387,0.00096074084,0.00045702522,0.0004769694,0.0008251101,0.00034198552,0.00048663025,0.0014317564],"category_scores_gemma":[0.00417088,0.000283288,0.0011676658,0.0009913278,0.0004705072,0.00057863636,0.00035389443,0.0007921352,0.0002699348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048398953,0.0005953641,0.98630303,0.0002453687,0.0009823288,0.00018931371,0.0001741455,0.00009662395,0.00060576864,0.000021372078,0.00025647116,0.005690371],"study_design_scores_gemma":[0.0006385362,0.0042625726,0.9918018,0.000026372898,0.001046673,0.0003990975,0.00017192942,0.00038732076,0.00023545056,0.000027137732,0.0009844325,0.000018757286],"about_ca_topic_score_codex":0.0020481385,"about_ca_topic_score_gemma":0.002161539,"teacher_disagreement_score":0.002500732,"about_ca_system_score_codex":0.0007342551,"about_ca_system_score_gemma":0.0008000988,"threshold_uncertainty_score":0.013225257},"labels":[],"label_agreement":null},{"id":"W2738241641","doi":"10.1007/s10637-017-0488-2","title":"Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"BC Cancer Agency; Canadian Cancer Society Research Institute","keywords":"Clioquinol; Plumbagin; Platinum; Carboplatin; Cisplatin; Copper; Chemistry; Denticity; Pharmacology; Cancer research; Chemotherapy; Biochemistry; Medicine; Internal medicine; Biology; Metal; Organic chemistry","score_opus":0.0754335186395352,"score_gpt":0.3180040468573997,"score_spread":0.2425705282178645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738241641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365413,0.0016091154,0.0027138044,0.000057935114,0.000024717448,0.000040989635,0.00011639536,0.00013126642,0.0016516271],"genre_scores_gemma":[0.99574655,0.00037511688,0.0018661461,0.000032286174,0.0000069453563,0.000028035389,0.00016001947,0.00001290497,0.0017720247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985933,0.00004021599,0.000013335917,0.000030247906,0.000032188163,0.00002460155],"domain_scores_gemma":[0.99988866,0.000026510026,0.000022984299,0.000014865445,0.000025594494,0.000021294214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015101788,0.00025019917,0.00024529628,0.00014363493,0.00009269536,0.00027477252,0.00023119323,0.00023293166,0.00086310686],"category_scores_gemma":[0.00027674856,0.00012271425,0.000082945844,0.00014766643,0.00019859771,0.00010480091,0.00016430762,0.00022555437,0.0002041611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018080452,0.000021108204,0.00017552591,0.000072031915,0.000008900741,0.00003664579,0.00001850829,0.00015970923,0.9973537,0.0000646716,0.00012913435,0.0017792495],"study_design_scores_gemma":[0.000028022278,0.00049491046,0.0007260425,0.0000043258055,0.000013475055,0.00014642088,0.000013628487,0.00082907436,0.9955201,0.000025361764,0.002194792,0.0000037888747],"about_ca_topic_score_codex":0.00091236294,"about_ca_topic_score_gemma":0.0010231809,"teacher_disagreement_score":0.00091236294,"about_ca_system_score_codex":0.00023985787,"about_ca_system_score_gemma":0.00012934339,"threshold_uncertainty_score":0.0028873682},"labels":[],"label_agreement":null},{"id":"W2754566416","doi":"10.1007/s10637-017-0510-8","title":"Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications","year":2017,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Interquartile range; Adverse effect; Internal medicine; Clinical endpoint; MEDLINE","score_opus":0.9371062626576229,"score_gpt":0.7366516816469256,"score_spread":0.20045458101069724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754566416","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018169795,0.98190343,0.005982407,0.0013920739,0.00096342457,0.0012069228,0.003368392,0.000073057425,0.0032933],"genre_scores_gemma":[0.069657445,0.900449,0.0147632845,0.0028087683,0.0017359129,0.005147472,0.0043289876,0.00013916238,0.0009699815],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.8695021,0.063238256,0.04378554,0.0047408203,0.017982142,0.0007512063],"domain_scores_gemma":[0.52343285,0.40167248,0.0515145,0.008774117,0.013708604,0.0008973892],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10900985,0.0012825631,0.0063544535,0.01501424,0.000382534,0.005268931,0.002957041,0.0019948038,0.012401999],"category_scores_gemma":[0.39607498,0.00081598776,0.007693172,0.019620605,0.001756671,0.0064177834,0.0029864984,0.0024293063,0.0010567287],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027355033,0.0000458016,0.0024295046,0.569682,0.026456231,0.00008378806,0.00029127975,0.0006405512,0.0002693394,0.0059544533,0.008765515,0.38264605],"study_design_scores_gemma":[0.006839578,0.0014457543,0.019248,0.5786891,0.14029257,0.0015545761,0.0008123361,0.001342541,0.0019685542,0.03813687,0.2094,0.00027019778],"about_ca_topic_score_codex":0.0011715184,"about_ca_topic_score_gemma":0.001979275,"teacher_disagreement_score":0.89099014,"about_ca_system_score_codex":0.0023552263,"about_ca_system_score_gemma":0.0079377275,"threshold_uncertainty_score":0.5765061},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["metaresearch"],"domain":"reporting","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2771486844","doi":"10.1007/s10637-017-0549-6","title":"Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database","year":2017,"lang":"en","type":"review","venue":"Investigational New Drugs","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Database; Internal medicine; Computer science","score_opus":0.9608405442956974,"score_gpt":0.7387906900373383,"score_spread":0.2220498542583591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771486844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024664145,0.9028525,0.004305171,0.000815908,0.00036580203,0.0028502946,0.061311617,0.00016609859,0.0026684701],"genre_scores_gemma":[0.35480806,0.55581105,0.014428001,0.0023343475,0.0006610116,0.01227491,0.057882518,0.00030002816,0.0015001823],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.93540645,0.025301564,0.027141593,0.003632033,0.007894531,0.00062389625],"domain_scores_gemma":[0.84326315,0.11152587,0.02798903,0.007227391,0.009210504,0.00078409055],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.034225494,0.0016856479,0.012654221,0.01781289,0.0005577642,0.0030624135,0.0026006573,0.0014092636,0.0061284276],"category_scores_gemma":[0.14995806,0.0011570161,0.015996622,0.023941973,0.0008223699,0.002402084,0.0023864259,0.001699481,0.00068436575],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008732761,0.000059168353,0.013321493,0.54900354,0.37378174,0.00020946837,0.00027538562,0.00071479066,0.00039643483,0.0009238499,0.010085411,0.042495962],"study_design_scores_gemma":[0.009058336,0.0005828584,0.03824267,0.086347625,0.8253784,0.0006101687,0.00026801002,0.00045005308,0.00065189885,0.0018867789,0.036384184,0.00013901526],"about_ca_topic_score_codex":0.0037368098,"about_ca_topic_score_gemma":0.00941637,"teacher_disagreement_score":0.96577454,"about_ca_system_score_codex":0.002470298,"about_ca_system_score_gemma":0.005658983,"threshold_uncertainty_score":0.18100387},"labels":[],"label_agreement":null},{"id":"W2772605981","doi":"10.1007/s10637-017-0553-x","title":"A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; McMaster University Medical Centre; University of British Columbia","funders":"Terry Fox Research Institute","keywords":"Prednisone; Medicine; Prostate cancer; Internal medicine; Gastroenterology; Adverse effect; Clinical endpoint; Urology; Cancer; Surgery; Randomized controlled trial","score_opus":0.024409912031311976,"score_gpt":0.3215747798365999,"score_spread":0.2971648678052879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2772605981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869824,0.002077373,0.0008718585,0.0011760694,0.0009008795,0.0041605094,0.0014102741,0.00015557856,0.0022651986],"genre_scores_gemma":[0.9808311,0.0017969026,0.0024711865,0.0018715558,0.00089943164,0.0054990044,0.0015582533,0.00006284918,0.005009769],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990097,0.00053043413,0.00003899498,0.00019273866,0.00004779191,0.00018039094],"domain_scores_gemma":[0.998044,0.0006406129,0.00027169878,0.00015776121,0.00008575553,0.00080002076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002476313,0.0030385994,0.004255159,0.0008762209,0.0007156889,0.0016986246,0.0014410965,0.002446925,0.010162791],"category_scores_gemma":[0.0023462118,0.0012010741,0.0025544723,0.0007522965,0.002516809,0.0022506132,0.00069178274,0.005436214,0.001330529],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9821469,0.008441786,0.00027327708,0.00014707663,0.00031787157,0.000018625067,0.00003628174,0.0003664637,0.0015887427,0.00007725679,0.0003419644,0.006243655],"study_design_scores_gemma":[0.9030062,0.09508279,0.0007036405,0.0000089638,0.0002095573,0.000016117769,0.000022395474,0.00024852293,0.00024981826,0.0001440096,0.0002939752,0.000013929],"about_ca_topic_score_codex":0.0019957437,"about_ca_topic_score_gemma":0.0038022306,"teacher_disagreement_score":0.010162791,"about_ca_system_score_codex":0.0013413477,"about_ca_system_score_gemma":0.0019991896,"threshold_uncertainty_score":0.033997953},"labels":[],"label_agreement":null},{"id":"W2795799317","doi":"10.1007/s10637-018-0591-z","title":"A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pharmacokinetics; Tolerability; Dosing; Pharmacodynamics; Adverse effect; Internal medicine; Gastroenterology; Nausea; Pharmacology","score_opus":0.023426818378666114,"score_gpt":0.3401203968094243,"score_spread":0.3166935784307582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2795799317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012136,0.0013422357,0.0010389714,0.00043626447,0.00018550226,0.0040455023,0.0012464162,0.00010900477,0.0014748521],"genre_scores_gemma":[0.9805418,0.0016837422,0.0032555202,0.0011722074,0.00029313544,0.006153495,0.0027017563,0.00006679785,0.004131435],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999353,0.00024165906,0.00002978372,0.00014193186,0.000061405444,0.00017226476],"domain_scores_gemma":[0.99890494,0.00017055795,0.00016971375,0.00014559325,0.000058477744,0.00055075105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020907132,0.0022669544,0.0035368002,0.00064718357,0.0006748999,0.0011768395,0.0010420722,0.0016050014,0.0041679796],"category_scores_gemma":[0.0012381078,0.0010042761,0.0020180256,0.0006583645,0.0018539893,0.0020363708,0.00051241077,0.0047523933,0.0010542801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7612383,0.1273113,0.0059315176,0.0006123325,0.0010538481,0.00026499978,0.00031621123,0.002714981,0.032784518,0.0003777208,0.0027291928,0.064665176],"study_design_scores_gemma":[0.4471851,0.540849,0.006112595,0.000013553432,0.0003055442,0.00017366087,0.000063574116,0.0009678251,0.0025834772,0.00022620744,0.0014829615,0.00003645299],"about_ca_topic_score_codex":0.0010534689,"about_ca_topic_score_gemma":0.0027950385,"teacher_disagreement_score":0.0041679796,"about_ca_system_score_codex":0.001380291,"about_ca_system_score_gemma":0.0028269605,"threshold_uncertainty_score":0.013943255},"labels":[],"label_agreement":null},{"id":"W2796296273","doi":"10.1007/s10637-018-0595-8","title":"Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Institut National de la Recherche Scientifique","funders":"Canadian Institutes of Health Research","keywords":"Autophagy; In vivo; Prostate cancer; Apoptosis; Programmed cell death; Cancer research; Medicine; Cancer; Pharmacology; Prostate; TUNEL assay; Growth inhibition; Internal medicine; Biology; Immunohistochemistry; Biochemistry","score_opus":0.02092564730317531,"score_gpt":0.2962967590629427,"score_spread":0.2753711117597674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796296273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547535,0.0012193426,0.0008417858,0.00014109343,0.00006227065,0.000023919352,0.00041913506,0.00012382191,0.0016933295],"genre_scores_gemma":[0.99378127,0.0012700687,0.000990965,0.000042393764,0.00000942386,0.000024213772,0.00058866694,0.000024034049,0.003268919],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999287,0.000009068987,0.000005771486,0.000014334717,0.000016180176,0.000025934973],"domain_scores_gemma":[0.99994254,0.000008228365,0.000012615665,0.0000075014846,0.0000056206136,0.000023462102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010253053,0.0003404738,0.00036354642,0.000366382,0.0002282208,0.0001933313,0.00026679056,0.00023796245,0.0016942291],"category_scores_gemma":[0.00006398448,0.00012161864,0.00025382027,0.00026364974,0.00021744407,0.00028972104,0.0001350583,0.0008132426,0.00022834029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016834912,0.0004397082,0.00015434372,0.00009652552,0.000019391588,0.000047564452,0.000027435075,0.00030970844,0.9924712,0.00020084156,0.00031200357,0.0042376937],"study_design_scores_gemma":[0.00005219739,0.001479352,0.0010807875,0.000004368092,0.00002694772,0.00006908848,0.000024712306,0.0006815661,0.9946779,0.000042476346,0.0018533205,0.0000073325414],"about_ca_topic_score_codex":0.0015858405,"about_ca_topic_score_gemma":0.0034383163,"teacher_disagreement_score":0.0016942291,"about_ca_system_score_codex":0.00027746003,"about_ca_system_score_gemma":0.00042662694,"threshold_uncertainty_score":0.005667746},"labels":[],"label_agreement":null},{"id":"W2797850256","doi":"10.1007/s10637-018-0597-6","title":"A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Developmental Biology and Gene Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Nausea; Notch signaling pathway; Adverse effect; Dosing; Tolerability; Internal medicine; Toxicity; Pharmacology; Oncology; Gastroenterology","score_opus":0.01184836436950387,"score_gpt":0.291251166487549,"score_spread":0.27940280211804513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797850256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929289,0.0014335052,0.00059168844,0.0006347633,0.00015612056,0.0014694413,0.00086321833,0.000097259704,0.0018251167],"genre_scores_gemma":[0.98506236,0.0023701622,0.0023511802,0.001154557,0.00012084079,0.0021631052,0.0024464242,0.000059158174,0.004272344],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996532,0.000113957605,0.000017675104,0.00007101023,0.000035001143,0.000109149194],"domain_scores_gemma":[0.9995346,0.000057385023,0.00006399509,0.00005073869,0.000023896713,0.00026933255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010958622,0.0016658661,0.0027734465,0.00070571824,0.00041129862,0.001256657,0.00095064886,0.0011563986,0.0036469155],"category_scores_gemma":[0.00063323823,0.0006843321,0.0019006189,0.0006722609,0.0009979536,0.0011218233,0.0005235663,0.004008252,0.0009087568],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69583213,0.069313794,0.0063114576,0.0008979108,0.002278574,0.0002663402,0.00043334454,0.008312939,0.053972945,0.00073492364,0.0058169332,0.15582874],"study_design_scores_gemma":[0.5984374,0.3810824,0.010464759,0.000037210615,0.00067384064,0.00021751002,0.00011467439,0.0021618567,0.0030105023,0.00053141336,0.0032122117,0.000056121775],"about_ca_topic_score_codex":0.0014316222,"about_ca_topic_score_gemma":0.0042659044,"teacher_disagreement_score":0.0036469155,"about_ca_system_score_codex":0.0010669999,"about_ca_system_score_gemma":0.0015919949,"threshold_uncertainty_score":0.012200117},"labels":[],"label_agreement":null},{"id":"W2800067592","doi":"10.1007/s10637-018-0599-4","title":"A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; University of Alberta; St. Michael's Hospital","funders":"Sanofi; Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Irinotecan; Capecitabine; Phases of clinical research; Neutropenia; Oxaliplatin; Nausea; Febrile neutropenia; Clinical endpoint; Toxicity; Cancer; Surgery; Clinical trial; Colorectal cancer","score_opus":0.04650012193401043,"score_gpt":0.31679964612210926,"score_spread":0.2702995241880988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800067592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943158,0.0014070007,0.00037778117,0.00034398973,0.00019746229,0.0017244326,0.0007453667,0.000046089794,0.0008420916],"genre_scores_gemma":[0.9886197,0.0017679154,0.001773927,0.00096970645,0.00042635415,0.0023028525,0.0022427402,0.00003523425,0.0018615982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99892896,0.00057138025,0.000050683917,0.00021301316,0.000074573756,0.00016137483],"domain_scores_gemma":[0.9979766,0.00040702586,0.00035703805,0.00020463714,0.00011563058,0.0009390614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029920365,0.002029568,0.003913145,0.0005896096,0.0007310048,0.0015465387,0.0012996218,0.0016380138,0.0036502334],"category_scores_gemma":[0.002309584,0.0011751311,0.0025636752,0.0008859809,0.0021305305,0.0017394397,0.0006442576,0.0048345462,0.0008168747],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93608975,0.040268835,0.003326262,0.00030673534,0.0009442505,0.00006291696,0.00015047392,0.0006834589,0.0051176283,0.00006774433,0.0007656841,0.012216248],"study_design_scores_gemma":[0.77364844,0.21559228,0.00828085,0.00001422647,0.0006423521,0.00006550438,0.00005903178,0.0004491053,0.00045233642,0.00006716831,0.0007030202,0.000025741381],"about_ca_topic_score_codex":0.0023901705,"about_ca_topic_score_gemma":0.0054106372,"teacher_disagreement_score":0.003913145,"about_ca_system_score_codex":0.0016081027,"about_ca_system_score_gemma":0.002447103,"threshold_uncertainty_score":0.015823603},"labels":[],"label_agreement":null},{"id":"W2803611443","doi":"10.1007/s10637-018-0600-2","title":"Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; MEK inhibitor; Adverse effect; Internal medicine; Rash; Cancer; Gastroenterology; Progressive disease; Response Evaluation Criteria in Solid Tumors; KRAS; Population; Pharmacokinetics; Nausea; Oncology; MAPK/ERK pathway; Chemotherapy; Colorectal cancer","score_opus":0.02750770921311321,"score_gpt":0.29886489760506607,"score_spread":0.2713571883919529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803611443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772553,0.014195592,0.00032176136,0.00092245627,0.00020199665,0.0012324819,0.0023594461,0.00004193109,0.0034690558],"genre_scores_gemma":[0.98077184,0.009704937,0.000990627,0.0010514244,0.00014726202,0.0010113186,0.003380348,0.000019207931,0.002923006],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959403,0.0002054616,0.000025165988,0.000044991415,0.000034094814,0.000096328404],"domain_scores_gemma":[0.99959797,0.00006567912,0.00007455406,0.00003211929,0.000052161704,0.00017748032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012474516,0.0007561428,0.001689216,0.00041299214,0.0003934501,0.000816528,0.0003984717,0.0006382257,0.0036633185],"category_scores_gemma":[0.00085512135,0.00044868691,0.0014148233,0.00052779046,0.00042093542,0.0006575142,0.00034718245,0.0019904606,0.00047565656],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76115644,0.021755423,0.02175731,0.0025639157,0.0043687113,0.00023856391,0.00022998743,0.0017129292,0.028353965,0.00041088017,0.007348941,0.1501029],"study_design_scores_gemma":[0.5054314,0.397485,0.06425645,0.00020293283,0.003608875,0.00063213543,0.00020905858,0.0009664461,0.009151188,0.00036687983,0.017623661,0.000065870205],"about_ca_topic_score_codex":0.001874908,"about_ca_topic_score_gemma":0.007974121,"teacher_disagreement_score":0.0036633185,"about_ca_system_score_codex":0.0011077769,"about_ca_system_score_gemma":0.0015337454,"threshold_uncertainty_score":0.012255073},"labels":[],"label_agreement":null},{"id":"W2805277822","doi":"10.1007/s10637-018-0618-5","title":"Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Centre for Drug Research and Development","funders":"","keywords":"S1PR1; Carboplatin; Sphingosine; Antibody; Sphingosine-1-phosphate; Cancer research; Sphingosine-1-phosphate receptor; Cytotoxicity; Pharmacology; Monoclonal antibody; Sphingolipid; Cancer cell; Chemistry; Cell growth; Receptor; Cancer; Biology; Medicine; Immunology; Internal medicine; Biochemistry; In vitro; Chemotherapy; Cisplatin","score_opus":0.01269533112936384,"score_gpt":0.3209698053832642,"score_spread":0.30827447425390037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805277822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918847,0.0026945933,0.0012526959,0.00030649343,0.00014426206,0.00021305651,0.00039442044,0.00010220301,0.0030075472],"genre_scores_gemma":[0.9936428,0.0021076137,0.0006508006,0.00008347169,0.000053395343,0.00012033148,0.0005087081,0.000012758106,0.0028201242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985135,0.00003731492,0.0000072674875,0.000020853844,0.000023371755,0.000059817936],"domain_scores_gemma":[0.9998288,0.00004983366,0.000024789397,0.000020129377,0.000022955695,0.000053447093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004841833,0.0005782543,0.00056721974,0.00047860167,0.00028510718,0.00021434198,0.0004988199,0.00042777314,0.002634642],"category_scores_gemma":[0.00022091683,0.00023314785,0.00039486593,0.00027189474,0.00029005465,0.00036598125,0.00012525448,0.0012468522,0.00038942954],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01152587,0.019951327,0.0008130421,0.00034479462,0.00012681601,0.0002447825,0.0001521435,0.0022178846,0.94017524,0.0010230162,0.0013286935,0.022096392],"study_design_scores_gemma":[0.003228921,0.11354685,0.0043228325,0.000019190393,0.0002989233,0.00042638104,0.00006098706,0.0035419548,0.86888343,0.00019091394,0.005466454,0.000013182071],"about_ca_topic_score_codex":0.0013952379,"about_ca_topic_score_gemma":0.0016667838,"teacher_disagreement_score":0.002634642,"about_ca_system_score_codex":0.00035851865,"about_ca_system_score_gemma":0.0005602046,"threshold_uncertainty_score":0.008813739},"labels":[],"label_agreement":null},{"id":"W2810093122","doi":"10.1007/s10637-017-0455-y","title":"Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Calcium channel; TRPV6; Calcium; Medicine; Phase (matter); Pharmacology; Internal medicine; Chemistry; Calcium metabolism","score_opus":0.032401360179402566,"score_gpt":0.31077772977999396,"score_spread":0.2783763696005914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810093122","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025467507,0.01769197,0.0018339342,0.14516142,0.8092555,0.0004382886,0.0052852323,0.00042624224,0.01736069],"genre_scores_gemma":[0.040897466,0.037801344,0.011475155,0.29165125,0.21140122,0.00074360054,0.014069235,0.0012401288,0.39072064],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989889,0.00017323412,0.00020116985,0.00009344407,0.00044748644,0.00009570748],"domain_scores_gemma":[0.99657935,0.0011376316,0.00034778687,0.00016236631,0.0014292003,0.00034372078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018008009,0.0013126808,0.0016592187,0.0010713296,0.0010381468,0.0013458418,0.0012370587,0.003152714,0.028042946],"category_scores_gemma":[0.009937798,0.00052861264,0.0013756393,0.0006220924,0.0006174922,0.0012079765,0.00046781963,0.0049291463,0.011321246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082273013,0.00007212119,0.00028996178,0.00036471646,0.00005946127,0.0005990843,0.000008386075,0.00012055413,0.00022537928,0.00038926024,0.97553,0.021518392],"study_design_scores_gemma":[0.0019701517,0.00078778865,0.002248835,0.00061334943,0.00034830804,0.0020315505,0.00005769246,0.0007093182,0.0018652888,0.001247552,0.98807037,0.00004976874],"about_ca_topic_score_codex":0.0035064744,"about_ca_topic_score_gemma":0.007954725,"teacher_disagreement_score":0.028042946,"about_ca_system_score_codex":0.0018281919,"about_ca_system_score_gemma":0.0022916016,"threshold_uncertainty_score":0.093813},"labels":[],"label_agreement":null},{"id":"W2885160762","doi":"10.1007/s10637-018-0644-3","title":"The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"Intracellular pH; Chemistry; Quercetin; Monocarboxylate transporter; Intracellular; In vivo; Intraperitoneal injection; Transporter; Tumor microenvironment; Pharmacology; Extracellular; Cancer cell; Cancer; Biochemistry; Medicine; Biology; Internal medicine; Antioxidant","score_opus":0.021182038711754312,"score_gpt":0.23557935971675015,"score_spread":0.21439732100499584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885160762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246854,0.0013577989,0.0044464073,0.00027826606,0.000048497724,0.000046012065,0.00037378323,0.00013653743,0.00084413687],"genre_scores_gemma":[0.99461126,0.0008479952,0.0021728498,0.000066017215,0.000012334868,0.000038985352,0.00026248032,0.000024432498,0.0019636103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998876,0.00001757888,0.0000058583105,0.000023660383,0.000022762018,0.000042610216],"domain_scores_gemma":[0.99991024,0.000008000061,0.000037672005,0.000006709286,0.000009731196,0.000027658036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018472766,0.00046307963,0.00029065393,0.00046140567,0.00012205768,0.00022256571,0.0003041075,0.0004472199,0.0007028321],"category_scores_gemma":[0.00008118156,0.0002174229,0.00026723684,0.00018856376,0.00030890063,0.00040854758,0.000151982,0.0007870203,0.00014999279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029853417,0.000053702315,0.00010809573,0.000016162248,0.0000061254714,0.00003094116,0.00000787712,0.000035497433,0.998777,0.000061381696,0.00004321045,0.00056158943],"study_design_scores_gemma":[0.000059916696,0.0007959368,0.0026714995,0.0000034460643,0.000043730437,0.00013117785,0.000029754012,0.0012114759,0.99438524,0.00006528436,0.00059676194,0.000005840681],"about_ca_topic_score_codex":0.0021837782,"about_ca_topic_score_gemma":0.003445475,"teacher_disagreement_score":0.0021837782,"about_ca_system_score_codex":0.0004725363,"about_ca_system_score_gemma":0.00024126569,"threshold_uncertainty_score":0.004342139},"labels":[],"label_agreement":null},{"id":"W2885345548","doi":"10.1007/s10637-018-0627-4","title":"Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Rash; Medicine; Pharmacokinetics; Toxicity; Pharmacology; Bioavailability; Adverse effect; In vivo; Mucositis; Population; Internal medicine; Gastroenterology; Biology","score_opus":0.020630088078205332,"score_gpt":0.28804445371272924,"score_spread":0.2674143656345239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885345548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909773,0.0027264687,0.0024038665,0.00023308437,0.00004139154,0.0011129435,0.0009305742,0.00013482326,0.001439552],"genre_scores_gemma":[0.98914295,0.0017166461,0.0027934585,0.00045453335,0.00004017293,0.00068036525,0.0033265266,0.000051466755,0.001793683],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99963236,0.00012878567,0.000023023464,0.00007469554,0.00006537256,0.000075716416],"domain_scores_gemma":[0.9997489,0.000023880715,0.000062145584,0.00003351713,0.000029641114,0.00010196964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008601906,0.00075557694,0.0010790197,0.00031343353,0.00020437554,0.00088522484,0.00067161984,0.00056484836,0.0012920388],"category_scores_gemma":[0.0003908011,0.00037628837,0.0005146759,0.00034456662,0.00037003245,0.00040913158,0.00020378125,0.0015081342,0.0005655821],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028218493,0.027828733,0.00698641,0.00075288874,0.00071404816,0.0005030683,0.00024352441,0.0069059674,0.8348512,0.00069934863,0.004172021,0.08812439],"study_design_scores_gemma":[0.056516204,0.5729554,0.038663425,0.00008149179,0.0014148199,0.0031388777,0.00023290359,0.015634358,0.28289747,0.0006751785,0.027680587,0.00010932671],"about_ca_topic_score_codex":0.0009007857,"about_ca_topic_score_gemma":0.0018752642,"teacher_disagreement_score":0.0012920388,"about_ca_system_score_codex":0.00073648326,"about_ca_system_score_gemma":0.0010833906,"threshold_uncertainty_score":0.005343616},"labels":[],"label_agreement":null},{"id":"W2885940270","doi":"10.1007/s10637-018-0643-4","title":"Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Endoplasmic Reticulum Stress and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Canadian Institutes of Health Research","keywords":"Pancreatic cancer; Unfolded protein response; Endoplasmic reticulum; In vivo; Cytotoxic T cell; Apoptosis; Medicine; Endocrinology; Internal medicine; Toxicity; Chemistry; Cancer; Cancer research; In vitro; Biology; Biochemistry","score_opus":0.010324257116953403,"score_gpt":0.25672939573111053,"score_spread":0.24640513861415714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885940270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937735,0.0010155399,0.0016958546,0.00027481333,0.00012614406,0.000036274098,0.00079437107,0.000251783,0.0020316802],"genre_scores_gemma":[0.98972964,0.0011210981,0.0019410626,0.000073260766,0.000021793638,0.00007317376,0.0012833062,0.00004930452,0.0057073096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999856,0.000015221754,0.000013787296,0.000032626172,0.000033097385,0.00004922042],"domain_scores_gemma":[0.999887,0.000015894639,0.000027978447,0.00001932116,0.000007442204,0.000042427684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012997641,0.00059398205,0.0005188331,0.00034272266,0.00020776321,0.00019920022,0.00031402605,0.0003636095,0.002144808],"category_scores_gemma":[0.0000726406,0.00020968108,0.0004099821,0.00032988374,0.00025505968,0.0003807369,0.00015111353,0.001782148,0.0006677493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012123515,0.0005361582,0.00023115639,0.00005910916,0.000013983214,0.00014895243,0.000026463958,0.0002360192,0.99438864,0.00017950787,0.00033101268,0.0026366268],"study_design_scores_gemma":[0.00007672761,0.0016737974,0.0017158164,0.0000042459305,0.000022784807,0.00018215863,0.000023827773,0.0011643103,0.9938491,0.000055428023,0.0012267908,0.0000051010434],"about_ca_topic_score_codex":0.0005850909,"about_ca_topic_score_gemma":0.00069318054,"teacher_disagreement_score":0.002144808,"about_ca_system_score_codex":0.0002373803,"about_ca_system_score_gemma":0.00028926868,"threshold_uncertainty_score":0.007175088},"labels":[],"label_agreement":null},{"id":"W2896825577","doi":"10.1007/s10637-018-0680-z","title":"Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens","year":2018,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hamilton Health Sciences; University of Toronto; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Selumetinib; Medicine; Carboplatin; Pemetrexed; Cohort; Internal medicine; Adverse effect; Chemotherapy; Tolerability; Neutropenia; Oncology; Cisplatin; Cancer; Gastroenterology; KRAS","score_opus":0.03154237553643747,"score_gpt":0.3657243787929642,"score_spread":0.33418200325652675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896825577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.957693,0.00946999,0.00038793014,0.0047648377,0.00062223035,0.0043192995,0.010118093,0.00022308982,0.012401571],"genre_scores_gemma":[0.95935416,0.0072258036,0.0021848565,0.004969534,0.00037025227,0.00265984,0.014639804,0.00007324479,0.008522636],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999398,0.0002149166,0.000019466332,0.00008074636,0.00009245466,0.00019450845],"domain_scores_gemma":[0.9992873,0.000078862475,0.000090748945,0.00003593271,0.000056167944,0.00045097468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017574229,0.0016917225,0.0025026891,0.00049425237,0.0010355277,0.0013793088,0.0012840109,0.001759328,0.00544345],"category_scores_gemma":[0.0013137932,0.0005578931,0.0021163991,0.00086850964,0.001323456,0.0007594013,0.000446602,0.00431151,0.0009766588],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77467936,0.029247796,0.012675572,0.0014224072,0.0040607923,0.00035073436,0.0003141836,0.003344878,0.013741434,0.00078661344,0.036378272,0.12299792],"study_design_scores_gemma":[0.8304784,0.12120364,0.027304728,0.00008578666,0.0017033507,0.00024180436,0.00012429322,0.0012192418,0.0014959042,0.00037337237,0.015687268,0.00008224186],"about_ca_topic_score_codex":0.06218669,"about_ca_topic_score_gemma":0.2526982,"teacher_disagreement_score":0.06218669,"about_ca_system_score_codex":0.0056184647,"about_ca_system_score_gemma":0.0088459505,"threshold_uncertainty_score":0.12364942},"labels":[],"label_agreement":null},{"id":"W2909480139","doi":"10.1007/s10637-019-00726-2","title":"Inhibition of AKT signalling by benzoxazine derivative LTUR6 through the modulation of downstream kinases","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Protein kinase B; Doxorubicin; Phosphorylation; Kinase; PI3K/AKT/mTOR pathway; Cell biology; p38 mitogen-activated protein kinases; Chemistry; Cancer research; Cytotoxicity; Sensitization; Signal transduction; Biology; Protein kinase A; Biochemistry; In vitro; Immunology; Chemotherapy","score_opus":0.011290109986856025,"score_gpt":0.24124372220894996,"score_spread":0.22995361222209393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909480139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312736,0.007950257,0.0024827083,0.00053144206,0.00011293601,0.00006079556,0.00052724354,0.00014813762,0.005059096],"genre_scores_gemma":[0.9918298,0.0040030223,0.0008782972,0.00008249891,0.000017865408,0.000028826915,0.0002663016,0.0000061952587,0.002887212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999404,0.000009455012,0.0000045467996,0.000007650415,0.000013733774,0.000024233519],"domain_scores_gemma":[0.9999821,0.0000020206433,0.0000065028835,0.0000019128402,0.000002480255,0.0000048841284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009392208,0.00020919103,0.00018206134,0.000121645426,0.00013926628,0.00018674532,0.00021173732,0.00019159747,0.0017474222],"category_scores_gemma":[0.00006170454,0.000068279536,0.00019030205,0.0001364189,0.0001579725,0.00016785525,0.00012090209,0.0006034284,0.00032276774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010474467,0.00013576496,0.00025243263,0.00015609858,0.00001826972,0.00016610001,0.00001914351,0.00026598174,0.98759925,0.0008738469,0.00034386836,0.009121781],"study_design_scores_gemma":[0.00016039649,0.0010603637,0.0035579375,0.000009901197,0.000023643213,0.00025931463,0.000020737229,0.001017119,0.98758173,0.000121093835,0.0061780917,0.000009745378],"about_ca_topic_score_codex":0.00045493303,"about_ca_topic_score_gemma":0.00094143476,"teacher_disagreement_score":0.0017474222,"about_ca_system_score_codex":0.00023686822,"about_ca_system_score_gemma":0.00021950922,"threshold_uncertainty_score":0.0058457255},"labels":[],"label_agreement":null},{"id":"W2936108326","doi":"10.1007/s10637-019-00768-6","title":"A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Antibody-drug conjugate; Internal medicine; Adverse effect; Nausea; Mesothelioma; Oncology; Germ cell tumors; Phases of clinical research; Gastroenterology; Toxicity; Chemotherapy; Antibody; Immunology; Lymphoma; Pathology; Monoclonal antibody","score_opus":0.027656533319971862,"score_gpt":0.3151312772962788,"score_spread":0.28747474397630696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936108326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950912,0.001484188,0.0004900668,0.0001782922,0.000060232956,0.0015681494,0.0005257985,0.00003655781,0.00056548725],"genre_scores_gemma":[0.9941835,0.0009123769,0.0011223782,0.0003504615,0.00014992246,0.0015720591,0.0010424412,0.000010407188,0.0006564317],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99963486,0.00021532085,0.000016890695,0.0000514349,0.000036736055,0.00004474383],"domain_scores_gemma":[0.9994037,0.00015560855,0.00011523421,0.000034147473,0.00004020506,0.0002511209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010668703,0.00085260934,0.0013435795,0.00026535903,0.0003135737,0.0005047955,0.00039901465,0.0007035338,0.0020383855],"category_scores_gemma":[0.00084001763,0.00032813504,0.0006537641,0.00027716075,0.0005869343,0.0005627448,0.00020074808,0.0014406864,0.00039587604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6977041,0.076708496,0.024696544,0.0012957369,0.0009894471,0.00092649704,0.0005020427,0.0030112695,0.072907835,0.0003953037,0.003565427,0.1172973],"study_design_scores_gemma":[0.48876953,0.47786236,0.023973048,0.000035722802,0.0002575683,0.00060434337,0.00007254437,0.0019526527,0.003850619,0.00025329072,0.0023427696,0.000025520781],"about_ca_topic_score_codex":0.00047164777,"about_ca_topic_score_gemma":0.0011272142,"teacher_disagreement_score":0.0020383855,"about_ca_system_score_codex":0.0005120712,"about_ca_system_score_gemma":0.0010059093,"threshold_uncertainty_score":0.0068190694},"labels":[],"label_agreement":null},{"id":"W2954170284","doi":"10.1007/s10637-019-00816-1","title":"Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Lethbridge; University of Calgary","funders":"","keywords":"Neuroblastoma; In vivo; Medicine; Cancer research; Pharmacology; Cytotoxicity; MAPK/ERK pathway; Apoptosis; In vitro; Kinase; Biology; Cell culture","score_opus":0.015092318103487405,"score_gpt":0.2386592850916971,"score_spread":0.2235669669882097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954170284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993134,0.0063179564,0.0009199171,0.000072174895,0.000040730778,0.000018354931,0.00013004719,0.000041208346,0.0025283515],"genre_scores_gemma":[0.9950906,0.0024760207,0.0013486814,0.000031967596,0.000014070673,0.000010292499,0.00009855084,0.0000072269268,0.00092251116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999428,0.000010222873,0.000004203869,0.000010626101,0.000011720335,0.00002055034],"domain_scores_gemma":[0.9999522,0.00000780002,0.000014113146,0.000004226372,0.000006387994,0.000015226137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086292195,0.00016129213,0.00019653575,0.00014840087,0.000095871845,0.00015893782,0.00019854867,0.00021025425,0.0010136212],"category_scores_gemma":[0.00008974042,0.000070125825,0.00010746909,0.0001055695,0.00014769024,0.0001708886,0.00015212657,0.0003116769,0.0001648869],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003475603,0.00004322942,0.00017093132,0.000106636486,0.000004958743,0.00015967978,0.000021310665,0.00009672875,0.9913469,0.0002062018,0.00009216921,0.007403681],"study_design_scores_gemma":[0.000039154045,0.0017467819,0.0017141496,0.000013132223,0.00002677571,0.00066155597,0.000022279515,0.0003327147,0.99092126,0.000027196173,0.004488963,0.0000060515094],"about_ca_topic_score_codex":0.00036764686,"about_ca_topic_score_gemma":0.00064163527,"teacher_disagreement_score":0.0010136212,"about_ca_system_score_codex":0.00013351013,"about_ca_system_score_gemma":0.00018233914,"threshold_uncertainty_score":0.0033908486},"labels":[],"label_agreement":null},{"id":"W2966036111","doi":"10.1007/s10637-019-00837-w","title":"Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","keywords":"Ibrutinib; Cancer research; Kinome; Downregulation and upregulation; XIAP; Tyrosine kinase; Bruton's tyrosine kinase; Apoptosis; Kinase; Signal transduction; Caspase; Pharmacology; Medicine; Biology; Programmed cell death; Cell biology; Immunology; Leukemia; Chronic lymphocytic leukemia; Biochemistry","score_opus":0.011200263854343957,"score_gpt":0.2952975540714463,"score_spread":0.28409729021710234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966036111","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2979605,0.65170646,0.0019684096,0.012497443,0.00085424393,0.000112906375,0.00047114483,0.00016365125,0.034265257],"genre_scores_gemma":[0.8242067,0.16134754,0.0018633491,0.0019492529,0.0007160909,0.000070136,0.0004775098,0.000045123525,0.009324302],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987125,0.000031900978,0.000009249919,0.000013549966,0.000031681233,0.00004227959],"domain_scores_gemma":[0.9999361,0.000015722793,0.000018786375,0.000005345586,0.0000081322705,0.0000158671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039965176,0.00039858432,0.00047475653,0.00042932876,0.0002841509,0.0011912567,0.00041323557,0.0004906429,0.00413962],"category_scores_gemma":[0.00023019747,0.00011976257,0.00046410464,0.00044149315,0.0004439246,0.0006926202,0.00037871805,0.0012067471,0.00056343415],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013686219,0.0009915797,0.00523188,0.0018409854,0.0003852151,0.0032434696,0.00018812796,0.0026570046,0.24437895,0.012731244,0.012034971,0.7026304],"study_design_scores_gemma":[0.006095888,0.016532766,0.057002697,0.001095985,0.0016857719,0.02080287,0.0008753555,0.0075164055,0.15327132,0.017643966,0.7172568,0.00022003696],"about_ca_topic_score_codex":0.0007687697,"about_ca_topic_score_gemma":0.002724809,"teacher_disagreement_score":0.00413962,"about_ca_system_score_codex":0.00077589357,"about_ca_system_score_gemma":0.00056115934,"threshold_uncertainty_score":0.013848424},"labels":[],"label_agreement":null},{"id":"W2972912130","doi":"10.1007/s10637-019-00814-3","title":"A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Toronto; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; KRAS; Panitumumab; Mucositis; Internal medicine; Colorectal cancer; Gastroenterology; Rash; Cancer; Oncology; Toxicity","score_opus":0.010342299013200922,"score_gpt":0.27251207476366757,"score_spread":0.2621697757504666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972912130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874614,0.004983548,0.0005607007,0.0008818424,0.00034037454,0.0017885397,0.00085532083,0.000117627824,0.0030106446],"genre_scores_gemma":[0.9891201,0.0036916097,0.0012800987,0.0007678318,0.00017955045,0.0012570556,0.0013808489,0.000034649758,0.002288216],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99956053,0.00017910494,0.000025373138,0.00007251782,0.000035401128,0.0001270925],"domain_scores_gemma":[0.9995372,0.0000690123,0.00006407056,0.00004155262,0.000030287974,0.00025781387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012762977,0.0014709977,0.0026582466,0.0007061132,0.0005813434,0.0015016991,0.0008857269,0.0013461604,0.0040748026],"category_scores_gemma":[0.0008038652,0.00088541297,0.0022471296,0.000722429,0.00100572,0.001336469,0.00040661398,0.0043960144,0.0010145352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7662791,0.06388333,0.0045970404,0.0013356861,0.0025327357,0.00032342627,0.00034006278,0.0027175124,0.036225777,0.00040484188,0.00339907,0.11796141],"study_design_scores_gemma":[0.57164633,0.41115674,0.007988001,0.00005250996,0.0010126499,0.0002813666,0.00011460133,0.0012168057,0.0030703146,0.00016873909,0.0032491828,0.00004284937],"about_ca_topic_score_codex":0.0018611274,"about_ca_topic_score_gemma":0.005499076,"teacher_disagreement_score":0.0040748026,"about_ca_system_score_codex":0.0012654472,"about_ca_system_score_gemma":0.0018008789,"threshold_uncertainty_score":0.013631582},"labels":[],"label_agreement":null},{"id":"W2984708337","doi":"10.1007/s10637-019-00875-4","title":"A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Terry Fox Research Institute; Canadian Cancer Society","keywords":"Glioblastoma; mTORC1; Cancer research; Medicine; Dual (grammatical number); Oncology; Internal medicine; Biology; Signal transduction; Philosophy; PI3K/AKT/mTOR pathway; Genetics","score_opus":0.010164630321915433,"score_gpt":0.26229846738537765,"score_spread":0.2521338370634622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984708337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894637,0.004335581,0.00043189642,0.00083040714,0.00021821419,0.0013106643,0.001441607,0.000086739194,0.001881211],"genre_scores_gemma":[0.9872913,0.003955161,0.00092540804,0.001525868,0.00020207805,0.0010484647,0.0032957727,0.000050983042,0.0017049524],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964345,0.00012231542,0.000016464983,0.000069962465,0.000038071972,0.0001098042],"domain_scores_gemma":[0.9994771,0.0000669345,0.000078632605,0.000039884802,0.00003877198,0.0002987463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010718273,0.0014855235,0.0026310883,0.00043121076,0.00052356825,0.0011105553,0.00082884525,0.0015133467,0.0021479996],"category_scores_gemma":[0.0007881859,0.00067135267,0.0020443655,0.00069555186,0.0008779391,0.00080260925,0.00030159124,0.0035522627,0.0006903266],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6938848,0.052243017,0.023382708,0.0015990806,0.005673653,0.0013479505,0.0005143407,0.0033696545,0.062353484,0.00051472394,0.01289785,0.14221874],"study_design_scores_gemma":[0.6285942,0.3153689,0.040561784,0.00007402461,0.0024157022,0.00095085247,0.00013537615,0.0015080892,0.0031706481,0.000305083,0.0068310467,0.000084306725],"about_ca_topic_score_codex":0.004914296,"about_ca_topic_score_gemma":0.015841413,"teacher_disagreement_score":0.004914296,"about_ca_system_score_codex":0.0016213948,"about_ca_system_score_gemma":0.0021002016,"threshold_uncertainty_score":0.011764109},"labels":[],"label_agreement":null},{"id":"W2986650118","doi":"10.1007/s10637-019-00869-2","title":"A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"F. Hoffmann-La Roche","keywords":"Pharmacokinetics; Medicine; Prodrug; Pharmacology; Nausea; Pharmacodynamics; Dosing; Cmax; Neutropenia; Internal medicine; Gastroenterology; Toxicity","score_opus":0.007137229277251686,"score_gpt":0.25166890298989547,"score_spread":0.24453167371264378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986650118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929162,0.0018398613,0.0006157996,0.0005729388,0.00013055705,0.0011514897,0.0008572423,0.00006238566,0.0018534933],"genre_scores_gemma":[0.9908275,0.0019647635,0.0014304842,0.0007230133,0.00009187351,0.00091399194,0.001713972,0.00003034791,0.0023041063],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99985087,0.000057046538,0.000006174443,0.000030066976,0.000013428637,0.000042315995],"domain_scores_gemma":[0.99978,0.000041007253,0.000028346874,0.000021289383,0.000013214921,0.000116133764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052613846,0.00086594804,0.0014493881,0.00027288107,0.00031332712,0.00065219373,0.00044882743,0.0008700532,0.0021945857],"category_scores_gemma":[0.0004492086,0.00036429823,0.00080634595,0.00025287943,0.00046071655,0.00049658236,0.00020891178,0.0023205467,0.00057851063],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.507701,0.08647963,0.010233872,0.0011786676,0.0018149635,0.0012256555,0.00063709903,0.0070668147,0.18907157,0.0010481238,0.008729769,0.18481292],"study_design_scores_gemma":[0.38171718,0.57409465,0.016051674,0.000046877594,0.0007057501,0.001022579,0.00014112203,0.0031810773,0.013165432,0.0004487022,0.009371188,0.00005381687],"about_ca_topic_score_codex":0.00094734685,"about_ca_topic_score_gemma":0.0022692399,"teacher_disagreement_score":0.0021945857,"about_ca_system_score_codex":0.00057359197,"about_ca_system_score_gemma":0.00085933896,"threshold_uncertainty_score":0.0073416233},"labels":[],"label_agreement":null},{"id":"W2997760522","doi":"10.1007/s10637-020-00892-8","title":"Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Clinical trial; Transcriptome; Medicine; Genome; Precision medicine; Oncology; Bioinformatics; Selection (genetic algorithm); Internal medicine; Gene; Computational biology; Gene expression; Biology; Pathology; Genetics; Computer science","score_opus":0.02847075282832528,"score_gpt":0.2639221654190349,"score_spread":0.23545141259070962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997760522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8756674,0.0032343166,0.056539483,0.008390595,0.0005500832,0.005501186,0.008805721,0.0009472352,0.040363945],"genre_scores_gemma":[0.89406043,0.0024296439,0.070347056,0.0068834885,0.0005061372,0.0037212016,0.010605307,0.00048654873,0.010960238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99953175,0.00011367535,0.00005519074,0.00008928881,0.0001246408,0.00008555367],"domain_scores_gemma":[0.99906975,0.0002716848,0.000098370794,0.000074939686,0.00021902371,0.00026624303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011142826,0.00038750403,0.00061196374,0.001048302,0.0006186465,0.00096792245,0.00032052555,0.0005826551,0.007820593],"category_scores_gemma":[0.002204683,0.0001367171,0.0006413002,0.0006483893,0.00017439261,0.0002773545,0.0005168521,0.00068097375,0.002110745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068232617,0.0020776982,0.43522716,0.00047445664,0.00021971557,0.016513031,0.0006016593,0.002712345,0.110978134,0.0031835516,0.046016775,0.37517217],"study_design_scores_gemma":[0.0011249812,0.008383555,0.6118807,0.0005743645,0.0012017741,0.035778828,0.001715447,0.017784264,0.11185461,0.0065004444,0.20298707,0.00021395096],"about_ca_topic_score_codex":0.0011145805,"about_ca_topic_score_gemma":0.0014023809,"teacher_disagreement_score":0.007820593,"about_ca_system_score_codex":0.0005158797,"about_ca_system_score_gemma":0.0015760575,"threshold_uncertainty_score":0.026162505},"labels":[],"label_agreement":null},{"id":"W3004651543","doi":"10.1007/s10637-020-00903-8","title":"Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Nausea and vomiting management","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Nausea; Medicine; Mirtazapine; Vomiting; Regimen; Aprepitant; Internal medicine; Chemotherapy; Chemotherapy regimen; Anesthesia; Chemotherapy-induced nausea and vomiting; Adverse effect; Clinical endpoint; Randomized controlled trial; Antiemetic; Antidepressant","score_opus":0.0477603290722459,"score_gpt":0.34115165526372804,"score_spread":0.2933913261914821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004651543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906888,0.004627555,0.00060175447,0.0004391178,0.00029066103,0.0015991786,0.00042864613,0.00007750964,0.001246737],"genre_scores_gemma":[0.98700756,0.005328755,0.002046234,0.00076439243,0.0003497894,0.0018228017,0.0007751019,0.00002725754,0.0018779304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99960965,0.00020850803,0.000023910134,0.00006241654,0.000031421274,0.00006400533],"domain_scores_gemma":[0.9992084,0.0002346916,0.00016649795,0.0000585506,0.000038853123,0.00029303704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011642178,0.0013626965,0.0026539315,0.0003628854,0.00038921184,0.0008266467,0.00096115615,0.0011791846,0.0033069442],"category_scores_gemma":[0.0014020223,0.00047608526,0.0013757338,0.0004673198,0.0009896915,0.0007938149,0.00030682408,0.0028738026,0.0004537479],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95009893,0.012966114,0.00075482094,0.00070995645,0.0012182523,0.00006945465,0.000067678884,0.0003615281,0.0057714595,0.00014408134,0.0007833245,0.027054466],"study_design_scores_gemma":[0.89171016,0.103913784,0.0020937487,0.0000318378,0.0004840765,0.0000735767,0.000022360266,0.00044467024,0.0006000064,0.000096841664,0.0005128932,0.00001607674],"about_ca_topic_score_codex":0.0011503876,"about_ca_topic_score_gemma":0.0032118307,"teacher_disagreement_score":0.0033069442,"about_ca_system_score_codex":0.0007347489,"about_ca_system_score_gemma":0.0011887572,"threshold_uncertainty_score":0.0110628605},"labels":[],"label_agreement":null},{"id":"W3004815730","doi":"10.1007/s10637-020-00907-4","title":"Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Nausea; Pharmacology; Internal medicine; Myeloid leukemia; Gastroenterology; Adverse effect; Leukemia; Prodrug; Vomiting","score_opus":0.021709417867157913,"score_gpt":0.28512605040206335,"score_spread":0.26341663253490544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3004815730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943316,0.0018929131,0.000506781,0.0002680765,0.000041131065,0.0012592137,0.0005581528,0.00007262449,0.0010695509],"genre_scores_gemma":[0.9920859,0.0018214536,0.0014832432,0.00043697088,0.00007923533,0.0011239146,0.0011748469,0.000023161414,0.0017712484],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997266,0.00013111874,0.000011941395,0.000048589736,0.000032851694,0.000048885533],"domain_scores_gemma":[0.9997775,0.000037126523,0.000055948763,0.00001576937,0.0000190481,0.00009468563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006237547,0.0011864512,0.0016724166,0.00030876993,0.00025773328,0.00046694707,0.00048760697,0.00066308124,0.002053081],"category_scores_gemma":[0.0004964465,0.0003931642,0.0005024016,0.00025855162,0.00036591938,0.0004225242,0.00023947466,0.0015675626,0.0006717588],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28665307,0.07523151,0.01712654,0.0014132215,0.0010659125,0.0015746045,0.000659819,0.0073612165,0.31082532,0.0007451256,0.008314591,0.28902912],"study_design_scores_gemma":[0.19316712,0.75051653,0.024698146,0.000053153537,0.0003734186,0.0015080391,0.00009223219,0.0024300714,0.018605657,0.00028731188,0.008221801,0.00004645628],"about_ca_topic_score_codex":0.0004817011,"about_ca_topic_score_gemma":0.0013725576,"teacher_disagreement_score":0.002053081,"about_ca_system_score_codex":0.00048023977,"about_ca_system_score_gemma":0.0007179152,"threshold_uncertainty_score":0.006868243},"labels":[],"label_agreement":null},{"id":"W3005499534","doi":"10.1007/s10637-020-00904-7","title":"A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Juravinski Cancer Centre; Queen's University","funders":"Canadian Cancer Society Research Institute","keywords":"Tremelimumab; Durvalumab; Tolerability; Medicine; Adverse effect; Internal medicine; Cohort; Oncology; Cancer; Nivolumab; Immunotherapy; Ipilimumab","score_opus":0.05438185365786288,"score_gpt":0.32869030911327457,"score_spread":0.2743084554554117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005499534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97391814,0.0060574454,0.00044830315,0.0025428457,0.0005519142,0.004228363,0.0045855483,0.00013459563,0.00753282],"genre_scores_gemma":[0.97454005,0.0050448454,0.002658258,0.0024183562,0.0003377996,0.0023376502,0.0056798947,0.00004567977,0.0069373148],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99943954,0.00018167162,0.000018232256,0.00009069675,0.00007582059,0.00019402392],"domain_scores_gemma":[0.9990939,0.0000919601,0.000093561874,0.000042509007,0.0000611842,0.00061681325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017992664,0.0019219264,0.0024212156,0.00050659775,0.0009865974,0.0011879978,0.001298512,0.0011822731,0.004592601],"category_scores_gemma":[0.0011658003,0.0006166171,0.0016740127,0.0009276939,0.0014601466,0.0006673167,0.00038329544,0.0037741421,0.00079836167],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87022555,0.027520794,0.005107794,0.000752918,0.0021679087,0.00016438366,0.0002355244,0.0022040452,0.0096794395,0.0004887098,0.011664754,0.069788046],"study_design_scores_gemma":[0.8421107,0.12807058,0.018817533,0.000045897894,0.0010930053,0.00016993897,0.00010156881,0.001072112,0.0009810488,0.00029114066,0.0071960115,0.000050448223],"about_ca_topic_score_codex":0.13529426,"about_ca_topic_score_gemma":0.38347155,"teacher_disagreement_score":0.86470574,"about_ca_system_score_codex":0.008282213,"about_ca_system_score_gemma":0.013235999,"threshold_uncertainty_score":0.26901352},"labels":[],"label_agreement":null},{"id":"W3006072911","doi":"10.1007/s10637-020-00909-2","title":"Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"University of Saskatchewan","keywords":"Apoptosis; Sphingosine; Cell culture; Triple-negative breast cancer; Cytotoxicity; Paclitaxel; Sphingolipid; Sphingosine-1-phosphate; Cancer research; Cell growth; Biology; Cell; Breast cancer; Docetaxel; Doxorubicin; Cancer; Chemotherapy; Internal medicine; Medicine; Cell biology; In vitro; Receptor; Biochemistry","score_opus":0.03565899534497211,"score_gpt":0.30247943567622537,"score_spread":0.26682044033125324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006072911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562824,0.0015710125,0.00080954254,0.000044956487,0.000021646194,0.00003212387,0.00015854578,0.0000210563,0.0017129568],"genre_scores_gemma":[0.994972,0.0015070054,0.0011298602,0.000021903828,0.00000866654,0.00003172542,0.0003104974,0.000005330697,0.0020129725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999293,0.000015750029,0.0000065347676,0.000009854368,0.00001970089,0.000018852654],"domain_scores_gemma":[0.99995303,0.000017541075,0.000004437211,0.0000056852627,0.000009669012,0.000009660642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018384749,0.00019142237,0.00020460716,0.00020594732,0.00013423314,0.00015899815,0.00010775817,0.00019411708,0.0010498506],"category_scores_gemma":[0.000093157396,0.00007587343,0.00014518695,0.00021462543,0.00010507187,0.00013407042,0.00007876266,0.00027550047,0.00017359694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003460229,0.00008268178,0.000326169,0.00003983466,0.000006580061,0.00004967722,0.000025001724,0.00012536296,0.99596417,0.000074313575,0.000035908906,0.0029243308],"study_design_scores_gemma":[0.000025420753,0.0010821872,0.0019444142,0.0000021229616,0.000022072794,0.00014490783,0.000019160358,0.0006508603,0.9951975,0.000017661941,0.00089196145,0.0000017706708],"about_ca_topic_score_codex":0.0008168587,"about_ca_topic_score_gemma":0.00073785917,"teacher_disagreement_score":0.0010498506,"about_ca_system_score_codex":0.00011499213,"about_ca_system_score_gemma":0.0001906744,"threshold_uncertainty_score":0.0035120845},"labels":[],"label_agreement":null},{"id":"W3024082028","doi":"10.1007/s10637-020-00928-z","title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Cetuximab; Medicine; KRAS; Colorectal cancer; Pharmacodynamics; Internal medicine; Adverse effect; Oncology; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; EGFR inhibitors; Epidermal growth factor receptor; Toxicity; Phases of clinical research; Cancer; Monoclonal antibody; Pharmacology; Antibody; Immunology","score_opus":0.01769703272519022,"score_gpt":0.29630376845401685,"score_spread":0.2786067357288266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024082028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99282384,0.0022238025,0.00023840551,0.00062699575,0.00024819135,0.0013505917,0.000811844,0.000044678938,0.0016316309],"genre_scores_gemma":[0.9906529,0.0019553225,0.0008733759,0.0009171678,0.0002303352,0.0011805561,0.0018485736,0.00002242126,0.0023194212],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99951494,0.00021570563,0.000021873828,0.000085365034,0.000038997252,0.00012316584],"domain_scores_gemma":[0.9992231,0.00013771652,0.00009408618,0.000050770308,0.00005970788,0.00043460555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015331176,0.001474661,0.002887746,0.00052259304,0.00060508674,0.0012132192,0.00083882944,0.0017620232,0.003992265],"category_scores_gemma":[0.001274384,0.00086219073,0.0022691912,0.0005226745,0.0008277635,0.001100537,0.00038071023,0.0044078757,0.0007556493],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8793407,0.04956114,0.0049523087,0.00069777865,0.0019111288,0.00023551029,0.00020070646,0.0018171441,0.015000472,0.00018642981,0.0029008212,0.043195847],"study_design_scores_gemma":[0.6699393,0.31203282,0.012583501,0.000030692063,0.0007083857,0.00017447422,0.00006564315,0.0009995687,0.0013844133,0.00009460494,0.001953511,0.000033115975],"about_ca_topic_score_codex":0.0024994344,"about_ca_topic_score_gemma":0.007892653,"teacher_disagreement_score":0.003992265,"about_ca_system_score_codex":0.0013239994,"about_ca_system_score_gemma":0.0018156827,"threshold_uncertainty_score":0.013355434},"labels":[],"label_agreement":null},{"id":"W3041329672","doi":"10.1007/s10637-020-00958-7","title":"Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Moiety; EGFR inhibitors; Quinazoline; Gefitinib; Chemistry; Transfection; Small molecule; Potency; Mechanism of action; Epidermal growth factor receptor; Penetration (warfare); Biophysics; Biochemistry; Phosphorylation; In vitro; Receptor; Biology; Stereochemistry","score_opus":0.0797261951099458,"score_gpt":0.30861932225513944,"score_spread":0.22889312714519364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041329672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546233,0.01246914,0.015496961,0.0010477422,0.0001079792,0.000060753475,0.0015700853,0.0005331213,0.014090989],"genre_scores_gemma":[0.9924845,0.0020205274,0.0024134822,0.000080496255,0.000010309988,0.000012371124,0.0004254702,0.00002386041,0.0025290723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999299,0.000010533072,0.0000031785032,0.00001774146,0.000016513017,0.00002204352],"domain_scores_gemma":[0.9999716,0.000006208167,0.0000073214087,0.0000036513684,0.000005406191,0.0000058896476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014351336,0.000208578,0.00021045702,0.000197242,0.0001853314,0.00040744356,0.00039805312,0.00031631324,0.001079304],"category_scores_gemma":[0.000077093304,0.00012845034,0.00024688215,0.00012868215,0.00025476582,0.00037460917,0.000101444704,0.0005316528,0.0004925442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006778726,0.00009231027,0.00017818538,0.00008131907,0.000011569554,0.000098997356,0.000023900608,0.000500155,0.9886501,0.002009526,0.00052844075,0.0071477313],"study_design_scores_gemma":[0.00006614993,0.00033793796,0.0016379114,0.0000036409049,0.000018656932,0.00038327053,0.000026374451,0.003008615,0.989739,0.00024036356,0.004530311,0.000007759008],"about_ca_topic_score_codex":0.0016659676,"about_ca_topic_score_gemma":0.0011803213,"teacher_disagreement_score":0.0016659676,"about_ca_system_score_codex":0.00059958873,"about_ca_system_score_gemma":0.00033707023,"threshold_uncertainty_score":0.004350364},"labels":[],"label_agreement":null},{"id":"W3043204261","doi":"10.1007/s10637-020-00971-w","title":"The proportion of North American cancer trials that evaluate novel targets","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Clinical trial; Cancer; Psychological intervention; Internal medicine; Cancer drugs","score_opus":0.05938365011528055,"score_gpt":0.310282317101327,"score_spread":0.2508986669860464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043204261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39239714,0.3619587,0.012429752,0.079996206,0.0053939605,0.0011146007,0.015530306,0.0006053804,0.13057393],"genre_scores_gemma":[0.877588,0.05949092,0.003708128,0.04089586,0.002788359,0.0010515924,0.0058277263,0.00014786962,0.008501672],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.978403,0.015776351,0.0011142405,0.001574423,0.0025488695,0.0005831989],"domain_scores_gemma":[0.9496601,0.033164106,0.008520422,0.0023577812,0.004137121,0.0021605114],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.020421112,0.000357588,0.0013461944,0.0011185218,0.00044248183,0.0020700956,0.00046056596,0.0012925798,0.0062668724],"category_scores_gemma":[0.044679508,0.00035359463,0.0013361196,0.0022106112,0.00109526,0.0013407742,0.0009896255,0.001476959,0.0012422014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017461447,0.00044370655,0.33690825,0.0030214358,0.0040965746,0.00028591458,0.00022087236,0.0024042246,0.004419257,0.008078421,0.10743635,0.5152236],"study_design_scores_gemma":[0.0062739397,0.005407744,0.5847147,0.001946928,0.0061020106,0.003997798,0.000897773,0.0033288135,0.0042743073,0.008597208,0.37436354,0.00009512493],"about_ca_topic_score_codex":0.0022340755,"about_ca_topic_score_gemma":0.0043076426,"teacher_disagreement_score":0.9986538,"about_ca_system_score_codex":0.0015941277,"about_ca_system_score_gemma":0.0021297976,"threshold_uncertainty_score":0.10799849},"labels":[],"label_agreement":null},{"id":"W3045633251","doi":"10.1007/s10637-019-00757-9","title":"Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor","year":2019,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Sunitinib; Medicine; Neuroendocrine tumors; Pancreatic neuroendocrine tumor; Internal medicine; Oncology; General surgery; Cancer","score_opus":0.02647094043585678,"score_gpt":0.3214914689410952,"score_spread":0.2950205285052384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045633251","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019985149,0.0009920218,0.00036854282,0.059645437,0.936012,0.000030506035,0.0009414146,0.00016227804,0.0016479112],"genre_scores_gemma":[0.018629098,0.010249122,0.0046921214,0.19641742,0.5792384,0.00028004753,0.003353535,0.0012265107,0.18591377],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99718153,0.00048305484,0.0005633615,0.0003699733,0.0011020578,0.00030004917],"domain_scores_gemma":[0.9832876,0.004315069,0.0011556058,0.0007113047,0.008959934,0.0015704955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037649828,0.001677443,0.0017567145,0.0024433567,0.0020029433,0.002376391,0.0026105298,0.0057415185,0.031062005],"category_scores_gemma":[0.03991273,0.00087846915,0.0017942794,0.0014374076,0.0014085029,0.0013472827,0.0010079618,0.010011132,0.014280168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000669589,0.000009092912,0.000088021196,0.00011421333,0.000020478827,0.00033399093,0.000015878233,0.00004314271,0.000039856444,0.0002459432,0.99446094,0.0045615523],"study_design_scores_gemma":[0.00024172767,0.000071201575,0.0016453423,0.00055131223,0.0001312243,0.0012947248,0.00006533893,0.00039153537,0.00040635225,0.0011073228,0.9940402,0.000053770742],"about_ca_topic_score_codex":0.017855084,"about_ca_topic_score_gemma":0.02426831,"teacher_disagreement_score":0.031062005,"about_ca_system_score_codex":0.004242852,"about_ca_system_score_gemma":0.005553803,"threshold_uncertainty_score":0.10391277},"labels":[],"label_agreement":null},{"id":"W3045754390","doi":"10.1007/s10637-020-00906-5","title":"Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Natural Science Foundation of China","keywords":"Biology; Colorectal cancer; Flow cytometry; Cancer; Microbiology; Apoptosis; Malignancy; Bacteria; Cancer cell; Bacillus (shape); Ovarian cancer; Cancer research; Gut flora; Immunology; Genetics","score_opus":0.028827298862139788,"score_gpt":0.28444923808792727,"score_spread":0.25562193922578746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045754390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97867364,0.010437616,0.0040089,0.0005028868,0.000203954,0.000081438135,0.0009290107,0.000131833,0.005030676],"genre_scores_gemma":[0.98020405,0.007999066,0.0057822163,0.00018422675,0.00009484809,0.000050508952,0.0018022906,0.00005079647,0.0038320103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988997,0.000020287816,0.000010483228,0.000016454445,0.0000374642,0.000025390627],"domain_scores_gemma":[0.9998827,0.000024298952,0.000022966678,0.00001576793,0.000019782621,0.000034421413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015276425,0.0003020525,0.0003521196,0.00028717643,0.000102894985,0.0002455443,0.00010871866,0.00022519937,0.0014434245],"category_scores_gemma":[0.00025782397,0.00010631841,0.00025046314,0.00025160745,0.00020277107,0.00011650511,0.00022527581,0.0007057791,0.0003844328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005402958,0.00010571992,0.0009193616,0.0001574659,0.000015259388,0.00015069959,0.00003119554,0.000112600974,0.98335856,0.00021658315,0.00023439918,0.01415793],"study_design_scores_gemma":[0.00012839928,0.0029133996,0.010390855,0.000043415028,0.00007932465,0.002015861,0.000102226404,0.00043857077,0.97145015,0.00017231527,0.012252736,0.000012710257],"about_ca_topic_score_codex":0.00030165334,"about_ca_topic_score_gemma":0.0005945145,"teacher_disagreement_score":0.0014434245,"about_ca_system_score_codex":0.000106589236,"about_ca_system_score_gemma":0.00020211826,"threshold_uncertainty_score":0.0048286915},"labels":[],"label_agreement":null},{"id":"W3118976699","doi":"10.1007/s10637-020-01043-9","title":"The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Cancer Institute; Fondation du cancer des Cèdres; Frank McGraw Memorial Chair in Cancer Research","keywords":"Pembrolizumab; Ovary; Medicine; Clinical trial; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.029754829291786605,"score_gpt":0.29047536963805537,"score_spread":0.2607205403462688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118976699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941765,0.0039705494,0.0002883309,0.00019004439,0.0000153988,0.00009825057,0.000096718395,0.0000059958957,0.0011580965],"genre_scores_gemma":[0.99780756,0.0012928717,0.00023580727,0.00019973291,0.000045741715,0.0000326134,0.0002536353,0.0000048755296,0.0001270802],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99960214,0.00011581396,0.000057027235,0.000066535285,0.00007414715,0.00008430442],"domain_scores_gemma":[0.99934715,0.00029357092,0.0001562132,0.000058132064,0.000039025563,0.000105835716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008629074,0.00026734287,0.00093199994,0.00029933054,0.00040630906,0.0007529222,0.00028579356,0.00067275116,0.00059364876],"category_scores_gemma":[0.0017718838,0.00014206034,0.0006968832,0.0004131542,0.00044843825,0.00052222086,0.00020527626,0.00072538893,0.0001708547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032763824,0.0036949508,0.5708609,0.00089532835,0.0012633489,0.084066,0.0010046298,0.001575774,0.04845348,0.0007181313,0.003053975,0.25164962],"study_design_scores_gemma":[0.011457298,0.054022707,0.5550909,0.00033385202,0.0027591381,0.3386751,0.0008692924,0.005939198,0.014619333,0.00090133,0.015221094,0.000110815956],"about_ca_topic_score_codex":0.00032354041,"about_ca_topic_score_gemma":0.00055023964,"teacher_disagreement_score":0.00093199994,"about_ca_system_score_codex":0.00047147245,"about_ca_system_score_gemma":0.00035377606,"threshold_uncertainty_score":0.00456357},"labels":[],"label_agreement":null},{"id":"W3121695703","doi":"10.1007/s10637-020-01049-3","title":"Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Paraza Pharma (Canada); McGill University Health Centre","funders":"","keywords":"Mucositis; Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Adverse effect; Nausea; Internal medicine; Diarrhea; Gastroenterology; Phases of clinical research; Pharmacokinetics; Vomiting; Toxicity; Oncology; Surgery","score_opus":0.009158176539371862,"score_gpt":0.2681257152139644,"score_spread":0.25896753867459255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121695703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845633,0.007983218,0.000913278,0.0007307011,0.00010519753,0.00088821177,0.00168456,0.00021232455,0.0029192667],"genre_scores_gemma":[0.9858686,0.005652179,0.0011743449,0.0007038085,0.000113343835,0.00071452855,0.0021816322,0.00006199055,0.0035296618],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998047,0.00008799286,0.000009853835,0.00003161206,0.00001693055,0.000048957005],"domain_scores_gemma":[0.9996371,0.000076642915,0.00008375714,0.000028024482,0.00002231549,0.00015218591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084458326,0.0010353783,0.0017948938,0.0004157624,0.00035590096,0.000880602,0.0006401727,0.00085562957,0.0032972815],"category_scores_gemma":[0.0005696358,0.0003940999,0.0009725981,0.0004200413,0.00052186084,0.0006576493,0.00024104449,0.0022498919,0.0007240936],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5456995,0.028776783,0.009939872,0.0021432964,0.0026272424,0.00056556636,0.0003915099,0.0045263283,0.13854119,0.00086031656,0.009345338,0.2565831],"study_design_scores_gemma":[0.51158506,0.4248336,0.030728357,0.00012767754,0.0013935482,0.0010025732,0.00017209048,0.003096542,0.015029791,0.00052448333,0.011431688,0.000074646654],"about_ca_topic_score_codex":0.00092496356,"about_ca_topic_score_gemma":0.0033968159,"teacher_disagreement_score":0.0032972815,"about_ca_system_score_codex":0.00062632194,"about_ca_system_score_gemma":0.0012258926,"threshold_uncertainty_score":0.011030436},"labels":[],"label_agreement":null},{"id":"W3176158528","doi":"10.1007/s10637-021-01141-2","title":"Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Nausea; Vomiting; Pharmacokinetics; Medicine; Dosing; Pharmacodynamics; Adverse effect; Pharmacology; Regimen; Gastroenterology; Antagonist; Internal medicine","score_opus":0.013022656407419012,"score_gpt":0.2603217956643449,"score_spread":0.24729913925692587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176158528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439806,0.0011560608,0.00082527444,0.00014893524,0.00006952338,0.001613543,0.00046914772,0.000068327085,0.0012511124],"genre_scores_gemma":[0.9934709,0.00076953013,0.0019797878,0.0002519155,0.000062880994,0.0013168749,0.0007735645,0.000020893742,0.0013535506],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99978644,0.000071164526,0.000011260689,0.000059915277,0.00002429251,0.0000470223],"domain_scores_gemma":[0.9997451,0.00003081327,0.000048407706,0.000033719793,0.000016775442,0.00012524778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005713982,0.00087305275,0.0016694647,0.00035333147,0.0003512929,0.000528029,0.00046700655,0.00052208646,0.0017103163],"category_scores_gemma":[0.00037712202,0.0004266052,0.00055133895,0.0003603179,0.00061343214,0.00047978817,0.0002708363,0.0016454956,0.00038577864],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3302455,0.109983824,0.016659418,0.00076021533,0.0012073957,0.00046093384,0.00068339915,0.0073873163,0.3388314,0.0008411431,0.004771018,0.18816842],"study_design_scores_gemma":[0.12736022,0.8121195,0.025273137,0.000026252397,0.00047890347,0.00045815896,0.00009631618,0.0031149623,0.02487104,0.0003290467,0.0058343643,0.000038055026],"about_ca_topic_score_codex":0.0007255238,"about_ca_topic_score_gemma":0.0014676158,"teacher_disagreement_score":0.0017103163,"about_ca_system_score_codex":0.00066988816,"about_ca_system_score_gemma":0.0010103509,"threshold_uncertainty_score":0.0057216287},"labels":[],"label_agreement":null},{"id":"W3179641925","doi":"10.1007/s10637-021-01146-x","title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Toxicity; Cancer; Radioimmunotherapy; Antibody-drug conjugate; Phases of clinical research; Gastroenterology; Antibody; Oncology; Pharmacology; Monoclonal antibody; Immunology","score_opus":0.017280771592894664,"score_gpt":0.31509242098452545,"score_spread":0.2978116493916308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179641925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898085,0.001882342,0.0010506281,0.0007603261,0.0001834024,0.0021296763,0.0012248955,0.000119224365,0.0028410756],"genre_scores_gemma":[0.9876581,0.0019354045,0.0016671171,0.00089550164,0.00012108819,0.0016899679,0.0022095488,0.0000474279,0.0037758376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997346,0.00010759741,0.000007853619,0.000048630503,0.000023860139,0.00007747882],"domain_scores_gemma":[0.9995739,0.00009184737,0.000044563443,0.000028825274,0.000025228823,0.00023556533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009107349,0.0013606806,0.0017395631,0.00046022344,0.0005094177,0.0008330787,0.00062620646,0.0014750325,0.003477606],"category_scores_gemma":[0.0007187017,0.00055093155,0.0011339524,0.00039079756,0.00075690873,0.00067492406,0.0002754062,0.0030204896,0.00092809834],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53656703,0.11716972,0.007699546,0.0011809426,0.00133764,0.0015442005,0.0010009245,0.011106178,0.14145455,0.0013127174,0.01404148,0.16558513],"study_design_scores_gemma":[0.39145315,0.58066773,0.00957686,0.00003172155,0.00031700885,0.00081602944,0.00011423783,0.0027659403,0.008350247,0.00038131865,0.005473158,0.000052576444],"about_ca_topic_score_codex":0.0016766527,"about_ca_topic_score_gemma":0.0032228122,"teacher_disagreement_score":0.003477606,"about_ca_system_score_codex":0.0007342537,"about_ca_system_score_gemma":0.0013167409,"threshold_uncertainty_score":0.011633754},"labels":[],"label_agreement":null},{"id":"W3216437033","doi":"10.1007/s10637-021-01202-6","title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tolerability; Medicine; Prostate cancer; Nausea; Pharmacokinetics; Adverse effect; Internal medicine; Vomiting; Androgen receptor; Pharmacology; Oncology; Cancer; Gastroenterology","score_opus":0.03486849492790454,"score_gpt":0.34264569075683055,"score_spread":0.307777195828926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216437033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484926,0.0012958706,0.0005579419,0.00021382215,0.00006683293,0.0010931048,0.0007165062,0.00005734991,0.0011492866],"genre_scores_gemma":[0.99081975,0.0015490322,0.0013501057,0.00062647765,0.00014769983,0.0011607043,0.0020037824,0.000036528858,0.0023059114],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995215,0.00024658634,0.000016121721,0.000079820675,0.000048280435,0.00008776683],"domain_scores_gemma":[0.99912626,0.0002036746,0.0001460855,0.00007945197,0.00004147062,0.00040298892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012955552,0.0012917282,0.001924201,0.00038002722,0.00039672473,0.00071705977,0.00069238135,0.0009135702,0.0027672576],"category_scores_gemma":[0.0012023218,0.000566909,0.001085679,0.0003759167,0.0009857918,0.00079686206,0.00024725928,0.0030146556,0.0005261728],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7363158,0.09469081,0.009510802,0.00056425645,0.0011576919,0.00045661905,0.0003401596,0.003978999,0.06394678,0.0004135013,0.0031102297,0.08551437],"study_design_scores_gemma":[0.2772541,0.6963315,0.017755548,0.000016385588,0.0003549893,0.00047945062,0.00005320091,0.0015173851,0.004015731,0.00020395004,0.0019771277,0.000040585284],"about_ca_topic_score_codex":0.0013350868,"about_ca_topic_score_gemma":0.0033404946,"teacher_disagreement_score":0.0027672576,"about_ca_system_score_codex":0.00084854715,"about_ca_system_score_gemma":0.0017011233,"threshold_uncertainty_score":0.009257436},"labels":[],"label_agreement":null},{"id":"W4226403841","doi":"10.1007/s10637-022-01227-5","title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Orphan drug; Cancer drugs; Food and drug administration; Drug approval; Clinical trial; Confidence interval; Odds ratio; Clinical research; Cancer; Family medicine; Drug; Internal medicine; Environmental health; Pharmacology; Bioinformatics","score_opus":0.148947661525033,"score_gpt":0.3762924999720464,"score_spread":0.2273448384470134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226403841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76013416,0.06491073,0.0036776685,0.020882731,0.00046747975,0.0013390325,0.010346562,0.00022352149,0.13801813],"genre_scores_gemma":[0.97947204,0.00810625,0.0033605688,0.0030042864,0.000102277816,0.00013462178,0.0017084533,0.000027366825,0.004084146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9813541,0.005770568,0.001186307,0.0013968284,0.008568676,0.0017234867],"domain_scores_gemma":[0.8795256,0.048909593,0.026308049,0.0031678653,0.033215158,0.008873688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022353457,0.00020730749,0.00054187136,0.0029137903,0.00084832933,0.0016961972,0.00066429155,0.0007361002,0.005775475],"category_scores_gemma":[0.056314785,0.0002042191,0.00086116284,0.0034651917,0.0013520515,0.00070032355,0.0009001803,0.0013451248,0.0003731994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006279803,0.00023441068,0.68814504,0.0033051232,0.0011008455,0.0006203809,0.00077042007,0.0010993689,0.0024426586,0.007808848,0.034180127,0.2540129],"study_design_scores_gemma":[0.0004921986,0.0008744659,0.9249225,0.0012848172,0.00071929884,0.0009876824,0.000767782,0.0010556993,0.0017255255,0.0008601273,0.06625325,0.000056696656],"about_ca_topic_score_codex":0.25906873,"about_ca_topic_score_gemma":0.41313604,"teacher_disagreement_score":0.25906873,"about_ca_system_score_codex":0.011363423,"about_ca_system_score_gemma":0.042033464,"threshold_uncertainty_score":0.5151216},"labels":[],"label_agreement":null},{"id":"W4283832186","doi":"10.1007/s10637-022-01266-y","title":"Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Institute on Minority Health and Health Disparities; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Programmed cell death; Apoptosis; Cancer research; Cell culture; Cytotoxicity; Cytotoxic T cell; Lymphoma; DNA fragmentation; Cell cycle; Cancer cell; Cancer; Chemistry; Biology; Pharmacology; Biochemistry; Immunology; In vitro","score_opus":0.014182906786536206,"score_gpt":0.26274941122646456,"score_spread":0.24856650443992834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283832186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857121,0.005509,0.0038351445,0.0001395267,0.0000640861,0.00011444975,0.0004804047,0.0001515782,0.0039937613],"genre_scores_gemma":[0.9903189,0.002793518,0.0032817267,0.000059527876,0.000022214772,0.000047579582,0.00055728015,0.000012851163,0.0029064205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999949,0.000012518178,0.0000051103248,0.000007878441,0.00001186757,0.000013628299],"domain_scores_gemma":[0.9999262,0.000020158599,0.000016330256,0.000009014812,0.000011266571,0.000016985672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011497317,0.00027977693,0.00019529166,0.0002430291,0.00015010338,0.00013698278,0.00016857397,0.00014645558,0.0014224335],"category_scores_gemma":[0.00011716275,0.00010694414,0.00015780554,0.00013566198,0.00014309782,0.00017482234,0.00014056975,0.00035170137,0.000206342],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009218376,0.00021147174,0.00046321173,0.0001791133,0.000012944865,0.00029493074,0.0000682111,0.00021878027,0.9818055,0.00031558244,0.00023972648,0.015268666],"study_design_scores_gemma":[0.0001709463,0.0034990057,0.005399639,0.000013657033,0.00003722875,0.0011029568,0.000048749298,0.00065595633,0.9809239,0.00007974222,0.008058592,0.000009723461],"about_ca_topic_score_codex":0.00023623466,"about_ca_topic_score_gemma":0.00083620386,"teacher_disagreement_score":0.0014224335,"about_ca_system_score_codex":0.0001542239,"about_ca_system_score_gemma":0.00016058623,"threshold_uncertainty_score":0.004758537},"labels":[],"label_agreement":null},{"id":"W4285387375","doi":"10.1007/s10637-022-01282-y","title":"Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes","year":2022,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Survivin; Cancer research; Small interfering RNA; Breast cancer; Delivery system; Medicine; Cancer; Chemistry; Transfection; Pharmacology; Internal medicine; Biochemistry; Gene","score_opus":0.007668571935846592,"score_gpt":0.2147022064033051,"score_spread":0.2070336344674585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285387375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771615,0.0041662767,0.012589923,0.00026103223,0.00010372209,0.00010532645,0.0003490061,0.00035275365,0.0043557975],"genre_scores_gemma":[0.98798555,0.0011070383,0.0064673773,0.00009549772,0.000014573437,0.00008044975,0.00025612683,0.00003320591,0.003960151],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970216,0.0000380802,0.000040132203,0.00007055529,0.00009366019,0.00005540003],"domain_scores_gemma":[0.9999405,0.000011150593,0.000012794865,0.000007086917,0.00001683593,0.00001171309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002376423,0.00038697573,0.0003562749,0.00032742004,0.0001828475,0.00048580024,0.0003362135,0.0003995125,0.0007398108],"category_scores_gemma":[0.00013557365,0.00021100233,0.00024323032,0.00021147424,0.00017898,0.00026831703,0.00026078522,0.00043808925,0.0002880528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006775402,0.000020052037,0.000067434805,0.000048233254,0.000007966122,0.000030990304,0.000021975773,0.000090991714,0.99769753,0.00017426055,0.00007231974,0.0017004632],"study_design_scores_gemma":[0.0000072636085,0.00007695594,0.0003153367,0.0000018201014,0.000019479436,0.00005562453,0.0000065780882,0.0005575715,0.9974324,0.000009806858,0.0015139672,0.0000031932045],"about_ca_topic_score_codex":0.0012881635,"about_ca_topic_score_gemma":0.001981651,"teacher_disagreement_score":0.0012881635,"about_ca_system_score_codex":0.0005384999,"about_ca_system_score_gemma":0.00034773725,"threshold_uncertainty_score":0.0039070845},"labels":[],"label_agreement":null},{"id":"W4323036146","doi":"10.1007/s10637-023-01342-x","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Peripheral blood mononuclear cell; Medicine; CD8; Tolerability; Immune system; Antigen; Pharmacodynamics; Immunotherapy; Immunology; Human leukocyte antigen; Pharmacology; Adverse effect; Internal medicine; Pharmacokinetics; Biology","score_opus":0.04542277026582583,"score_gpt":0.3424850493680232,"score_spread":0.2970622791021974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323036146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736184,0.00023864754,0.0005995529,0.00008056202,0.000036977806,0.001036141,0.00021795186,0.000024947858,0.00040336925],"genre_scores_gemma":[0.9938883,0.00022335861,0.001853558,0.00030827985,0.00007400495,0.0016168207,0.00052573095,0.000013520673,0.0014963252],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971396,0.00013132446,0.000012016001,0.00005803539,0.000033189997,0.000051520765],"domain_scores_gemma":[0.999624,0.00009076437,0.00009671247,0.00004642179,0.000030581556,0.00011140161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009643101,0.00065088447,0.000896086,0.00017726008,0.00023595891,0.0004308868,0.0003294817,0.0006314643,0.0023612136],"category_scores_gemma":[0.0005027372,0.00028728158,0.00048289855,0.00012267541,0.0004280401,0.00034236102,0.00018670618,0.0015340501,0.00043437537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24667434,0.14131479,0.021116743,0.0005019706,0.0004583591,0.00050226366,0.00062804396,0.0055120564,0.4517749,0.0006157174,0.0033659597,0.12753484],"study_design_scores_gemma":[0.038700268,0.9266506,0.008471669,0.000010306341,0.00009187239,0.0002456849,0.00004823702,0.0013862888,0.022050316,0.00015301941,0.0021796948,0.000012017821],"about_ca_topic_score_codex":0.00017952968,"about_ca_topic_score_gemma":0.00035100666,"teacher_disagreement_score":0.0023612136,"about_ca_system_score_codex":0.00036818194,"about_ca_system_score_gemma":0.0006109186,"threshold_uncertainty_score":0.007899046},"labels":[],"label_agreement":null},{"id":"W4364353540","doi":"10.1007/s10637-022-01326-3","title":"Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Selumetinib; Nausea; Discontinuation; Vomiting; MEK inhibitor; Internal medicine; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Population; Cancer; Phases of clinical research; Surgery; Oncology; Chemotherapy; MAPK/ERK pathway; Kinase; Colorectal cancer","score_opus":0.034795656958310404,"score_gpt":0.3114770306345717,"score_spread":0.27668137367626133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364353540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993948,0.0020287393,0.0004985998,0.00024514727,0.0000709051,0.0012282802,0.00082008133,0.000046532023,0.0011138213],"genre_scores_gemma":[0.9931069,0.0012196592,0.0013385088,0.00045713154,0.00010545737,0.0007821923,0.0017647553,0.000022666141,0.0012027466],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99941564,0.0003020216,0.00004105827,0.000090517446,0.00007309579,0.00007757096],"domain_scores_gemma":[0.99932444,0.00013629837,0.00014971805,0.000043285123,0.0000621544,0.000284064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020625708,0.001161114,0.0016429597,0.0003254799,0.00037190877,0.0006498245,0.00051342574,0.00071179145,0.0027024162],"category_scores_gemma":[0.00084755005,0.00044641364,0.00096993725,0.00027019205,0.0005987358,0.0008332974,0.00025028767,0.002205942,0.0006064328],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5940633,0.13634801,0.01595664,0.0012948283,0.0030381822,0.0004433645,0.000423766,0.0037846162,0.11501646,0.00019627814,0.0048052305,0.12462937],"study_design_scores_gemma":[0.2688163,0.6849177,0.03263955,0.000043947737,0.001104225,0.00043152965,0.00007881713,0.0013714377,0.00740368,0.00013552912,0.0030231525,0.000034242792],"about_ca_topic_score_codex":0.0005342476,"about_ca_topic_score_gemma":0.0019278399,"teacher_disagreement_score":0.0027024162,"about_ca_system_score_codex":0.0006683911,"about_ca_system_score_gemma":0.0010622669,"threshold_uncertainty_score":0.010908067},"labels":[],"label_agreement":null},{"id":"W4391614640","doi":"10.1007/s10637-023-01410-2","title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Randomized controlled trial; Pembrolizumab; Medicine; Antagonist; Internal medicine; Cancer; Immunotherapy; Receptor","score_opus":0.012628129560671114,"score_gpt":0.30921781692091993,"score_spread":0.2965896873602488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391614640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98697215,0.0036904428,0.0006683516,0.0008827922,0.00027632862,0.003914555,0.0010544731,0.00014948737,0.0023913623],"genre_scores_gemma":[0.981047,0.0034837034,0.0021215472,0.0014622776,0.0004313927,0.006130613,0.0017257156,0.000030289413,0.0035674614],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996203,0.0002058475,0.000018012313,0.000058461555,0.00003082024,0.00006650363],"domain_scores_gemma":[0.9996044,0.000079547324,0.00009471737,0.000029995133,0.000027649523,0.00016364898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015151115,0.0014961212,0.0018452414,0.0004011761,0.000374035,0.00090485613,0.00073952536,0.0012760394,0.004554959],"category_scores_gemma":[0.0008833606,0.00055414287,0.0011042319,0.00037841251,0.00078345666,0.0007979247,0.00028526437,0.0021616472,0.0007676416],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9299379,0.01582317,0.0013533424,0.000713977,0.00093532016,0.00012670513,0.000114665854,0.0009648429,0.008732216,0.00031958852,0.0028626882,0.038115587],"study_design_scores_gemma":[0.92087567,0.07466237,0.0016137796,0.000031656215,0.00021970435,0.00007229923,0.000018795903,0.0007665445,0.0004959474,0.00014700595,0.0010854404,0.000010881616],"about_ca_topic_score_codex":0.0008916541,"about_ca_topic_score_gemma":0.002466495,"teacher_disagreement_score":0.004554959,"about_ca_system_score_codex":0.00080442854,"about_ca_system_score_gemma":0.0011419827,"threshold_uncertainty_score":0.015237868},"labels":[],"label_agreement":null},{"id":"W4392805481","doi":"10.1007/s10637-024-01428-0","title":"A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Selumetinib; Medicine; Pembrolizumab; Adverse effect; Internal medicine; MEK inhibitor; Gastroenterology; Pharmacology; Urology; Oncology; Cancer; Colorectal cancer; MAPK/ERK pathway; Immunotherapy; Chemistry; Kinase","score_opus":0.02116369759197948,"score_gpt":0.29944718956827593,"score_spread":0.2782834919762964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392805481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199986,0.0024212268,0.00051754824,0.00045648022,0.00012976595,0.001972877,0.0006723551,0.000070302536,0.0017595852],"genre_scores_gemma":[0.9872875,0.0024670642,0.0020993447,0.0008764178,0.00017087648,0.0022700205,0.002049023,0.00002523463,0.0027544592],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996964,0.00015376383,0.000012069503,0.000053720745,0.000029346927,0.00005477303],"domain_scores_gemma":[0.9996737,0.000053745047,0.00006249905,0.000018275947,0.000021851198,0.00016996881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012454333,0.001519028,0.0015116329,0.00039472684,0.0003378702,0.0006720037,0.0005487355,0.00094783166,0.002536543],"category_scores_gemma":[0.000579935,0.00053266116,0.0009047488,0.0002620024,0.0005698761,0.00056656427,0.00028101038,0.0025741938,0.00061294704],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6547149,0.08463463,0.005651883,0.0015165267,0.0017971444,0.0006398732,0.00045116676,0.0041526146,0.099808864,0.0005765681,0.007701109,0.13835481],"study_design_scores_gemma":[0.5030928,0.47876632,0.0073269857,0.000045267745,0.00039261303,0.00035813576,0.00004328864,0.001784083,0.0048037507,0.00022865582,0.0031327358,0.000025352445],"about_ca_topic_score_codex":0.00063596567,"about_ca_topic_score_gemma":0.0016600128,"teacher_disagreement_score":0.002536543,"about_ca_system_score_codex":0.0005887681,"about_ca_system_score_gemma":0.0009728437,"threshold_uncertainty_score":0.008485556},"labels":[],"label_agreement":null},{"id":"W4398141543","doi":"10.1007/s10637-024-01444-0","title":"Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","year":2024,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Antagonist; Internal medicine; Oncology; Immunotherapy; Cancer; Receptor","score_opus":0.010908600771500552,"score_gpt":0.3068487250344997,"score_spread":0.29594012426299915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398141543","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025190317,0.0043383986,0.00050450955,0.07989611,0.9088031,0.0001730914,0.0026489766,0.00016767572,0.0032162545],"genre_scores_gemma":[0.012969027,0.01634505,0.004784416,0.3128286,0.50870484,0.0010851037,0.0049005714,0.0010602343,0.13732211],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965389,0.0009903441,0.00055447774,0.00037749243,0.0012064232,0.00033247843],"domain_scores_gemma":[0.9854624,0.0056459373,0.0012148746,0.00058720825,0.0057786587,0.0013109319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065105427,0.0018213938,0.0026490944,0.0016777936,0.0011728504,0.0031852908,0.002270755,0.004788504,0.051480502],"category_scores_gemma":[0.037925765,0.00088003423,0.002496577,0.0012777209,0.001095285,0.0011371413,0.0008577282,0.008321959,0.014122514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046084757,0.000011832278,0.00005722242,0.00041558815,0.000071153634,0.00007778457,0.000004541183,0.00003443161,0.00004234736,0.00022964357,0.99339724,0.0051973825],"study_design_scores_gemma":[0.0053127413,0.00020446004,0.0014018543,0.0017703117,0.00083123357,0.00042777832,0.000033654687,0.00042883668,0.0005081968,0.001363985,0.9876621,0.00005478033],"about_ca_topic_score_codex":0.0073794564,"about_ca_topic_score_gemma":0.012078403,"teacher_disagreement_score":0.051480502,"about_ca_system_score_codex":0.0035243179,"about_ca_system_score_gemma":0.005593215,"threshold_uncertainty_score":0.17221946},"labels":[],"label_agreement":null},{"id":"W4399361197","doi":"10.1007/s10637-024-01448-w","title":"A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal; Crosslight Software (Canada); University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Nausea; Adverse effect; Medicine; Vomiting; Pharmacokinetics; Internal medicine; Pharmacology; Gastroenterology; Refractory (planetary science); Dosing; Tolerability; Toxicity; Biology","score_opus":0.008491999688964535,"score_gpt":0.2465649185336351,"score_spread":0.23807291884467058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399361197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914807,0.001378188,0.00058626593,0.00035845593,0.00009180475,0.0030789915,0.0011362714,0.00011792237,0.0017713762],"genre_scores_gemma":[0.9865096,0.001538398,0.0018597761,0.0008324992,0.00015979008,0.003069049,0.002649631,0.00003935704,0.0033418555],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99969006,0.00013854139,0.000014829787,0.00005959671,0.000022527358,0.000074471456],"domain_scores_gemma":[0.9993969,0.00009663879,0.000087870954,0.00004958652,0.00003591729,0.00033311063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013319288,0.0018298607,0.0016965041,0.00046274162,0.0005042929,0.0008313876,0.0007839493,0.0009921805,0.0029478343],"category_scores_gemma":[0.0007218128,0.0007370984,0.0010178065,0.0003477288,0.001075636,0.0008475916,0.00036607214,0.0028056484,0.0007794942],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7106654,0.106174946,0.0072180326,0.00070300396,0.00097580836,0.0006397055,0.00049982267,0.0040438017,0.07398875,0.0004266713,0.0069133737,0.08775068],"study_design_scores_gemma":[0.44763935,0.53302205,0.009393743,0.000024288176,0.00027530314,0.00033272072,0.00007684788,0.0015622806,0.004330042,0.00027527253,0.003036409,0.000031749492],"about_ca_topic_score_codex":0.00097561907,"about_ca_topic_score_gemma":0.0026185303,"teacher_disagreement_score":0.0029478343,"about_ca_system_score_codex":0.0008432596,"about_ca_system_score_gemma":0.0012817645,"threshold_uncertainty_score":0.009861469},"labels":[],"label_agreement":null},{"id":"W4402538375","doi":"10.1007/s10637-024-01461-z","title":"A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; MAPK/ERK pathway; Internal medicine; Pharmacology; Chemistry; Kinase; Immunotherapy; Cancer","score_opus":0.010907936607217268,"score_gpt":0.2797415372715782,"score_spread":0.2688336006643609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402538375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993026,0.0016922373,0.0005754986,0.00040626066,0.00008591054,0.0025454126,0.00052447314,0.000051612114,0.0010924655],"genre_scores_gemma":[0.98955566,0.0019845485,0.002407159,0.0007256902,0.00016108934,0.00243195,0.0011446724,0.000016161783,0.0015730589],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961543,0.00022608375,0.00001960616,0.000054628796,0.000034041735,0.000050111463],"domain_scores_gemma":[0.99958485,0.00008292429,0.000096042975,0.000024470472,0.000032203337,0.00017954163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017961535,0.0011765984,0.0012386191,0.00039970453,0.00029655674,0.00048662655,0.00052203523,0.00086111523,0.0021858239],"category_scores_gemma":[0.00064497214,0.0005306683,0.00077148946,0.0003461853,0.00061298243,0.0005210526,0.0002475265,0.0023512077,0.00047517577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5722397,0.16051444,0.0137080075,0.0013013715,0.0014765053,0.00045391818,0.00040363928,0.0027729925,0.10411814,0.0005042263,0.0068844487,0.13562274],"study_design_scores_gemma":[0.5375756,0.4437537,0.010450052,0.000031825337,0.00033381415,0.00022517655,0.00003956125,0.0014258747,0.0038243998,0.00014524066,0.0021761823,0.000018574976],"about_ca_topic_score_codex":0.00065988686,"about_ca_topic_score_gemma":0.0020314897,"teacher_disagreement_score":0.0021858239,"about_ca_system_score_codex":0.00061022554,"about_ca_system_score_gemma":0.0013586442,"threshold_uncertainty_score":0.009499073},"labels":[],"label_agreement":null},{"id":"W4408246183","doi":"10.1007/s10637-025-01518-7","title":"First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Cmax; Pharmacodynamics; Pharmacokinetics; Adverse effect; Maculopapular rash; Rash; Internal medicine; Gastroenterology; Area under the curve; Lymphoma; Pharmacology; Toxicity","score_opus":0.012745993595768064,"score_gpt":0.30562469083016436,"score_spread":0.2928786972343963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408246183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932365,0.0015261914,0.00063983374,0.00038848334,0.000112573,0.0012546527,0.00080045225,0.00012805128,0.0019133129],"genre_scores_gemma":[0.99283195,0.0010512713,0.0009830412,0.00048629232,0.000077190445,0.00079049874,0.0011179589,0.00003914333,0.0026226437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996263,0.00013866671,0.000011632721,0.00006354846,0.00003375548,0.00012610911],"domain_scores_gemma":[0.99964094,0.000049348946,0.000039771076,0.000033398683,0.000017633942,0.00021884777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011830667,0.0015790781,0.0020189842,0.0005319752,0.00051318866,0.0011961972,0.0008277099,0.00097978,0.002779989],"category_scores_gemma":[0.0004866073,0.00062936527,0.0010393462,0.00042623386,0.0011403325,0.0008766585,0.00034167757,0.0033919879,0.00082070206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47126833,0.2055162,0.008011415,0.00092413166,0.0017419792,0.000614096,0.00077265286,0.010016872,0.13539332,0.0008017847,0.009838243,0.15510108],"study_design_scores_gemma":[0.31610987,0.64764744,0.013299733,0.000027186465,0.0005381285,0.00039142236,0.00017005725,0.0032730617,0.013186773,0.00040532852,0.00489739,0.000053629206],"about_ca_topic_score_codex":0.0019125347,"about_ca_topic_score_gemma":0.004564729,"teacher_disagreement_score":0.002779989,"about_ca_system_score_codex":0.0014328498,"about_ca_system_score_gemma":0.0014840334,"threshold_uncertainty_score":0.010396123},"labels":[],"label_agreement":null},{"id":"W4409868775","doi":"10.1007/s10637-025-01537-4","title":"Does anamorelin have beneficial effects in advanced cancer patients with systemic inflammation in the real world?","year":2025,"lang":"en","type":"letter","venue":"Investigational New Drugs","topic":"Adipokines, Inflammation, and Metabolic Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Systemic inflammation; Medicine; Inflammation; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.0064073090568764505,"score_gpt":0.24453849045297707,"score_spread":0.23813118139610062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409868775","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011485943,0.007673074,0.00006475033,0.97635466,0.011232484,0.000012204948,0.00007731456,0.000018177274,0.0034188014],"genre_scores_gemma":[0.009935662,0.009269326,0.0003140387,0.9058041,0.06949644,0.000042800777,0.00005524799,0.000015949401,0.005066482],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990126,0.0003384395,0.00015008541,0.000095073665,0.00027269695,0.00013108447],"domain_scores_gemma":[0.99648947,0.002012146,0.00033908157,0.00008374508,0.0005163399,0.00055918325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022113023,0.00048662655,0.0016894757,0.00045235446,0.0015828137,0.0017873555,0.0008108338,0.01971588,0.0046646176],"category_scores_gemma":[0.010224851,0.0002973778,0.0010820465,0.0005062184,0.0013177478,0.001999358,0.0006498233,0.015650494,0.0035044877],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010508448,0.00020231913,0.0030882747,0.0003241043,0.00010871644,0.005152783,0.00014353145,0.00018272102,0.00096839573,0.0044961735,0.90057546,0.0837068],"study_design_scores_gemma":[0.001192862,0.00056465855,0.0039714426,0.0007236233,0.00013706477,0.004756784,0.00040802977,0.0005320694,0.00050800055,0.012212588,0.97490746,0.00008550017],"about_ca_topic_score_codex":0.0028928528,"about_ca_topic_score_gemma":0.0077533615,"teacher_disagreement_score":0.01971588,"about_ca_system_score_codex":0.0021492532,"about_ca_system_score_gemma":0.0021265077,"threshold_uncertainty_score":0.015604734},"labels":[],"label_agreement":null},{"id":"W4412543666","doi":"10.1007/s10637-025-01566-z","title":"Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Isotretinoin; Medicine; Drug development; Drug; Dermatology; Intensive care medicine; Pediatrics; Pharmacology; Acne","score_opus":0.08752378600377417,"score_gpt":0.3623963156119547,"score_spread":0.27487252960818054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412543666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97198796,0.0056260615,0.0021807454,0.0064383824,0.00019954701,0.00008540231,0.0000893137,0.000056790726,0.013335823],"genre_scores_gemma":[0.9890943,0.0038428686,0.0022262037,0.0015947726,0.0002874101,0.000015712927,0.000039691895,0.00003688756,0.0028621003],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99943894,0.00009399429,0.000080527265,0.0000968874,0.00012004869,0.00016947718],"domain_scores_gemma":[0.99878377,0.00027168062,0.0003764653,0.0000473475,0.00011442704,0.0004063032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035017193,0.0008896802,0.0007819932,0.0015751685,0.0026704483,0.001311135,0.0007406645,0.0031151478,0.0017573929],"category_scores_gemma":[0.002468179,0.00047869593,0.0010222758,0.0009618157,0.0013415982,0.0015513307,0.0011959261,0.0020906716,0.0003243434],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019013247,0.000045757843,0.008938367,0.000025494075,0.000009170561,0.98730034,0.00057027454,0.00006898509,0.0005532379,0.00031258835,0.00029327066,0.0018634477],"study_design_scores_gemma":[0.0000043884706,0.00003709079,0.0029544113,0.000026816628,0.000031028958,0.99341375,0.0009986912,0.0003382349,0.0004831267,0.00015009011,0.0015505361,0.000011805063],"about_ca_topic_score_codex":0.010872765,"about_ca_topic_score_gemma":0.019140318,"teacher_disagreement_score":0.010872765,"about_ca_system_score_codex":0.001952966,"about_ca_system_score_gemma":0.0021312097,"threshold_uncertainty_score":0.021618903},"labels":[],"label_agreement":null},{"id":"W4413318599","doi":"10.1007/s10637-025-01573-0","title":"Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Colorectal cancer; Triple-negative breast cancer; Internal medicine; Oncology; Breast cancer; Metastatic breast cancer; Open label; Cancer; Cancer research; Immunotherapy; Clinical trial","score_opus":0.05132265043575454,"score_gpt":0.3734473502891841,"score_spread":0.3221246998534295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413318599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97917527,0.001985261,0.0010272227,0.0007202056,0.00036152132,0.011995577,0.0021404668,0.00014410618,0.0024503178],"genre_scores_gemma":[0.9632921,0.0018214933,0.003788732,0.0023846058,0.00034314147,0.01964715,0.0023582082,0.00004758401,0.0063170074],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995933,0.00016483758,0.000019769315,0.00010698307,0.00004004205,0.00007508808],"domain_scores_gemma":[0.99935323,0.00010038194,0.00012658705,0.000045473396,0.00009343483,0.00028082743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016719088,0.0018629957,0.0018559236,0.0002703165,0.00067986234,0.0008685435,0.0008604894,0.0017292531,0.0063877455],"category_scores_gemma":[0.00122583,0.0011788635,0.0011838981,0.00023103523,0.00080958265,0.0010876372,0.0003938458,0.0038376427,0.0015436308],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81321305,0.116695106,0.00419278,0.0011237214,0.0017258078,0.0001635047,0.00033884693,0.0005831783,0.024587473,0.0002633152,0.004315495,0.03279791],"study_design_scores_gemma":[0.68588465,0.30176562,0.0064424137,0.0000457501,0.00063018413,0.00012253269,0.00009537233,0.0004955782,0.0011754155,0.0003145413,0.0029979912,0.000029931343],"about_ca_topic_score_codex":0.0011929895,"about_ca_topic_score_gemma":0.0044417074,"teacher_disagreement_score":0.0063877455,"about_ca_system_score_codex":0.0008031467,"about_ca_system_score_gemma":0.0017885971,"threshold_uncertainty_score":0.0213691},"labels":[],"label_agreement":null},{"id":"W45844253","doi":"10.1023/a:1020625423524","title":"Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group","year":2002,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hôpital Notre-Dame; Hamilton Regional Laboratory Medicine Program; Princess Margaret Cancer Centre; Nova Scotia Cancer Centre; Ottawa Regional Cancer Foundation; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Melanoma; Cancer; Biopsy; Internal medicine; Gastroenterology; Fibrosis; Clinical trial; Necrosis; Matrix metalloproteinase; Pathology; Oncology; Cancer research","score_opus":0.1056938063737493,"score_gpt":0.37627511406933667,"score_spread":0.27058130769558736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W45844253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98923993,0.003387017,0.0005939495,0.0008243523,0.00020707876,0.0021080507,0.0014407546,0.00007986742,0.0021189854],"genre_scores_gemma":[0.9804002,0.0042710444,0.00210436,0.0011724193,0.00036322005,0.0020712349,0.003819415,0.00005519233,0.005742891],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99930274,0.00039648407,0.000020218535,0.000074657815,0.000067140754,0.00013868108],"domain_scores_gemma":[0.9990422,0.00013689199,0.00014962767,0.00007353236,0.00007273295,0.00052498287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021811468,0.0020869004,0.0025077427,0.00055081054,0.0006314402,0.0009251297,0.0011365641,0.0015005671,0.0028292723],"category_scores_gemma":[0.00096659263,0.0008678814,0.0014121667,0.00047044933,0.0010535873,0.00068065134,0.00031955435,0.0033837173,0.0010198837],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73015237,0.058276165,0.007629356,0.0006089975,0.001657734,0.00049424346,0.00027273767,0.0033394455,0.09939926,0.0004268052,0.007365368,0.09037753],"study_design_scores_gemma":[0.53448236,0.424226,0.025953665,0.00003665726,0.00068567286,0.00047049805,0.00008916762,0.0017375854,0.008356847,0.00025441835,0.003654133,0.00005298093],"about_ca_topic_score_codex":0.0053650443,"about_ca_topic_score_gemma":0.012935393,"teacher_disagreement_score":0.0053650443,"about_ca_system_score_codex":0.0013921964,"about_ca_system_score_gemma":0.0020845106,"threshold_uncertainty_score":0.011535108},"labels":[],"label_agreement":null}]}